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1 Doping 
The desire to win and the search to improve performance is inherent to sport. This 
endeavor has tempted the athlete for centuries to explore different ways to take a 
lead on his or her opponents. Nowadays, sports, whether professional or not, are 
often practiced using a scientific approach. Indeed, research conducted in sport 
related areas has led to more efficient training methods, targeted to the needs of the 
athlete. In addition to customized training schedules, attention is also paid to optimal 
diet and – if applicable – the best equipment and technical facilities.  
However, there is a thin line between scientific optimization of sports and the misuse 
of scientific knowledge. Starting from the 20th century, rapid advances in the medical 
and pharmaceutical industry have led to (incorrect) use of drugs in sports. The 
doping story started with stimulating agents as amphetamine and strychnine to 
suppress pain and fatigue, mainly in sport disciplines where endurance is of great 
importance [1]. These products had been used for years without the public 
(authorities) paying attention to the impact on the health of the athlete. However, in 
the 1960s, the general public and the authorities became aware of the seriousness of 
the situation due to two fatalities in cycling. Although not officially confirmed [2], both 
the death of Knud Enemark Jensen (Olympic Games, 1960) and Tom Simpson (Tour 
de France, 1967) were linked with rumored stimulant abuse [3], although no hard 
evidence of the direct link can be provided, even today, as other factors were also 
involved. Nevertheless, triggered by these incidents the International Olympic 
Committee (IOC) formed a Medical Commission, in charge of testing and monitoring 
doping in sports and a (short) list of prohibited substances was drafted. As a result, 
tests for stimulants were developed based upon gas chromatographic separation [4] 
and used for the first doping controls during the Olympics in Mexico City in 1968 [1]. 
Later, other federations like the International Association of Athletics Federations 
(IAAF) and the International Cycling Union (UCI) introduced their own anti-doping 
rules and further tests were developed for anti-doping purposes [3]. 
In the following years, the scope of sports affected by doping and classes of doping 
agents grew and continuous efforts were made to tackle the doping problem. 
Similarly, anti-doping methods needed to be developed (Fig. 1.1). In the 1950s and 
1960s anabolic steroids were introduced in sports mainly to improve the recovery 
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after great efforts [5]. Over the following years the use of (synthetic) derivatives of 
testosterone increased in sports all over the world for their effect on the athlete’s 
muscle mass and strength. Together with the development of detection strategies for 
these compounds, the IOC prohibited the use of anabolic steroids in competition in 
1974. This measure resulted in a shift in use of steroids towards the training period to 
avoid detection in competition. It became clear after several high profile doping 
scandals, including the anabolic steroid program of the German Democratic Republic 
[6] and the famous stanozolol positive test of sprinter Ben Johnson at the Olympic 
Games of Seoul in 1988 [5], that the use of these products was well organized. To 
counter this evolution, the IAAF was the first organization to set up out of competition 
testing in 1991. However, then again, users adapted quickly to the new situation by 
changing to steroid precursors or specially synthesized designer steroids [7]. Effective 
tests for these substances were only gradually developed and only in the late 1980s, 
beginning of the 1990s an effective testing program could be implemented. 
In addition to anabolic agents, which have been the major group of adverse analytical 
findings for years, other drugs found their way into sports as well. In disciplines 
where not the physical effort but the control of movement and calmness is required, 
beta-blockers were introduced. These products were inserted in the IOC list in 1985 
together with diuretics, which are taken to effect a rapid reduction in weight and in 
that way reach weight class limits or to increase the excretion rate of urine and 
reduce urinary concentrations of prohibited drugs [8,9]. Also in the 1980s, recombinant 
human erythropoietin was introduced on the market for clinical purposes. Concerned 
with the potential performance enhancing capabilities and the severe side-effects of 
growth hormone and erythropoietin (EPO), the IOC added the class of peptide 
hormones to the prohibited list in 1989, however no direct test was available at that 
time for these substances. Only for human chorionic gonadotrophin (hCG) a test was 
available. Indeed, until the development of a screening test for EPO in 2000 [10], 
indirect tests based upon maximal haematocrit levels were the only indirect indicative 
tests which could be applied [11]. 
Next to the use of EPO, intravenous administration of red blood cells is another way 
to increase the blood oxygen carrying capacity. While homologous blood transfusion 
can be detected via flow cytometry based upon differences in minor blood group 
antigens [12], an autologous administration is harder to trace. Indirect indications can 
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find sufficient international support for the next necessary step. The public attention 
and appall for the doping scandal during the 1998 Tour de France, created a 
momentum that was used to gather all the partners in the fight against doping: the 
IOC, governments, (inter)national organizations and other public and private 
institutions [3]. The result of the World Conference on Doping in 1999 was the 
foundation of the independent World Anti-Doping Agency (WADA) [11]. The main aim 
was to harmonize the anti-doping rules in between international federations and 
national anti-doping organizations. Today, WADA has grown to the global leading 
organization, which develops protocols and guidelines, promotes research and 
education and coordinates the World Anti-Doping Program [20]. The best known 
achievement has been the implementation of the World Anti-Doping Code. This Code 
aims: 
• To protect the Athletes' fundamental right to participate in doping-free sport 
and thus promote health, fairness and equality for Athletes worldwide, and  
• To ensure harmonized, coordinated and effective anti-doping programs at 
the international and national level with regard to detection, deterrence and 
prevention of doping [21]. 
Further WADA annually publishes the Prohibited List, which contains all prohibited 
substances and prohibited methods divided into In-Competition and Out-of-
competition (Table 1.1). A compound can be included in the list if it fulfills at least two 
out of the three following criteria: it has potential to enhance sport performance, it 
constitutes a health risk to the athlete or it violates the spirit of sport described in the 
Code [21]. 
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Table 1.1: Categories of the 2013 Prohibited List 
  
Prohibited at all times 
S0  Non‐approved substances 
S1  Anabolic agents 
S2  Peptide hormones, growth factors and related substances 
S3  Beta‐2 agonists 
S4  Hormone and metabolic modulators 
S5  Diuretics and other masking agents 
M1  Enhancement of oxygen transfer 
M2  Chemical and physical manipulation 
M3  Gene doping 
  
Prohibited in competition 
S6  Stimulants 
S7  Narcotics 
S8  Cannabinoids 
S9  Glucocorticosteroids 
  
Prohibited in particular sports 
P1  Alcohol 
P2  Beta‐blockers 
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3 WADA-accredited laboratories 
An essential part in setting up a proficient anti-doping system is the use of well-
performing laboratories, responsible for the analyses of the doping control samples. 
Additionally, these labs are often also the key players in the research around doping 
and related fields.  
3.1 Accreditation and quality control 
The WADA Code stipulates that anti-doping tests can only be performed in WADA 
accredited laboratories. To obtain such accreditation, a laboratory needs the support 
of a National Anti-Doping Organisation (NADO), must hold 17025 accreditation of the 
International Organization for Standardization/International Electrotechnical 
Commission (ISO/IEC) and participate successfully in the external quality 
assessment scheme (EQAS) of WADA [22].  
ISO17025 accreditation requires the implementation of a quality management 
system, including different aspects of the laboratory organization. Particular attention 
is paid to the documentation, on the one hand concerning the analytical procedures, 
on the other hand to enable traceability of all handlings. This ranges from installation 
of equipment, to its calibration and the appropriate training of staff members. The 
methods used should fit for the purpose and should be properly validated. According 
to the ISO definition this validation procedure is performed to “confirm by examination 
and provision of objective evidence that the particular requirements for a specified 
intended use are fulfilled” [23]. On a regular basis, the competence of the laboratory is 
tested by means of both internal and external audits and the participation in 
proficiency tests. 
3.2 The instrumentation 
In the beginning of sport drug testing in the 1970s, thin layer chromatography (TLC) 
and gas chromatography (GC) were the workhorses of the first anti-doping labs [24]. 
Over the years, the list of available techniques has grown at high speed. Although in 
the 1970s the first methods for anabolic steroids were based upon immunoassay 
technology [11], the switch was made to chromatographic methods only a few years 
later. Both gas chromatography and liquid chromatography (LC) were coupled to 
mass spectrometry (MS), whereupon this mass spectrometric detection was brought 
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to higher levels with the implementation of tandem mass spectrometry (MS/MS), high 
resolution mass spectrometry (HRMS) and isotope ratio mass spectrometry (IRMS) 
[5]. The continuous implementation of these new techniques allows to detect (new) 
doping substances better and faster. And this is an absolute necessity, given the 
continuously increasing complexity and more stern demands imposed to doping 
control laboratories. Indeed, over the years the number of samples analyzed 
increased (Fig. 1.2) together with a growing list of substances to be screened for. 
Regarding these compounds, it should be noted that WADA has defined minimum 
required performance levels (MRPL) [25] to be met by every accredited lab. These 
MRPLs are neither thresholds nor reporting limits, but define the levels at or below 
which substances should be detected routinely. Also, the number of metabolites 
implemented in methods to detect the abuse of a certain compound increased as 
well. The latter is mainly the result of the research conducted in the anti-doping field. 
The fact that WADA laboratories play a key role in this is reflected in their scientific 
output describing the improved methodologies, new metabolism studies, etc. [26]. 
 
 
Fig. 1.2 Evolution in the number of samples analyzed at DoCoLab up to 2012. 
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Together with the analytical challenges, also economic concerns should be taken into 
account. During the period 2008 to 2011, the global number of analyzed doping 
control samples has stagnated. Much has to do with the economical situation lately, 
since doping control programs and corresponding research projects usually rely on 
government resources. To cope with this situation, laboratories aim towards 
increased efficiency to reduce costs: this goes from reducing the number of analytical 
methods over increasing the sample turn-around and throughput to automation of 
sample preparation procedures. It should be mentioned that - compared to 2011 – a 
12% increase in analyzed doping control samples was observed in 2012. If this is 
related to an increase in testing for the 2012 London Olympic Games or really 
constitutes a turning-point, currently remains an open question. 
3.3 Improved detection strategies in DoCoLab 
In terms of analytical equipment, over the last years DoCoLab has invested with two 
objectives in view. Next to the above-mentioned challenges in terms of detection 
limits, the course was set towards the introduction of an open screening approach 
and an improved steroid profiling strategy. 
In the LC-department, the open screening strategy has been made possible by the 
installation of a high resolution mass spectrometer based upon Orbitrap™ 
technology. The method developed on this Exactive mass spectrometer is capable of 
detecting over 200 compounds from the classes S1, S3, S4 (e.g. tamoxifen), S5, S6, 
S7, S8 (e.g. JWH-compounds), S9, P1 (e.g. ethylglucuronide) and P2 (Table 1.1) by 
acquiring high resolution accurate mass data in full scan mode [27]. This makes the 
traditional development of MS methods – containing specific ions or transitions for 
every compound – redundant. Indeed, the previously used tandem MS technology 
only acquired data for the predefined components, while the HRMS detector is 
capable of measuring full scan data after which the compounds of interest are 
extracted in the data processing part, based upon retention time and the accurate 
mass of the given compound. This enables the retrospective data analysis of all 
samples analyzed with the method in the case of a new detected doping agent, a 
new long-term metabolite, etc. Under the current regulations [22] these full scan data 
are stored for eight years, while the storage of the corresponding urine samples is 
between three months and eight years. Since this long time storage of urine samples 
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in a secure location under a continuous chain of custody leads to logistical problems, 
this is currently only done for big events as the Olympic Games or on special 
request. 
Detection of the abuse of endogenous steroids requires a different approach. It is 
known that administration of testosterone or one of its precursors alters the 
concentrations of the endogenous steroids excreted in urine. To detect this, methods 
were developed capable of quantifying testosterone (T), epitestosterone (E), 
androsterone (A), etiocholanolone (Etio), 5α-Androstane-3α,17β-diol (5ααβ-Adiol) 
and 5β-Androstane-3α,17β-diol (5βαβ-Adiol), together the so-called steroid profile [28]. 
Detecting an altered steroid profile however, is not that straightforward. To diagnose 
endogenous steroid abuse, the distinction between normal and elevated levels is 
based upon thresholds for every steroid, derived from population statistics [29].  
Over the last years, it was possible to improve the existing steroid profiling methods 
in DoCoLab thanks to the installation of a new GC-system equipped with a triple 
quadruple mass spectrometer. The improved selectivity and specificity of this GC-
MS/MS system together with the use of deuterated internal standards, the addition of 
markers to control the complete sample preparation procedure for every step and the 
additional quantification of minor metabolites [30,31], allows for a more accurate 
quantification of the - extended - steroid profile [32,33]. 
3.4 The athlete biological passport 
Nevertheless, the disadvantages of using population based statistics to establish 
thresholds remain. It is known that urinary excretion of the above-mentioned 
endogenous steroids is subject to both intra-, inter-individual and genetic variations 
[29]. Since laboratories don’t have access to personal details of the athlete and his or 
her steroid profile, the current general threshold may allow steroid takers to slip 
through the net. 
To avoid this, individual reference ranges should be established for every single 
athlete. This was already done in the 2000s, as follow-up studies conducted when a 
suspicious result was found [31], but can now be made possible in the framework of 
the ABP, in use from 2009 [34]. At the moment, this contains only blood passport data 
to detect the use of EPO or blood transfusion. Therefore, selected blood parameters 
obtained from hematological tests over time are registered in the athlete’s personal 
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database. This enables the calculation of reference ranges for each parameter, 
specifically for every individual athlete in a way that abnormal values can be 
detected, which can result in intelligent and targeted testing. 
The future steroid module in the athlete passport necessitates an accurate 
determination of endogenous steroid concentrations. To support this, more research 
projects are in the DoCoLab pipeline, both towards analytical methodologies and 
factors influencing this steroid profile [35]. 
4 Cannabis and doping 
Classified under category S8 of the 2013 Prohibited List [36], the status of cannaboids 
in competition is described as: 
“Natural (e.g. cannabis, hashish, marijuana) or synthetic delta 9-tetrahydrocannabinol 
(THC) and cannabimimetics (e.g. “Spice”, JWH-018, JWH-073, HU-210) are 
prohibited.” 
Since the Medical Commission of the IOC placed marijuana on the list of doping 
substances in 1989 till this last update on the List of 2013, this decision has given 
rise to controversy. The inclusion of cannabis as a doping agent has been heavily 
debated. The supporters of the prohibition point out that cannabis can have an 
impact on the performance in particular sports and/or take the view that athletes 
serve as role models, while the opponents refute the argument of performance 
enhancement and state that the use of cannabinoids is only a private social issue [37].  
The influence of cannabis on the athletes’ sport performance has been the subject of 
research for many years and conflicting results have been reported. In most studies 
negative effects of cannabis use on the sporting achievements were found, ranging 
from increased heart rate and reduced peak performance to reduction of reaction 
times and psychomotor skills [37–40]. When the level of concentration is important, 
cannabis use can influence this in a positive way [37]. On the other hand, the sedative 
effects can be used to reduce the stress and anxiety of the athlete before and after 
competition [37,38]. Also the sleeping time and quality could be improved by cannabis 
use [39], making it a matter of indirect performance enhancing. 
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Moreover, these sedative properties have an impact on the estimation of risks, which 
results in a health risk for both the user and his or her fellow athletes. Indeed, 
especially for team sports, motorized disciplines or equipment handling, an athlete 
under the influence of cannabis may suffer reduced coordination, slowed reaction 
times and can misjudge situations, potentially leading to afflicting injuries upon the 
athlete itself, fellow competitors or even spectators. When using cannabis chronically 
different studies diagnose withdrawal symptoms and other serious health effects 
[37,41]. 
When considering the spirit of sport, the classification of cannabis in most countries 
is an important argument. Cannabis is still illegal in most countries and even in 
countries where its use has been legalized; it is - similar to alcohol use or smoking - 
not encouraged. Hence, the position of the athlete as a role model does not fit with 
the (illegal) status of cannabis. 
4.1 A threshold substance 
To date, these arguments are strong enough to maintain the status of cannabis on 
the Prohibited List. This means that WADA accredited laboratories have the task to 
report a concentration of 11-nor-Δ9-tetrahydrocannabinol-9-carboxylic acid (THCA), 
the major metabolite of cannabis in urine, higher than the decision limit as an 
Adverse Analytical Finding (AAF). The threshold of 15 ng/mL was installed to avoid 
positive testing after passive inhalation of cannabis smoke [39]. For this purpose, in 
our lab, confirmation procedures were developed and improved over time [42–44].  
On May 11 2013, WADA published an update on the Technical Document [45] 
containing a tenfold increase of the threshold concentration for THCA in urine to 150 
ng/mL. It was clear that there was a big discrepancy between the duration of the 
effect – which has an impact in competition – and the time period that out-of-
competition use can be detected. Raising the threshold to 150 ng/mL (decision limit = 
175 ng/ml) aims at reducing the chance for a positive test after (allowed) out-of-
competition use and will probably reduce the high number of AAFs for cannabis. 
Indeed, in 2011 THCA was responsible for 7.9% of all positive findings reported by 
WADA accredited laboratories. 
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Fig. 1.3 Number of positive reported samples for cannabis in DoCoLab 
(threshold 15 ng/mL) until May 1, 2013. 
 
From 2005 to mid-2013, 381 samples were reported positive for cannabis in 
DoCoLab (Fig. 1.3). When it comes to sport disciplines, DoCoLab statistics on the 
last eight years show that the prevalence is higher in team sports like soccer, 
baseball and basketball. Besides these, also in the category of martial arts and 
strength sports cannabis turns out to be more popular (Fig. 1.4). 
When the new threshold of 150 ng/mL, with corresponding decision limit of 175 
ng/mL, is applied for this time period, only 41.2% of this number would still be 
positive. However, changing the threshold entails more. Indeed, although the method 
in force can be maintained for the greater part (sample preparation, chromatographic 
and mass spectrometric conditions), a complete validation procedure should be 
performed in order to use the method for the newly installed threshold. The changes 
imply the adjustment of the range of calibration curves and a new estimation of the 
measurement uncertainty (MU), lower than the maximum combined standard 
uncertainty (uc Max) imposed by WADA [45]. Given the short time period before the 
date of commencement (11 May 2013), validation and implementation of the updated 
methodology should be completed as fast as possible.  
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Fig. 1.4 Distribution of disciplines for positive cannabis samples in DoCoLab 
between 2005 and mid-2013. 
 
4.2 The emergence of synthetic cannabinoids 
The first synthetic cannabinoid - HU-210 - was mentioned on the Prohibited List of 
2010 [46] and on the List of 2011 [47] the definition was extended to the above-
mentioned, covering the broad range of cannabimimetics currently on the market. 
The arguments behind this run parallel to these of classical cannabis, while for the 
cannabimimetics even more importance can be attached to the health risk. Indeed, 
little or no information is available on the (side-)effects of these products on the 
human body (cfr. Chapter 6). Due to their higher potency compared to classical 
cannabis of cannabis sativa, the impact of these synthetic analogues is hard to 
predict and even life-threatening intoxications cannot be ruled out [48–52]. To this day 
the occurrence of synthetic cannabinoids in sports is rather small compared to 
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traditional THC. Indeed, compared to the 398 adverse analytical findings for the latter 
in 2012, only 6 were found positive for JWH-018 and 2 for JWH-073 [53]. 
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The research described in this work is carried out in DoCoLab, the only laboratory 
with WADA accreditation in the Benelux. It is built up around two main objectives and 
copes with the growing challenges in sport drug testing. 
1 Routine screening 
The first part focuses on the improvements made in the routine analysis of urine 
samples. According to WADA’s International Standard for Laboratories [1], for the 
analysis of urine samples a two-step approach is used. The Initial Testing Procedure 
(also ‘screening’) should yield the information on the potential presence of 
substances mentioned on the Prohibited List [2], possibly via its metabolites or 
markers. Any so-called presumptive analytical finding is subsequently referred to a 
Confirmation Procedure, in which a new aliquot is analyzed to obtain more 
information in support of an Adverse Analytical Finding (AAF).  
When a method for screening is developed in DoCoLab, the aim is always to cover 
as many prohibited substances as possible. This has several reasons. It is obvious 
that in terms of efficiency and the analysis costs per sample, reducing the number of 
analytical procedures is the way to go. Moreover, this is also a good evolution in 
terms of sample consumption since the amount of urine available to perform all 
necessary screening (and confirmation) procedures is limited (60 mL in the A-
sample). 
This thesis starts with the introduction of the new GC-MS/MS system in the gas 
chromatography department of the lab. This system was chosen as a successor of 
the older GC-MS systems, based upon its (claimed) good characteristics in terms of 
scan time, selectivity and sensitivity. These properties – which should be evaluated - 
allow for the development of a new GC-screening method incorporating the 
compounds previously screened by GC-MS.  
The new screening method should be able to detect the increasing number of 
compounds and/or corresponding metabolites at decreasing MRPL’s. Additionally, 
the correct quantification of endogenous steroids will become even more important in 
the future, when the steroid module in the Athlete Biological Passport is 
implemented. Therefore, the use and advantages of more and “better” internal 
standards for the construction of calibration curves and monitoring of other quality 
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control aspects should be explored. Concerning the latter, it should be possible to 
follow-up every step of the sample preparation protocol and monitor the factors which 
could potentially influence the measured concentrations of the endogenous steroids. 
In the first part of this thesis, the aim is to evaluate if the GC-MS/MS system is able to 
tackle the abovementioned challenges. Furthermore, attention should be paid to the 
efficiency of the methodology: the new screening method should cover all 
compounds previously screened for by two different GC-MS methods using the 
shortest possible sample turnaround time.  
Similarly, the new GC-MS/MS instrument should be capable of improving existing 
confirmation procedures as well. Therefore research will aim at optimizing both the 
sample preparation part and the instrumental part of the procedure for the 
confirmation of THCA, the main metabolite of cannabis in urine.  
2 Synthetic cannabinoids 
Over the last years several new illicit drugs appeared on the market, complementing 
cannabis in the prohibited group S8. These so-called synthetic cannabinoids are a 
class of substances that is expanding rapidly. Around 2008, these products were 
detected for the first time as additives in smoking mixtures known as ‘Spice’. The 
packages, promised only to containing a few grams of herbal material, pretended to 
be the legal alternatives for the classical cannabis from cannabis sativa. This 
immediately explains their popularity all over the world: producing similar effects, 
these products do not trigger the well-known tests for cannabis abuse in urine [3–5], 
plasma [6] or oral fluid [7] and were for a long time not prohibited. Due to the increased 
abuse of these products, several national and international organizations started 
banning the first known compounds [8,9]. However, from the moment the first 
compounds were added to any list of forbidden drugs, the next herbal mixtures 
turned out to contain new cannabimimetics [10]. This steady increase in the number of 
synthetic cannabinoids - often only slightly chemically modified compared to first 
discovered - makes it hard for controlling instances to follow-up this new 
phenomenon. Furthermore, it is known that these compounds are excessively 
metabolized in the human body [11,12]. Since no parent compound is excreted in urine, 
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knowledge of the metabolism of these cannabimimetics is necessary to design 
screening methods using this matrix. 
Excretion studies are then used to reveal the metabolic pathways of the human body. 
Unfortunately, since for these compounds no pharmacological data are available, 
administering them to humans is ethically questionable. Therefore models are 
developed which allow circumventing this problem and can elucidate the metabolism 
of the compound. In DoCoLab, two different models are developed which could be 
used to tackle this problem. Since metabolism of xenobiotic compounds mainly 
occurs in the liver [13], both models mimic the properties of the human liver in terms of 
metabolomics. 
The in vitro approach uses human liver microsomes (HLM). These sub-cellular 
fractions, isolated from human liver via differential centrifugation, contain the 
enzymes (cytochrome P450) involved in metabolism [13]. This model has the 
advantage that it is fast and easily applicable in analytical laboratories using the 
available equipment. On the other hand, it also contains some weaknesses. Since 
only cell fractions are used, factors like absorption, distribution and excretion are not 
taken into account [14]. Therefore in vivo models are still used to provide additional 
information. To reduce the inter-species differences between the metabolism of test 
animals and that of the human body and better mimic the human metabolism, a 
chimeric mice model was developed in cooperation with the Center for Vaccinology 
(CEVAC). This model was initially developed to study the infection and treatment of 
hepatitis virus [15] and is based on the transplantation of human hepatocytes to uPA-
SCID mice. Therefore mice were used in which overexpression of the urokinase 
plasminogen activator (uPA) caused a chronic liver disease. This functional liver 
deficit creates a growth advantage for liver regeneration by transplanted hepatocytes. 
However, to avoid graft rejection when transplanting human hepatocytes, these mice 
were crossed with “severe immune deficient’’ mice. In that way a uPA-SCID mouse is 
obtained in which successful transplantation of human hepatocytes is possible. 
Previous research on steroid metabolism showed that these mice with humanized 
liver can be a good model for metabolic studies [16]. 
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Fig. 2.1 The DoCoLab strategy: from metabolism investigation towards routine 
implementation. 
 
Both models will be used to investigate the metabolism of some new synthetic 
cannabinoids, i.e. JWH-122 and JWH-200. Starting from the low-complexity model (in 
vitro), it will be tried to identify metabolites for both compounds, which can 
subsequently be confirmed in vivo. Using the in vivo model should also allow 
obtaining information on the phase II metabolism of the given compounds.  
The final aim will be the selection of the most optimal metabolite to implement in the 
existing routine screening methods and in that way make detection of both JWH-122 
and JWH-200 abuse in urine possible (Fig. 2.1).  
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Abstract 
The use of performance enhancing drugs in sports is prohibited. For the detection of 
misuse of such substances gas chromatography or liquid chromatography coupled to 
mass spectrometry are the most frequently used detection techniques. In this work the 
development and validation of a fast gas chromatography tandem mass spectrometric 
method for the detection of a wide range of doping agents is described. 
The method can determine 13 endogenous steroids (the steroid profile), 19-
norandrosterone, salbutamol and 11-nor-Δ9-tetrahydrocannabinol-9-carboxylic acid in 
the applicable ranges and is able to detect qualitatively over 140 substances in 1 mL of 
urine in accordance with the minimum required performance levels of the World Anti-
Doping Agency. The classes of substances included in the method are anabolic 
steroids, beta-2-agonists, stimulants, narcotics, hormone antagonists and modulators 
and beta-blockers. Moreover, by using a short capillary column and hydrogen as a 
carrier gas the run time of the method is less than 8 min. 
Chapter 3: A fast, comprehensive screening method 
35 
1 Introduction 
The use of performance enhancing drugs in sports is prohibited by the World Anti-
Doping Agency and a wide range of pharmacological classes of drugs can be found on 
the Prohibited List [1]. In the framework of the fight against doping, mostly urine samples 
are collected and analysed for the presence of prohibited drugs or metabolites. In 
general, except for peptide hormones, screening for the misuse of doping substances is 
performed using chromatography. Moreover, to combine the necessary selectivity with 
the required sensitivity to detect the different classes of prohibited substances at or 
below the minimum required performance limit (MRPL), hyphenated chromatographic 
mass spectrometric methods are preferred [2]. 
Within the group of low molecular weight doping agents (MW < 1000 Da), the anabolic 
steroids are probably the most challenging and important class. They are the most 
misused substances in doping control [3], they are intensively metabolized in humans 
and have the lowest MRPL [2]. Adequate screening for misuse of these substances 
therefore relies on the detection of metabolites in urine samples collected from athletes 
[4]. 
Most of the studies investigating the metabolism of pharmaceutically available steroids 
were performed in the 1980’s and early 1990’s [5,6]. This research resulted in the 
selection of appropriate metabolites for the detection of steroid misuse. Over the years 
the selection of metabolites was further elaborated to include several metabolites that 
can result in prolonged detection times [7]. Gas chromatography-mass spectrometry 
(GC-MS) was essential as a technique for these findings and was therefore also 
employed to screen doping control samples routinely for the misuse of anabolic steroids. 
GC-MS remained the technology of choice for the detection of anabolic steroids until the 
appearance of tetrahydrogestrinone (THG) as a designer steroid on the underground 
market, which was almost undetectable by the GC-MS screening methods used at that 
time. THG lead to the introduction of liquid chromatography tandem mass spectrometry 
(LC-MSn) as a screening technology in doping control laboratories. As a result GC-MS 
and LC-MS are now used as complementary techniques in doping control [8–10].  
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Besides anabolic steroids, GC-MS is also routinely applied for many other groups of 
doping agents. Particularly for stimulants and narcotics, GC-MS is still the most 
employed technology [11,12]. 
For routine purposes quadrupole GC-MS methods are normally used in the selected ion 
monitoring mode (SIM) for anabolic steroids and in full scan or a combination of 
SIM/scan for narcotics and stimulants. SIM-methods monitor a limited number of m/z-
values (typical for a substance) rather than a range of m/z-values (full scan mode). 
Although less structural information is obtained in the SIM mode, in this way higher 
sensitivity is achieved, which is typically required for anabolic agents. Most screening 
methods for the detection of anabolic steroids have a run time of 20-35 minutes [13,14]. In 
the past several fast tandem mass spectrometric methods, using ion trap technology, 
have been published. However, these methods normally lacked the combination of a 
quantitative determination of the steroid profile (a range of endogenous steroids 
monitored to detect use of natural steroids) and a qualitative analysis of a wide range of 
exogenous steroids and other doping agents [15,16]. 
In this paper the use of a gas chromatograph coupled to a triple quadrupole mass 
spectrometer for the detection of a wide range of exogenous anabolic steroids and other 
doping agents as well as the determination of a full steroid profile within a single run of 
less than 10 minutes was investigated. 
2 Material and methods 
2.1 Reagents 
N-Methyl-N-(trimethylsilyl)trifluoroacetamide (MSTFA) was purchased from Chem. 
Fabrik Karl Bucher (Waldstedt, Germany) and the enzyme preparation β-glucuronidase 
from E. coli K12 was obtained from Roche Diagnostics GmbH (Mannheim, Germany). 
Diethyl ether was purchased from Acros (Geel, Belgium), methanol and sodium 
hydrogen carbonate (NaHCO3) from Fisher Scientific (Loughborough, UK), potassium 
carbonate (K2CO3), disodium hydrogen phosphate (Na2HPO4), sodium dihydrogen 
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phosphate (NaH2PO4), and sodium sulphate (Na2SO4) were all from Merck (Darmstadt, 
Germany). 
The phosphate buffer (pH 7) was prepared by dissolving 7.1 g Na2HPO4.2H2O and 1.4 g 
NaH2PO4.H2O in 100 mL water. The carbonate buffer (pH=9.5) was prepared by 
dissolving 135 g K2CO3 and 111 g NaHCO3 in 900 aqua bidest. 
2.2 Reference standards 
2.2.1 Internal standards 
D3-testosterone glucuronide (d3-T-gluc), d3-epitestosterone glucuronide (d3-E-gluc), 
d4-androsterone glucuronide (d4-A-gluc), d5-etiocholanolone (d5-Etio), d3-
dihydrotestosterone glucuronide (d3-DHT-gluc), d3-5α-androstane-3α,17β-diol (d3-ααβ-
Adiol), d5-5β-androstane-3α,17β-diol (d5-βαβ-Adiol) and d3-salbutamol (d3-Sal) were 
from NMI (Pymble, Australia). 17α-methyltestosterone (MT) was a kind gift from 
Organon (Oss, The Netherlands). A mixture was made in methanol containing 2 µg/mL 
d4-A-gluc, d5-Etio and d3-Sal, 1 µg/mL d3-ααβ-Adiol, d5-βαβ-Adiol and MT, 1.2 µg/mL 
d3-T-gluc, 0.3 µg/mL d3-E-gluc and 0.4 µg/mL d3-DHT-gluc. 
2.2.2 Natural steroids 
Testosterone, epitestosterone, androsterone, etiocholanolone, 11β-
hydroxyandrosterone (11β-OH-androsterone), 11β-hydroxyetiocholanolone (11β-OH-
etiocholanolone), 5α-androstane-3α,17β-diol, 5α-androstane-3β,17β-diol, 5β-
androstane-3α,17β-diol, 4-androstene-3,17-dione, 5β-androstane-3,17-dione and 5α-
androstane-3,17-dione were obtained from Sigma (Bornem, Belgium), 19-
norandrosterone from NMI (Pymble, Australia), dehydroepiandrosterone (DHEA) from 
Serva (Heidelberg, Germany) and dihydrotestosterone (DHT) from Piette International 
Laboratories (Drogenbos, Belgium). 
2.2.3 Exogenous steroids 
3α-Hydroxytibolone (tibolone metabolite) was a kind gift from Akzo Nobel (Oss, The 
Netherlands), fluoxymesterone was obtained from Ciba-Geigy, boldenone and 
oxymesterone were purchased from the Institut für Biochemie of the Deutsche 
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Sporthochschule (Cologne, Germany). 3α,5α-tetrahydronorethisterone, was a kind gift 
from the Institute of Organic Chemistry and Biochemistry (Academy of Sciences of the 
Czech Republic, Prague, Czech Republic) and metenolone from the Drug Control 
Centre of King’s College (London, UK). 
16α-OH-furazabol, 16α-OH-stanozolol, 17α-ethyl-5α-estrane-3α,17β-diol, 17α-ethyl-5β-
estrane-3α,17β-diol, 17α-methyl-5α-androstane-3α,17β-diol, 17α-methyl-5β-androstane-
3α,17β-diol, 17α-trenbolone, 17β-hydroxy-17α-methyl-5α-androst-1-ene-3-one, 1α-
methyl-5α-androstan-3α-ol-17-one, 1-methylene-5α-androstan-3α-ol-17-one, 1-
testosterone, 2α-hydroxymethyl-17α-methyl-1,4-androstadiene-11α,17β-diol-3-one, 2α-
hydroxymethylethisterone, 2α-methyl-5α-androstan-3α-ol-17-one, 4-chloro-4-androsten-
3α-ol-17-one, 4-OH-testosterone, 5β-androst-1-en-17β-ol-3-one, 5α-Androst-1-ene-
3β,17β-diol, 6β-hydroxy-dehydrochloromethyltestosterone, 6β-hydroxyfluoxymesterone, 
6β-hydroxymethandienone, epimetendiol, 7β,17α-dimethyl-5β-androstane-3α,17β-diol, 
7β,17α-dimethyl-5β-androstane-3α,17β-diol, 9α-fluoro-17,17-dimethyl-18-nor-androstan-
4,13-diene-11β-ol-3-one, 9α-fluoro-17α-methyl-4-androsten-3α,6β,11β,17β-tetra-ol, 
dehydrochloromethyltestosterone, epioxandrolone, methyldienolone, 13,17α-diethyl-
5β-gonane-3α,17β-diol, 13,17α-diethyl-5α-gonane-3α,17β-diol, oxabolone were 
purchased from NMI (Pymble, Australia). Oxandrolone was a gift from Searle & Co 
(Chicago, Ill, USA), 1-androstene-3,17-dione, 4-androstene-17α-methyl-11α,17β-diol-3-
one, 7β-OH-DHEA, calusterone and mibolerone were from Steraloids (Newport, RI, 
USA). Madol and 2α,17α-dimethyl-17β-hydroxy-5α-androstan-3-one were bought from 
TRC (Toronto, Canada). Bolasterone was a gift from Upjohn and danazol from Withrop. 
2.2.4 Narcotics 
11-nor-Δ9-tetrahydrocannabinol-9-carboxylic acid, normethadone, ((±)-2-ethyl-1,5-
dimethyl-3,3-diphenylpyrrolinium perchlorate (EDDP), fentanyl, norfentanyl, 
fenbutrazate, buprenorphine, morphine, codeine, ethylmorphine, 6-monoacetylmorphine 
(6-MAM), oxymorphone were purchased from Cerilliant. Pethidine, hydromorphone, 
oxycodone, heroin, dextromoramide and methadone were bought from Sigma (Bornem, 
Belgium). Pentazocine was a gift from Whintrop Laboratories (Newcastle, United 
Kingdom). 
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2.2.5 Stimulants 
Pipradrol and pemoline were gifts from Merrell-Dow (Cincinnati, OH, USA) and 
Boehringer-Ingelheim (Brussels, Belgium), respectively. Cocaine and benzoylecgonine 
were purchased from Cerilliant. Fenethylline was a gift from Chemiwerk Hamburg 
(Germany) and methylphenidate from Ciba-Geigy (Groot-Bijgaarden, Belgium). 
Fencamine was obtained from Laboratoires Miquel S.A. (Barcelona, Spain), fenspiride 
from Laboratoires Servier (Orléans, France) and amineptine and amineptine C5 
metabolite from Laboratoires Servier (Orleans, France). Strychnine and fencamfamine 
were donated by Merck. Carphedon, 6-OH-bromantan, crotethamide, cropropamide, 
cyclazodone and famprofazone were bought from NMI. Dimefline was from Recordate 
Industria Chemica & Farmaceutica (Milan, Italy) and furfenorex and clobenzorex from 
Roussel Uclaf (Romainville, France). Amiphenazole and octopamine were purchased 
from Sigma (Bornem, Belgium), while ethamivan, chloorphentermine and 
benzphetamine were gifts from Sinclair Pharmaceuticals (Godalmings, UK), Tropon 
Werke (Cologne) and Upjohn (Kalamazoo, USA), respectively 3,3-diphenylamine and 
prenylamine were gifts from the World Association of Anti-Doping Scientists (WAADS). 
2.2.6 Beta-blockers 
Beta-blockers obtained as reference substances were: acebutolol from Rhone-Poulenc 
(Brussels, Belgium), alprenolol from Astra Chemicals (Holstein, Germany), propranolol 
from ICI (Kortenberg, Belgium), betaxolol from Synthelabo (Brussels, Belgium), labetolol 
from Glaxo (Brussels, Belgium), metoprolol from Ciba-Geigy, nadolol from Squibb 
(Braine l’Alleud, Belgium), oxprenolol from CIBA (Dilbeek, Belgium), pindolol from 
Sandoz (Vilvoorde, Belgium), sotalol from Pfizer, timolol from MSD (Brussels, Belgium), 
bisoprolol from Merck (Overijse, Belgium), carvedilol from Roche (Mannheim, Germany). 
Levobunolol (l-bunolol), esmolol were a kind gift from the South African Doping Control 
Laboratory. Carteolol was a gift from the Portuguese Doping Control Laboratory. The 
following products were extracted from therapeutical preparations: celiprolol (Selectol, 
Pharmacia, Brussels, Belgium) and metipranolol (Beta-Ophtiole, Tramedic, Sint-Niklaas, 
Belgium).  
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2.2.7 Beta-2-agonists 
Salbutamol, terbutaline and clenbuterol were purchased from RIVM. Salmeterol 
xinafoate was a gift from GlaxoSmithKline (Philadelphia, PA, USA). Fenoterol was a gift 
from Boehringer & Sohn (Ingelheim am Rhein and formoterol from Novartis (Arnhem, 
The Netherlands). Bambuterol was donated by the Instituto Nacional do Desporto 
(Lisbon, Portugal). 
2.2.8 Hormone antagonists and modulators 
Anastrazole, toremifene, exemestane, 17β-hydroxy-6-methylene-androsta-1,4-diene-3-
one (exemestane metabolite), were generous gifts from Astra Zeneca (Macclesfield, 
UK), WAADS, Pfizer (Groton, UK) and the Faculty of Pharmacy of the Helsinki 
University (Helsinki, Finland), respectively. 6α-OH-androstenedione, 4-OH-
androstenedione (formestane), 4-hydroxycyclofenil, 3-hydroxy-4-methoxytamoxifen and 
bis-(4-cyanophenyl)methanol (Letrozole metabolite) were purchased from NMI. 4-OH-
tamoxifen was bought from Sigma-Aldrich. 
2.2.9 Other substances 
Zilpaterol and zeranol were purchased from NMI, probenecid from Federa (Brussels, 
Belgium) and 5-hydroxypentoxyfylline (5-OH-pentoxyfylline) from Hoechst (Frankfurt, 
Germany) 
2.2.10 Excretion urines 
Excretion urines from the stimulants prolintane (Catovit®) and sibutramine (Reductil®) 
were obtained after the controlled administration of an oral therapeutic dose (10 mg 
each) to healthy volunteers, which had given written consent, and were provided by 
other doping control laboratories. The samples were stored at -20°C awaiting analysis. 
Steroid stripped urine was prepared by bringing urine from children over an XAD-2 
(Serva, Heidelberg, Germany) column which was conditioned with methanol and water. 
The obtained steroid stripped urine was subsequently tested for the presence/absence 
of endogenous steroids. 
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2.3 Sample preparation 
To 1 mL of urine, 50 µl of the internal standard mixture, 1 mL phosphate buffer (pH=7.0) 
and 50 µl of β-glucuronidase from E. coli were added. The samples were incubated for 
1.5h at 56°C. 1 mL of a liquid mixture NaHCO3/K2CO3 (pH=9.5) and 5 mL of diethyl ether 
were added to hydrolyzed urine samples and extracted for 20 minutes by rolling. The 
organic layer was evaporated to dryness under oxygen free nitrogen (OFN) at room 
temperature.  
To the dried residues, 20 µl of acetonitrile was added, followed by derivatisation for 1 h 
at 80°C with 100 µl MSTFA/ethanethiol/NH4I (500:4:2). 
2.4 Instrumentation 
An Agilent (Agilent Technologies, Palo Alto, USA ) model GC 7890 gas chromatograph 
coupled with an Agilent 7000A triple quadrupole mass spectrometer (Agilent 
Technologies) and a MPS2 autosampler and PTV-injector from Gerstel (Mülheim an der 
Ruhr , Germany) were used.  
The GC was equipped with a 12.5 m capillary column (HP-Ultra 1, column length 
12.5m×0.2mm with a 0.11μm film thickness) from J&W Scientific (Agilent Technologies, 
USA).  
The column temperature was programmed as follows: the initial temperature was 100°C 
(0.2 min), 90°C/min185°C, 9°C/min230°C, 90°C/min310°C (0.95 min). The 
transfer line was maintained at 310°C. Hydrogen (α-gas1, Airliquide, Desteldonk, 
Belgium) was used as a carrier gas at a flow rate of 1 mL/min. 
Five µl was injected and the PTV-injector settings were 100°C (0.15min), 
12°C/s280°C. 
Helium was used as a quench gas at a flow of 2.25 mL/min and nitrogen as a collision 
gas at a flow of 1.5 mL/min.  
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2.5 Method validation 
2.5.1 Quantitative 
Six point calibration curves were made by spiking steroid stripped urine samples (3 
replicates per concentration). Unweighted least squares regression was used to 
construct the calibration curves. 
Accuracy and precision (repeatability) of the method were subsequently tested at every 
level (n=6). Acceptable tolerances (%) for precision were calculated from 2/3RSDmax = 
2(1-0.5logC) [17]. Tolerances for the accuracy -expressed as bias- were set at a maximum 
15% [18].  
Additionally, 50 urine samples were analyzed using the traditional method on a single 
quadrupole instrument and on the triple quadrupole instrument. 
2.5.2 Qualitative analysis 
The method validation was performed according the Eurachem guidelines [19] on 10 
different, randomly chosen urine samples. 
To determine the limits of detection (LOD), 10 different urine samples were spiked with 
reference mixtures at different levels in the concentration range of 0.05, 0.1, 0.2, 0.5, 1 
and 2 times the MRPL level. The LOD was defined as the lowest concentration at which 
a substance can be detected in all samples analysed (n = 10). Repeatability was 
assessed through the analysis of multiple samples spiked at different levels during the 
determination of the LOD. Selectivity and specificity were tested by the analysis of blank 
urine samples. 
3 Results and discussion 
3.1 Sample preparation 
One of the main difficulties for doping control laboratories is that the methods used need 
to be able to detect very low levels of a wide variety of prohibited substances in a small 
volume of a dirty matrix (predominantly urine). Indeed, the volume of urine delivered to 
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laboratories is currently 60 mL [20]. This amount needs to be sufficient for laboratories to 
screen for and eventually confirm (using a totally independent analysis) the presence of 
any prohibited substance. Therefore methods used in doping control laboratories need 
to be able to detect a wide variety of substances in as little urine as possible. The 
method in this work only uses 1 mL of urine for the screening of a wide range of doping 
agents. In general the volume is 2-5 times lower than the volume normally used for 
screening methods for anabolic steroids [13–16] and therefore constitutes a drastic 
reduction thanks to the PTV-injection. This is useful since in doping control a limited 
amount of urine is available for screening and confirmation of a wide range of 
substances. 
The developed method is very comprehensive. Only a few anabolic agents for which 
GC-MS is not particularly suitable (e.g. tetrahydrogestrinone, methyltrienolone, 
stanozolol) and for which LC-MS offers a valuable alternative [21] are not included in the 
current method. The method also includes one or more metabolites of all prohibited 
narcotics, the most frequently used beta-2-agonists and hormone antagonists and 
modulators and beta-blockers. Additionally, the method contains a high number of 
stimulants and several substances from all other groups of prohibited substances 
(except peptide hormones and glucocorticosteroids).  
The method encorporates a high number of quality assurance measures which cover the 
three basic steps in sample preparation: hydrolysis, extraction and derivatisation.  
The use of a high amount of β-glucuronidase allows for an efficient hydrolysis after 1.5h 
at 56°C. Moreover, the use of both glucuronidated and free steroids with similar 
structure (d4-A-gluc, d5-Etio) allows for an adequate evaluation of hydrolysis efficiency.  
By using a diverse mixture of internal standards, the differences in physicochemical 
properties, possibly leading to changes in extraction efficiency of the broad spectrum of 
target compounds in the current method is covered. This has several important benefits, 
besides the obvious advantages for the quantitation of the non-deuterated structural 
analogues. 
The inclusion of transitions for mono-TMS derivatised androsterone and etiocholanolone 
in the method additionally allows for the evaluation of the derivatisation efficiency.  
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Hence, this integrated approach allows for a comprehensive evaluation of the sample 
preparation efficiency per sample (rather than per batch or solely at the time of 
validation) since all major sample preparation steps are monitored. 
To evaluate possible microbiological sample degradation, 5α-androstane-3,17-dione and 
5β-androstane-3,17-dione are monitored. This is important since microbiological 
degradation can affect the steroid profile (the combination of endogenous steroids 
quantified to detect misuse with natural steroids). In cases where elevated 
concentrations of 5α-androstane-3,17-dione or 5β-androstane-3,17-dione are detected, 
particular care must be taken in the evaluation of the steroid profile.  
3.2 Gas chromatography 
The aim of this study was to develop a fast GC-MS/MS method, capable of quantifying 
the endogenous steroids given in Table 3.1 and at the same time detecting a wide range 
of other substances qualitatively. Sufficient resolution between compounds is a 
prerequisite for adequate quantitation. In this method, the separation of the isomers 
androsterone and etiocholanolone, present at relatively large concentrations (Table 3.1), 
and to a minor extent the other isomers (11β-OH-A and 11β-OH-Etio and 5ααβ-Adiol 
and 5βαβ-Adiol) put restrictions on chromatographic speed and injected volumes. 
Nevertheless, in this method 5 µl of sample could be injected using a PTV-injector. This 
is substantially higher than in previous methods using split/splitless injection [22]. 
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Table 3.1. Target substances for a quantitative analysis 
 
Substance 
Internal 
standard 
calibrators (ng/mL) 
Correlation 
coefficient (r2) 
testosterone d3-T-gluc 2-5-20-50-100-200 0.9918 
epitestosterone d3-E-gluc 2-5-20-50-100-200 0.9933 
androsterone d4-A-gluc 48-120-600-1200-2400-4800 0.9903 
etiocholanolone d5-E 48-120-600-1200-2400-4800 0.9716 
11β-OH-androsterone d4-A-gluc 40-100-500-1000-2000-4000 0.9769 
11β-OH-etiocholanolone d5-E 40-100-500-1000-2000-4000 0.9877 
dihydrotestosterone d3-DHT-gluc 4-10-40-100-200-400 0.9755 
dehydroepiandrosterone d3-DHT-gluc 4-10-40-100-200-400 0.9927 
4-androstene-3,17-dione d3-DHT-gluc 4-10-40-100-200-400 0.9908 
5α-androstane-3α,17β-diol d3-ααβ-Adiol 4-10-40-100-200-400 0.9841 
5β-androstane-3α,17β-diol d5-βαβ-Adiol 4-10-40-100-200-400 0.9603 
5α-androstane-3β,17β-diol d3-ααβ-Adiol 4-10-40-100-200-400 0.9933 
5α-androstane-3,17-dione MT 4-10-40-100-200-400 0.9975 
5β-androstane-3,17-dione MT 4-10-40-100-200-400 0.9853 
19-norandrosterone MT 1-3-5-10-15-20 0.9902 
salbutamol d3-Sal 100-300-500-1000-1500-2000 0.9807 
THCA MT 5-15-25-50-75-100 0.9862 
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Table 3.2 shows the final instrumental settings of the mass spectrometer for the 
investigated target analytes. 
3.4 Method validation 
3.4.1 Quantitative  
The substances included in the quantitative part of the method include those steroids 
traditionally used in doping control to establish the use of a prohibited substance (T, E, 
A, Etio, DHT, DHEA, Adion, 5ααβ-Adiol, 5βαβ-Adiol). Additionally the method monitors 
other endogenous steroids which are not affected by the intake of natural anabolics 
(11bOH-A and 11b-OH-Etio) as well as markers of microbiological degradation (5α-
androstanedione and 5β-androstanedione). The inclusion of these parameters can 
greatly assist in the evaluation process of atypical steroid profiles due to increased 
production of endogenous steroids or alteration by microbiological degradation. Besides 
these steroids the method also quantifies salbutamol, the most widely used beta-2-
agonist, norandrosterone and the major metabolite of cannabis (11-nor-Δ9-
tetrahydrocannabinol-9-carboxylic acid, THCA). 
Although large differences in calibration ranges exist between the monitored 
compounds, correlation coefficients of 6-point calibration curves (3 replicates per 
calibrator) made in steroid stripped urine were acceptable. Additional analysis revealed 
that the residual standard deviations at every point of the calibration curves were lower 
than 2/3 of the maximum residual standard deviation as calculated by Horwitz. 
Moreover, the bias at each of these points was below 15%, showing acceptable 
accuracy as well. Therefore, in agreement with Eurachem guidelines, the method can be 
regarded as validated for quantitative purposes. 
A comparison between the traditionally used GC-MS method in selected ion monitoring 
and the new methodology using selected reaction monitoring (SRM) for the testosterone 
to epitestosterone ratio is shown in Fig. 3.2. These results indicate an excellent 
correlation (r2=0.95) and comparability (slope is almost equal to 1) between both 
methodologies. 
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Fig. 3.2. Testosterone to epitestosterone ratio (T/E) in 50 urine samples using a single quadrupole mass 
spectrometer in Selected Ion Monitoring (SIM) and using a triple quadrupole mass spectrometer in 
selected reaction monitoring (SRM). 
 
3.5 Qualitative analysis 
The method validation for the non-threshold substances was also performed in 
accordance with Eurachem guidelines. Selectivity was tested by analyzing ten blank 
urine samples and verifying that there were no matrix interferences. Additionally these 
samples were spiked at different concentration levels. The lowest concentration at which 
concurrent signals (S/N>3) for each monitored transition were obtained at the expected 
retention time (± 1%) in all samples was assigned as the lower limit of detection (LOD). 
These LODs for the exogenous substances are given in Table 3.2. The method 
comprises 41(metabolites) of anabolic steroids, 4 other anabolic agents, 6 beta-2-
agonists, 11 hormone antagonists and modulators, 19 narcotics, 16 stimulants and 15 
beta-blockers. 
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It should be noted that in some cases, the observed LOD for a metabolite exceeds 
WADA’s MRPL. For these substances, the method was regarded as non-validated, 
although they remained part of the method. For all such cases, the method includes 
another metabolite (of the same parent drug) that has an LOD at or below the MRPL. 
This is the case for e.g. fluoxymesterone: the LOD for 6β-hydroxyfluoxymesterone 
(Table 3.2) is 20 ng/mL, while WADA’s MRPL is set at 10 ng/mL. However, the LOD of 
9α-fluoro-17,17-dimethyl-18-nor-androstan-4,13-diene-11β-ol-3-one, another 
fluoxymesterone metabolite, is compliant with the MRPL. Because - except for a few 
substances - WADA’s technical document does not specify which metabolites need to 
be monitored, the method can therefore still be considered as WADA-compliant for the 
detection of fluoxymesterone. Moreover the detection of multiple metabolites instead of 
a single metabolite to determine misuse of a doping agent has multiple advantages. 
Firstly, it can provide additional supporting evidence for misuse since in most cases the 
concentration in a “positive” sample will be clearly above the MRPL. Additionally, the 
inclusion of multiple metabolites can assist in the detection of a prohibited substance at 
different time points after use. Indeed, it is widely known that the excretion profile of 
metabolites is time and inter-individual dependent. Therefore, a metabolite which is the 
major metabolite in one individual after a definite post-administration time, might only be 
a minor metabolite in another individual which took the drug at another point in time. The 
current method is also capable of detecting all compounds from the class of “other 
anabolic agents”, except the group of selected androgen receptor modulators for which it 
was not tested, as these compounds are still in clinical phase trials. 
 
Table 3.2. Substances (as TMS-enol-TMS ether derivatives) included in the method 
according to WADA prohibited class, instrument settings, limit of detection and 
applicable minimum required performance limit (MRPL). 
class RT (min) substance transitions 
collision 
energy 
(eV) 
LOD 
(ng/mL) 
MRPL
(ng/mL
) 
S
1a
 
4.14 5-androst-1-en-17-ol-3-one 432.0 -> 194.0 15 5 10 
432.0 -> 206.0 15 
5.32 Boldenone 
430.0 -> 206.0 10 
10 10 
430.0 -> 191.0 30 
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5.09 1-Androstenediol 
434.0 -> 195.0 20 
5 10 
434.0 -> 127.0 20 
5.05 1-testosterone 
432.0 -> 194.0 5 
10 10 
432.0 -> 206.0 10 
5.09 17-methyl-5-androstane-3,17-diol 435.0 -> 255.0 20 2 2 
435.0 -> 213.0 20 
5.12 17-methyl-5-androstane-3,17-diol 435.0 -> 255.0 20 5 2 
435.0 -> 213.0 20 
6.7 oxymesterone 
534.0 -> 389.0 20 
10 10 
534.0 -> 444.0 20 
4.15 epimetendiol 
358.0 -> 301.0 15 
2 2 
358.0 -> 196.0 5 
6.57 6-hydroxymethandienone 517.0 -> 229.0 20 5 10 
517.0 -> 337.0 15 
5.63 Metenolone PC 
446.0 -> 208.0 10 
5 10 
446.0 -> 195.0 15 
4.92 1-Methylene-5-androstan-3-ol-17-one  (metenolone metab) 
446.0 -> 341.0 15 
20 10 
446.0 -> 195.0 5 
5.64 17-Ethyl-5-estrane-3,17-diol  (norethandrolone major metab) 
421.0 -> 241.0 15 
10 10 
421.0 -> 331.0 5 
5.4 17-Ethyl-5-estrane-3,17-diol  (norethandrolone minor metab) 
421.0 -> 241.0 15 
5 10 
421.0 -> 145.0 25 
4.77 2-methyl-5-androstan-3-ol-17-one  (drostanolone metab) 
448.0 -> 433.0 10 
10 10 
448.0 -> 253.0 25 
6.05 Bolasterone PC 
460.0 -> 355.0 15 
10 10 
460.0 -> 315.0 15 
5.62 717-dimethyl-5-androstane-3,17-diol  (bolasterone metab) 
284.0 -> 269.0 5 
10 10 
284.0 -> 213.0 10 
6.13 Calusterone PC 
460.0 -> 355.0 15 
10 10 
460.0 -> 315.0 15 
5.45 717-dimethyl-5-androstane-3,17-diol  (calusterone metab) 
229.0 -> 105.0 30 
/ 10 
269.0 -> 159.0 5 
5.07 1-Methyl-5-androstan-3-ol-17- one  (mesterolone metab) 
448.0 -> 433.0 10 
5 10 
448.0 -> 253.0 20 
5.63 4-Chloro-4-androsten-3-ol-17-one  (clostebol metab) 
466.0 -> 181.0 20 
10 10 
466.0 -> 431.0 15 
6.47 norclostebol 
452.0 -> 216.0 20 
2 10 
452.0 -> 321.0 15 
6.67 fluoxymesterone PC 
552.0 -> 407.0 15 
/ 10 552.0 -> 357.0 15 
552.0 -> 319.0 15 
6.93 6-OH-fluoxymesterone 640.0 -> 640.0 10 20 10 
640.0 -> 143.0 25 
5.04 9-fluoro-17,17-dimethyl-18-nor-androstan-4,13-diene-11-ol-3-one 
462.0 -> 208.0 15 
5 10 
462.0 -> 337.0 15 
6.17 oxandrolone 
363,0 -> 161,0 15 
10 10 
308.0 -> 117.0 15 
5.56 epioxandrolone 
363,0 -> 161,0 15 
20 10 
308.0 -> 117.0 15 
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6.68 dehydrochloromethyltestosterone PC 
478.0 -> 285.0 20 
10 10 
478.0 -> 353.0 5 
6.82 6-hydroxy-dehydrochloromethyltestosterone 315.0 -> 227.0 20 20 10 
315.0 -> 241.0 15 
5.19 17-trenbolone 307.0 -> 291.0 10 10 10 
307.0 -> 275.0 20 
7.1 2-Hydroxymethyl-17-methylandrostadiene-11,17-diol-3-one (formebolone metab) 
444.0 -> 356.0 25 
/ 10 
367.0 -> 257.0 25 
6.48 17-methyl-4-androstene-11,17-diol-3-one  (formebolone metab) 
534.0 -> 389.0 15 
10 10 
534.0 -> 339.0 25 
5.85 mibolerone 
446.0 -> 431.0 15 
10 10 
446.0 -> 341.0 20 
6.14 ethisterone 
456.0 -> 316.0 15 
1 10 
456.0 -> 301.0 15 
4.76 3,5-tetrahydronorethisterone 431.0 -> 167.0 20 2 10 
431.0 -> 193.0 20 
7.11 16-OH-furazabol 
490.0 -> 231.0 15 
10 10 
490.0 -> 143.0 35 
5.94 methyldienolone 
430.0 -> 285.0 10 
10 10 
430.0 -> 325.0 10 
5.97 13,17-diethyl--gonane-3, 17-diol  (norbolethone metab) 
435.0 -> 255.0 10 
20 10 
435.0 -> 159.0 15 
6.14 13,17-diethyl--gonane-3, 17-diol  (norbolethone metab) 
435.0 -> 255.0 20 
5 10 
435.0 -> 345.0 5 
3.68 madol 
345.0 -> 255.0 15 
10 10 
345.0 -> 201.0 15 
6.11 217-dimethyl-17-hydroxy-5-androstane-3-one 462.0 -> 141.0 15 10 10 
462.0 -> 143.0 15 
6.27 4-OH-nandrolone  (oxabolone) 
506.0 -> 147.0 20 
2 10 506.0 -> 93.0 25 
506.0 -> 195.0 20 
6.48 4-OH-testosteron 
520.0 -> 225.0 15 
2 10 
520.0 -> 431.0 15 
6.33 6-OH-androstenedione 
518.0 -> 319.0 15 
1 10 
518.0 -> 413.0 15 
5.19 7-OH-DHEA 430.0 -> 325.0 10 20 10 
430.0 -> 220.0 10 
s1
b 
4.04 19-norandrosterone 
405.0 -> 225.0 10 
1 2 
405.0 -> 315.0 5 
4.12 5-Androstane-3,17-dione 290.0 -> 275.0 10 
EAAS / 
290.0 -> 185.0 10 
4.64 5-androstane-3,17-diol 256.0 -> 185.0 15 
256.0 -> 157.0 15 
4.71 5-androstane-3,17-diol 256.0 -> 185.0 15 
256.0 -> 157.0 15 
4.58 androsterone 
239.0 -> 167.0 35 
239.0 -> 117.0 35 
4.63 etiocholanolone 
239.0 -> 167.0 35 
239.0 -> 117.0 35 
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5.09 5-Androstan-3,17-dione 290.0 -> 275.0 10 
290.0 -> 185.0 10 
4.98 DHEA 
432.0 -> 327.0 10 
432.0 -> 237.0 10 
5.14 epitestosterone 
432.0 -> 209.0 10 
432.0 -> 327.0 10 
5.13 5-androstane-3,17-diol 421.0 -> 255.0 20 
421.0 -> 213.0 20 
5.29 4-androstenedione 
430.0 -> 209.0 15 
430.0 -> 234.0 15 
5.24 DHT 
434.0 -> 195.0 20 
434.0 -> 182.0 20 
5.41 testosteron 
432.0 -> 209.0 10 
432.0 -> 327.0 10 
5.52 11-OH-androsterone 522.0 -> 236.0 10 
522.0 -> 324.0 10 
5.6 11-OH-etiocholanolone 522.0 -> 236.0 10 
522.0 -> 324.0 10 
4.13 Mono TMS Androsterone 347.0 -> 253.0 20 qas / 
S
1c
 
3.37 zilpaterol 
308.0 -> 218.0 10 
5 10 308.0 -> 203.0 15 
291.0 -> 219.0 15 
6.43 zeranol 
433.0 -> 295.0 15 
10 10 
433.0 -> 309.0 15 
2.42 clenbuterol 
335.0 -> 227.0 10 
0,2 2 
335.0 -> 300.0 10 
5.37 3-hydroxytibolone  443.0 -> 193.0 35 5 10 
443.0 -> 167.0 30 
S3
 
2.17 salbutamol 
369.0 -> 207.0 15 
25 100 
369.0 -> 191.0 15 
1.96 terbutaline 
356.0 -> 267.0 25 
50 100 
356.0 -> 355.0 25 
6.07 fenoterol  
322.0 -> 68.0 15 
100 100 
322.0 -> 279.0 15 
6.6 fenoterol C,N-methylene 
308.0 -> 207.0 15 
/ 50 
308.0 -> 179.0 15 
6.73 formoterol 
178.0 -> 121.0 20 
50 100 
178.0 -> 135.0 20 
7.82 salmeterol 
311.0 -> 149.0 15 
100 100 
311.0 -> 121.0 25 
5.02 bambuterol 
354.0 -> 72.0 25 
5 100 
354.0 -> 282.0 10 
S
4 
3.63 aminogluthetimide deriv.1 
361.0 -> 206.0 30 
5 50 
361.0 -> 221.0 10 
5.26 aminogluthetimide deriv.2 
580.0 -> 551.0 20 
/ 50 
580.0 -> 519.0 20 
3.16 anastrazole 
293.0 -> 70.0 10 
50 50 
293.0 -> 209.0 15 
3.17 letrozole metabolite 291.0 -> 160.0 15 2,5 50 
Chapter 3: A fast, comprehensive screening method 
53 
291.0 -> 217.0 20 
6.94 exemestane PC 
441.0 -> 307.0 20 
/ 50 
441.0 -> 193.0 20 
6.94 17-hydroxy-6-methylene-androsta-1,4-diene-3-one  443.0 -> 207.0 20 25 50 
443.0 -> 193.0 20 
6.43 4-OH-androstene-3,17-dione  (formestane) 
518.0 -> 221.0 15 
2 10 
518.0 -> 190.0 10 
6.57 toremifene 
405.0 -> 58.0 15 
25 50 
405.0 -> 72.0 5 
6.86 4-hydroxy-methoxytamoxifen 1 
489.0 -> 72.0 5 
25 50 
489.0 -> 58.0 15 
7.02 4-hydroxy-methoxytamoxifen 2 
489.0 -> 72.0 5 
25 50 
489.0 -> 58.0 15 
5.78 4-OH-tamoxifen 
459.0 -> 72.0 5 
2,5 50 
459.0 -> 58.0 15 
7.74 raloxifene 
578.0 -> 193.0 35 
25 50 
578.0 -> 413.0 30 
6.57 4-OH-cyclofenil 
512.0 -> 422.0 10 
2,5 50 
512.0 -> 343.0 5 
S
5 
3.13 probenecid 
328.0 -> 103.0 25 
12,5 250 
328.0 -> 193.0 15 
S6
 
2.16 carphedon 
272.0 -> 104.0 25 
50 500 
272.0 -> 229.0 15 
4.98 6-OH-bromantan 
395.0 -> 91.0 30 
2,5 500 
393.0 -> 91.0 30 
2.08 pemoline 
178.0 -> 104.0 10 
5 500 
392.0 -> 178.0 10 
2.28 octopamine 
174.0 -> 86.0 5 
100 500 426.0 -> 206.0 15 
426.0 -> 179.0 15 
7.14 strychnine 
316.0 -> 144.0 15 
100 200 
316.0 -> 220.0 10 
1.37 crotethamide 
154.0 -> 86.0 10 
50 500 
154.0 -> 69.0 15 
1.97 ethamivan 
295.0 -> 223.0 25 
50 500 
295.0 -> 265.0 20 
1.36 fencamfamine 
215.0 -> 186.0 5 
50 500 
215.0 -> 98.0 15 
4.24 fenspiride 
241.0 -> 96.0 10 
25 500 
241.0 -> 154.0 10 
4.65  prenylamine 
238.0 -> 58.0 20  
50 
 
500 238.0 -> 91.0 20 
1.94  clobenzorex 
168.0 -> 125.0 20  
100 
 
500 168.0 -> 89.0 35 
2.51  cyclazodone 
360.0 -> 178.0 15  
10 
 
500 360.0 -> 247.0 15 
6.57  286.0 -> 72.0 20   
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famprofazone 286.0 -> 214.0 15 50 500 
1.66  benzphetamine 
148.0 -> 91.0 20  
10 
 
500 148.0 -> 65.0 35 
1.74  methylphenidate 
156.0 -> 45.0 35  
100 
 
500 156.0 -> 84.0 10 
6.47  amineptine 
193.0 -> 115.0 15  
10 
 
500 193.0 -> 178.0 15 
4.53  amineptine C5 metabolite 
193.0 -> 115.0 15  
50 
 
500 193.0 -> 178.0 15 
2.7 cocaine 
303.0 -> 82.0 15 
50  500 303.0 -> 198.0 5 
3.07  benzoylecgonine 
240.0 -> 82.0 20 
100  500 361.0 -> 82.0 20 
3.56  prolintane metabolite14 
322.0 -> 293.0 20 
excr  500 322.0 -> 205.0 20 
2.28/2.
34 
 
prolintane metabolite 5a/b 
304.0 -> 142.0 20 
excr  500 304.0 -> 75.0 20 
2.67 prolintane metabolite 9 
228.0 -> 158.0 20 
excr  500 228.0 -> 138.0 20 
2.52 sibutramine metabolite 1 
158.0 -> 116.0 10 
excr  500 158.0 -> 102.0 10 
2.74/2.
82 sibutramine metabolite 2/3 
246.0 -> 156.0 20 
excr 500 
246.0 -> 84.0 20 
S7
 
7.47  buprenorphine 
554.0 -> 522.0 15  
0,5 
 
10 554.0 -> 450.0 20 
6.57  dextromoramide 
265.0 -> 166.0 15  
20 
 
200 265.0 -> 98.0 10 
4.91  heroin 
369.0 -> 327.0 10  
2,5 
 
200 369.0 -> 268.0 25 
4.66  MAM 
399.0 -> 287.0 15  
20 
 
200 399.0 -> 340.0 10 
5.37  fentanyl 
245.0 -> 189.0 10  
/ 
 
10 245.0 -> 146.0 15 
2.19  norfentanyl 
175.0 -> 120.0 5  
/ 
 
10 175.0 -> 56.0 15 
4.32  hydromorphone 
429.0 -> 234.0 15  
100 
 
200 429.0 -> 357.0 25 
2.73  methadone 
296.0 -> 191.0 20  
10 
 
200 296.0 -> 281.0 10 
2.93  methadone 2 
296.0 -> 191.0 20  
40 
 
200 296.0 -> 281.0 10 
2.37  normethadone 1 
224.0 -> 103.0 35  
100 
 
200 224.0 -> 191.0 35 
2.73  normethadone 2 
296.0 -> 191.0 20  
10 
 
200 296.0 -> 252.0 20 
2.14  EDDP 
277.0 -> 105.0 25  
40 
 
200 277.0 -> 220.0 20 
4.42  morphine 
429.0 -> 287.0 20  
10 
 
200 429.0 -> 220.0 35 
Chapter 3: A fast, comprehensive screening method 
55 
4.37  oxycodone 
459.0 -> 368.0 15  
200 
 
200 459.0 -> 312.0 15 
4.76  oxymorphone 
502.0 -> 70.0 30  
40 
 
200 517.0 -> 355.0 15 
3.12  pentazocine 
357.0 -> 246.0 15  
100 
 
200 357.0 -> 289.0 15 
1.47  pethidine 
247.0 -> 71.0 5  
4 
 
200 247.0 -> 173.0 5 
3.97  codeine 
371.0 -> 229.0 5  
10 
 
200 371.0 -> 234.0 5 
4.21  ethylmorphine 
385.0 -> 214.0 35  
10 
 
200 385.0 -> 234.0 10 
2.51  pipradrol 
239.0 -> 161.0 20  
5 
 
200 239.0 -> 221.0 20 
5.25  fenbutrazate 
261.0 -> 103.0 35  
50 
 
200 261.0 -> 175.0 15 
S
8 
6.06  THCA 
371.0 -> 289.0 15 
 
<5 
 
7,5 371.0 -> 265.0 15 
P
2 
1.91  oxprenolol 
150.0 -> 109.0 15  
50 
 
500 221.0 -> 72.0 15 
3.62  betaxolol 
364.0 -> 209.0 10  
100 
 
500 364.0 -> 172.0 10 
2.94  bisoprolol 
405.0 -> 56.0 25  
100 
 
500 405.0 -> 172.0 15 
3.07  pindolol 1 
204.0 -> 133.0 15  
500 
 
500 220.0 -> 75.0 15 
3.65  pindolol 2 
205.0 -> 130.0 15  
50 
 
500 292.0 -> 218.0 15 
3.05  esmolol 
352.0 -> 193.0 5  
100 
 
500 352.0 -> 56.0 15 
3.02  metipranolol 
366.0 -> 281.0 5  
25 
 
500 366.0 -> 239.0 15 
2.64  propanolol 
316.0 -> 231.0 5  
25 
 
500 316.0 -> 75.0 15 
3.15  timolol 
373.0 -> 186.0 15  
50 
 
500 373.0 -> 70.0 35 
4.12  carteolol 
421.0 -> 186.0 15  
50 
 
500 421.0 -> 365.0 5 
4.12  levobunolol 
234.0 -> 233.0 5  
25 
 
500 234.0 -> 217.0 10 
2  celiprolol 1 
319.0 -> 129.0 15 
 
/ 
 
500 205.0 -> 89.0 15 
205.0 -> 117.0 15 
3.45 celiprolol 2 
200.0 -> 128.0 15 
500 500 
200.0 -> 144.0 15 
4.53  nadolol 
510.0 -> 70.0 35  
250 
 
500 510.0 -> 186.0 20 
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6.2  acebutolol 1 + 2 
278.0 -> 166.0 30  
500 
 
500 278.0 -> 208.0 30 
1.72  alprenolol 
321.0 -> 72.0 15  
250 
 
500 306.0 -> 203.0 15 
6.67  labetolol 
383.0 -> 265.0 15  
100 
 
500 383.0 -> 251.0 15 
IS
TD
 
4.66  5-Androstane-3α,17β-diol-d5 
246.0 -> 190.0 15 
 
ISTD 
 
 
/ 
 
246.0 -> 164.0 15 
4.62  5-Androstane-3α,17β-diol-d3 
244.0 -> 202.0 15 
244.0 -> 188.0 15 
4.51 androsterone-d4 
423.0 -> 333.0 20 
423.0 -> 243.0 20 
4.56 etiocholanolone-d5 
424.0 -> 334.0 20 
424.0 -> 244.0 20 
5.12 epitestosterone-d3 
435.0 -> 330.0 5 
435.0 -> 209.0 20 
5.38 testosterone-d3 
435.0 -> 330.0 20 
435.0 -> 209.0 20 
5.17 DHT-d3 
437.0 -> 205.0 15 
437.0-> 195.0 15 
2.16 salbutamol-d3 
372.0 -> 210.0 20 
372.0-> 193.0 20 
5.97 -methyltestosterone 446.0 -> 301.0 25 
446.0-> 198.0 20 
 
Besides the anabolic agents, a wide variety of hormone antagonist and modulators can 
be detected at or below the MRPL. This list includes substances with a steroidal 
structure (formestane, 6α-OH-androstenedione and the metabolite of exemestane: 17β-
hydroxy-6-methylene-androsta-1,4-diene-3-one) as well as non steroidal compounds 
(aminogluthetimide, anastrazole, letrozole metabolite, raloxifene, toremifene, 4-OH-
cyclofenil, 4-OH-tamoxifen and the isomers of 4-OH-methoxytamoxifen). Moreover, as 
androsta-1,4,6-triene-3,17-dione also metabolizes to boldenone and its metabolites [24], 
the only substances from this class which are not included in the method are 
testolactone, clomiphene and fulvestrant, due to lack of reference standards for the 
metabolites of these substances. 
Similar as for the previous groups, most prohibited narcotics undergo extensive Phase I 
and Phase II metabolism. Therefore all WADA prohibited narcotics and/or metabolites 
were included in the current method. Except for fentanyl, which shows superior detection 
by LC-MS, all LOD’s were lower than WADA’s MRPL and therefore the methodology is 
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very well suited for monitoring the misuse of narcotics. In addition to the prohibited 
narcotics, the method also screens for codeine, because the use of codeine can result in 
the detection of morphine. In cases where the detection of morphine can be attributed to 
the use of codeine however, a laboratory should not report such cases [2]. Although in 
general, urine is not well suited to determine the post-administration time of sample 
collection, the current method offers some possibilities for several substances by 
monitoring multiple metabolites for which the excretion profile is time dependent. This is 
e.g. the case for heroin for which not only the parent substance but also morphine and 
6-monoacetylmorphine (MAM) are monitored. Besides these substances, which are also 
important in forensic science, toxicology and laboratories working in the field of drugs of 
abuse and work place testing, the method is also capable of simultaneously quantifying 
11-nor-Δ9-tetrahydrocannabinol-9-carboxylic acid (THCA), the major metabolite of 
cannabis and one of the most detected doping agents world-wide. 
In contrast to the narcotics, most stimulants are not excreted as conjugates. Therefore, 
the inclusion of these substances was not the focus of this research. Nevertheless, a 
wide range of stimulants (or metabolites), including cocaine and its metabolite 
benzoylecgonine are included in the method. 
The method covers the most frequently used β-agonists in sports. Moreover, in the case 
of fenoterol both the parent drug (O-TMS tetrakis derivatised) and a degradation 
product, C,N-methylene fenoterol-tetrakis-TMS derivatives were monitored [25]. Although 
the degradation product was not detected in the validation study, its inclusion in the 
method will increase the detection capability of the method for real samples substantially 
since fenoterol can be rapidly degraded. 
Although beta-blockers are only prohibited in particular sports, many drugs belonging to 
this group of substances are excreted as glucuronide conjugates. Therefore 15 beta-
blockers were included in the method. The inclusion of this group has the advantage, 
that in case their detection is requested, no additional analysis needs to be performed 
and hence this leads to an optimized laboratory efficiency. 
Although the derivatisation procedure uses an optimized protocol [26] and the method 
monitors the effectiveness by the detection of mono-TMS derivatised androsterone and 
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etiocholanolone, the formation of multiple derivatives of several compounds (e.g. 
celiprolol, pindolol) is still possible. Although in general one of the derivatives gives a 
better signal than the other, the inclusion of the second derivative can be regarded as a 
safety precaution. Taking into account the scan speed of the instrument (500 scans/s), 
this addition of transitions does not decrease the overall performance of the method. 
4 Conclusion 
A fast GC-MS/MS method for the quantitative determination of the steroid profile, 
salbutamol, THCA and norandrosterone as well as the qualitative detection of 142 
doping agents (or their metabolites) was developed and validated. Using hydrogen as a 
carrier gas and a short (12.5 m) capillary column all doping agents could be detected 
within a single run of less than 8 minutes. The use of a wide range of internal standards 
allows for an evaluation of the sample preparation efficiency. 
The current method shows that the combination of triple quadrupole technology and 
large volume injection can greatly improve the detection capabilities of target substances 
in complex matrices as biological fluids. 
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Abstract 
In the fight against doping gas chromatography (GC) coupled to mass spectrometry 
(MS) is by far the most used technique. Recently a method using the combination of 
GC and triple quadrupole technology was developed for the detection of a wide 
range of prohibited substances, leading to improved selectivity and sensitivity. Here, 
this system was used to detect over 150 compounds from different classes (steroids, 
narcotics, stimulants, beta-blockers, beta-2-agonists, hormone antagonists) in a 
qualitative way. 
In the quantitative part, the traditional steroid profile with most important endogenous 
steroids is expanded with 6 minor metabolites (4-hydroxy-androst-4-ene-3,17-dione, 
6α-hydroxy-androst-4-ene-3,17-dione, 16α-hydroxy-androst-4-ene-3,17-dione, 3β,7β-
dihydroxy-androst-5-en-17-one and 3β,16α-dihydroxy-androst-5-en-17-one) which 
further improves the detection and identification of endogenous steroid abuse. 
Besides these also norandrosterone, salbutamol and the major metabolite of 
cannabis are quantified.  
Taking into account the tremendous implications an adverse analytical finding can 
have on the (professional) life of an athlete, methods developed for anti-doping 
purposes should be subjected to the highest level of quality. Here, the addition of a 
combination of (deuterated) internal standards allows for an accurate quality control 
of every single step of the whole methodology: hydrolysis efficiency, derivatisation 
efficiency and microbiological degradation are individually monitored in every single 
sample. Additionally, evaluation of the pre-analytical phase is important. Therefore, 
special attention is paid to the relation between parameters indicating degradation by 
micro-organisms and the reliability of the steroid profile. The impact of the 
degradation is therefore studied by evaluation of the quantities and percentages of 
5α-androstane-3,17-dione and 5β-androstane-3,17-dione.  
Additionally, the concept of measurement uncertainty was introduced for the 
evaluation of relative abundances of mass-to-charge ratios and the obtained ranges 
were compared with the World Anti-Doping Agency (WADA) regulations on tolerance 
windows for relative ion intensities. The results indicate that both approaches are 
very similar.   
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1 Introduction 
Since 1999 the fight against doping in sports is regulated by the World Anti-Doping 
Agency (WADA), responsible for annual publication of the prohibited list [1,2]. This list 
contains hundreds of different specified compounds, each of them with other 
chemical properties, divided in different classes. The WADA accredited laboratories 
have the difficult task to screen for this wide range of compounds and report the data 
in a short period of time.  
Gas chromatography coupled to mass-spectrometry (GC-MS) is still the most popular 
technique for screening and confirmation of these compounds [1,3–5]. Using selected 
ion monitoring (SIM) mode the required limits can be detected in a GC run of about 
30 min [6]. Now, with the introduction of GC-MS triple quadrupole (QqQ) systems, 
these existing methods can be improved in terms of detection limits and run times. 
Normal screening methods for anabolic steroids in doping control laboratories 
consume 2 to 5 mL of urine and sample preparation contains several steps: 
enzymatic hydrolysis, liquid-liquid extraction and evaporation of the organic solvent 
[1,7,8]. To improve the characteristics of the compounds in terms of chromatography, 
silylation reagents are used for derivatisation [9]. Since both alcohol and carbonyl 
functionalities need derivatisation, the reactive trimethyliodosilane is chosen. This is 
formed in situ when mixing of N-methyl-N-trimethylsilyltrifluoroacetamide (MSTFA), 
ammonium iodide and ethanethiol [10].  
While in earlier described methods a single internal standard is used [1,6,11], multiple 
deuterated internal standards have been introduced to allow for an improved 
correction of losses during sample preparation steps. The combination of 
glucuronidated and free internal standards also allows for the determination of 
hydrolysis efficiency.  
Besides the screening for exogenous drugs, also the abuse of endogenous 
compounds should be detected. For the determination of the abuse of testosterone 
and related compounds steroid profiling is necessary. Traditionally, the steroid profile 
contains the concentrations of the most important endogenous steroids such as 
testosterone (T), epitestosterone (E), androsterone (A), etiocholanolone (Etio), 5α-
androstane-3α,17β-diol (5ααβ-Adiol), 5β-androstane-3α,17β-diol (5βαβ-Adiol), 
androstenedione (Adion), dehydroepiandrosterone (DHEA) and dihydrotestosterone 
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(DHT). Population-based reference ranges are set to distinguish natural steroid 
profiles from the ones influenced by steroid administration. According to the WADA 
technical document samples need to be submitted to isotope ratio mass spectrometry 
(IRMS) analysis if the T/E ratio is greater than 4, the concentration of T and E greater 
than 200 ng/mL and A greater than and 10 000 ng/mL respectively and the 
concentration of DHEA greater than 100 ng/mL [12]. The concentrations of these 
steroids can however show large interindividual variations, and these reference 
ranges, unfortunately, do not cover all natural variations. Additionally there are more 
steroids available today of which the intake does not always influence the traditional 
steroid profile to an important extent. This was already shown for oral administration 
of DHEA [13] and Adion [14]. Recent studies showed that the discriminating power of 
steroid profiling can be increased by adding minor steroid metabolites [15,16]. These 
are formed after administration of endogenous steroids, when the major metabolism 
pathways are saturated. Those minor metabolites are mostly hydroxylated and 
oxygenated at C4, C6, C7 and C16 positions, are more specific and can allow for a 
better determination of the abused steroid [8]. Hence, inclusion of some of these 
metabolites in a routine screening method should improve detection of misuse with 
natural steroids. 
Since a lot of factors can cause variations in the endogenous concentrations, ratios 
of these steroidal hormones concentrations can be regarded as more stable 
alternatives. Ratios including T/E, A/Etio, A/T, 5ααβ-Adiol/5βαβ-Adiol showed to be 
less susceptible to variables like exercise, physical performance, volume and density 
of the urine, etc. [17] 
In this paper a GC-QqQ-MS screening method is described for the determination of 
the traditional steroid profile together with the minor metabolites and corresponding 
concentration ratios. Further the method is able to detect over 150 components 
qualitatively, at concentration levels at or below WADA’s minimum required 
performance limit (MRPL) [18]. Next to this, an extensive set of quality control 
measures is implemented. In this way quality control can be done for every individual 
sample and per batch. 
Under quality control, special attention is paid to microbiological degradation of urine 
samples. It is shown that micro-organisms can be present in urine and can cause 
alterations in the steroid profile [19]. Micro-organism activity can in a first step induce 
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deconjugation of steroids and thereafter cause modifications in the steroidal structure 
by oxidoreductive reactions. The conversion of androsterone and etiocholanolone to 
5α-androstane-3,17-dione (5α-dion) and 5β-androstane-3,17-dione (5β-dion) 
respectively by consecutively deconjugation and bacterial 3-hydroxysteroid 
dehydrogenase activity is well-known [17,20] (Fig. 4.1). Similarly, unconjugated 
testosterone concentration can increase by bacterial conversion of 5-androstene-
3β,17β-diol, leading to an elevation of T/E ratios [17].  
 
 
Fig. 4.1 Microbiological conversion of androsterone tot 5α-androstane-3,17-dione. 
 
To avoid reporting atypical findings in steroid parameters caused by these effects, 
the WADA technical document TD2004EAAS [12] rejects results if the concentration of 
free testosterone and/or epitestosterone in the specimen exceeds 5% of the 
respective glucuroconjugates. Because screening for steroids is usually done in the 
total (free + glucuronidated) fraction, additional analyses are required if these 
concentrations needs to be determined. Elevated amounts of 5α-androstane-3,17-
dione and 5β-androstane-3,17-dione also indicate microbiological degradation. 
Recently it was shown that the 5% rule for free testosterone correlates well with 
threshold values for 5α-dion and 5β-dion in order to control microbiological 
degradation in the screening methods [21]. This paper describes the effect of these 
parameters on the complete steroid profile. 
OH
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Androsterone 5α-Androstane-3,17-dione 
(5α -Dion)
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2 Material and methods 
2.1 Reagents 
The enzyme β-glucuronidase from E. Coli, used for hydrolysis was purchased from 
Roche Diagnostics GmbH (Mannheim, Germany). Methanol, sodium hydrogen 
carbonate (NaHCO3) were obtained from Fisher Scientific (Loughborough, UK). 
Potassium carbonate (K2CO3), disodium hydrogen phosphate (Na2HPO4), sodium 
dihydrogen phosphate (NaH2PO4) and sodium sulphate (Na2SO4) were from Merck 
(Darmstadt, Germany) 
The phosphate buffer solution was prepared by dissolving 7.1 g Na2HPO4.2H2O and 
1.4 g NaH2PO4.H2O in 100 mL water. The carbonate buffer was prepared by 
dissolving 135g K2CO3 and 111g NaHCO3 in 900 mL aqua bidest. 
Diethylether en ethanethiol were purchased from Acros (Geel, Belgium). Acetonitrile 
was from Biosolve (The Netherlands) and ammoniumiodide (NH4I) from Sigma 
Aldrich (Bornem, Belgium). MSTFA was obtained from Chem. Fabrik Karl Bucher 
(Waldfstedt, Germany) and sodiumsulphate from Merck (Darmstadt, Germany).  
2.2 Internal standards 
17α-Methyltestosterone (IS) was a kind gift from Organon (Oss, The Netherlands). 
Following deuterated internal standards were from NMI (Pymble, Australia): d3-
testosterone glucuronide (d3-T-gluc), d3-epitestosterone glucuronide (d3-E-gluc), d4-
androsterone glucuronide (d4-A-gluc), d5-etiocholanolone (d5-Etio), d3-
dihydrotestosterone glucuronide (d3-DHT), d3-5α-androstane-3α,17β-diol (d3-ααβ-
Adiol), d5-5β-androstane-3α,17β-diol (d5-βαβ-Adiol) and d3-salbutamol (d3-Sal). D6-
dehydroepiandrosterone (d6-DHEA) was from Sigma-Aldrich (Bornem, Belgium) 
The internal standard mixture was prepared in methanol, containing 91.5 µg/mL d3- 
ααβ-Adiol and d5-βαβ-Adiol, 88.9 µg/mL d4-A-gluc, 48.7 µg/mL d3-DHT, 83 µg/mL 
d3-E-gluc, 52.8 µg/mL d5-Etio, 91.8 µg/mL IS, 100 µg/mL d3-Sal, 101 µg/mL d3-T-
gluc and 51.8 µg/mL d6-DHEA. This stock solution was diluted (4:1) prior to usage. 
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2.3 Endogenous steroids 
Testosterone, epitestosterone, androsterone, etiocholanolone, 11β-
hydroxyandrosterone, 11β-etiocholanolone, 5α-androstane-3α,17β-diol, 5β-
androstane-3α,17β-diol, 4-androstene-3,17-dione, 5β-androstane-3,17-dione, 5α-
androstane-3,17-dione and pregnanediol were purchased from Sigma (Bornem, 
Belgium), 19-norandrosterone, 4-hydroxy-androst-4-ene-3,17-dione (4OH-Adion) and 
3β,7β-dihydroxy-androst-5-en-17-one (7βOH-DHEA) from NMI (Pymble, Australia), 
dehydroepiandrosterone (DHEA) from Serva (Heidelberg, Germany) and 
dihydrotestosterone (DHT) from Piette International Laboratories (Drogenbos, 
Belgium). 6α-Hydroxy-androst-4-ene-3,17-dione (6αOH-Adion), 16α-Hydroxy-
androst-4-ene-3,17-dione (16αOH-Adion) and 3β,16α-dihydroxy-androst-5-en-17-one 
(16αOH-DHEA) were purchased from Steraloids (Newport, RI, USA).  
2.4 Exogenous steroids 
16α-OH-furazabol, 16α-OH-stanozolol,17α-ethyl-5α-estrane-3α,17β-diol 
(norethandrolone metab.), 17α-methyl-5α-androstane-3α,17β-diol (α-
methyltestosterone metab.), 17α-methyl-5β-androstane-3α,17β-diol (β-
methyltestosterone metab.), 17α-trenbolone, 17β-hydroxy-17α-methyl-5α-androst-1-
ene-3-one (methyl-1-testosterone), 1α-methyl-5α-androstan-3α-ol-17-one 
(mesterolone metab.), 1-methylene-5α-androstan-3α-ol-17-one (methenolone 
metab.), 1-testosterone, 2α-methyl-5α-androstan-3α-ol-17-one (drostanolone metab.), 
4-chloro-4-androsten-3α-ol-17-one (clostebol metab.), 4-OH-testosterone, 5β-
androst-1-en-17b-ol-3-one (boldenone metab.), 5α-Androst-1-ene-3β,17β-diol (1-
androstenediol), 6β-hydroxy-dehydrochloromethyltestosterone (oral turinabol metab.), 
6β-hydroxymethandienone, epimetendiol, 7α,17α-dimethyl-5β-androstane-3α,17β-
diol (bolasterone metab.), 7β,17α-dimethyl-5β-androstane-3α,17β-diol (calusterone 
metab.), 9α-fluoro-17,17-dimethyl-18-nor-androstan-4,13-diene-11β-ol-3-one (fluoxy-
18-nor), dehydrochloromethyltestosterone (oral turinabol), epioxandrolone, 
methyldienolone, 13β,17α-diethyl-5β-gonane-3α,17β-diol (norbolethone metab 2), 
13β,17α-diethyl-5α-gonane-3α,17β-diol (norbolethone metab 1), 3’-hydroxystanozolol, 
4-OH-nandrolone, 2-hydroxymethyl-17α-methylandrosta-1,4-dione-11α,17β-diol-3-
one (formebolone metab) and 17α-ethyl-5α-estrane-3α,17β-diol (norethandrolone 
minor metab.) were purchased from NMI (Pymble, Australia). Oxandrolone was a gift 
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from Searle & Co (Chicago, IL, USA), 1-androstene-3,17-dione, calusterone, 
mibolerone and norclostebol were from Steraloids (Newport, RI, USA). Bolasterone 
was a gift from Upjohn, danazol from Whintrop, oxymetholone from Parke Davis and 
mesterolone from Shering. 3α-hydroxytibolone (tibolone metab.) was a kind gift from 
Akzo Nobel (Oss, The Netherlands), fluoxymesterone was obtained from Ciba-Geigy, 
boldenone and oxymesterone were purchased from the Institut für Biochemie of the 
Deutsche Sporthochschule (Cologne, Germany). 3α,5α-tetrahydronorethisterone 
(norethisteron metab.), was a kind gift from the Institute of Organic Chemistry and 
Biochemistry (Academy of Sciences of the Czech Republic, Prague, Czech Republic), 
metenolone from the Drug Control Centre of King's College (London, UK), 
mestanolone from Doping Control Laboratory Barcelona, ethisteron from the Doping 
Control Laboratory ADOP (Lisbon, Portugal), 17β-hydroxy-6-methyleneandrosta-1,4-
dien-3-one (exemestane metab.) from Helsinki University, 6β-
hydroxyfluoxymesterone from the Laboratory for Doping Control Cologne and 
desoxymethyltestosterone (madol) from the Doping Control Laboratory Montreal. 
2α,17α-dimethyl-5α-androsta-17β-ol-3-one (superdrol) was from TRC (North York, 
Canada). 
2.5 Narcotics 
11-nor-∆9-tetrahydrocannabinol-9-carboxylic acid (THCA), normethadone, (±)-2-
ethyl-1,5-dimethyl-3,3-diphenylpyrrolinium perchlorate (EDDP), fentanyl, fenbutrazate, 
buprenorphine, morphine, codeine, ethylmorphine, 6-monoacetylmorphine (MAM), 
oxymorphone were purchased from Cerilliant. Pethidine, hydromorphone, oxycodone, 
heroine, dextromoramide and methadone were bought from Sigma (Bornem, 
Belgium). Pentazocine was a gift from Whintrop Laboratories (Newcastle, United 
Kingdom). 
2.6 Stimulants 
Pipradrol and pemoline were gifts from Merrell-Dow (Cincinnati, OH, USA) and 
Boehringer-Ingelheim (Brussels, Belgium), respectively. Cocaine and 
benzoylecgonine were purchased from Cerilliant. Fenethylline was a gift from 
Chemiwerk Hamburg (Germany) and methylphenidate from Ciba-Geigy (Groot-
Bijgaarden, Belgium). Fencamine was obtained from Laboratoires Miquel S.A. 
(Barcelona, Spain), fenspiride from Laboratoires Servier (Orléans, France) and 
Chapter 4: An improved methodology. 
71 
amineptine and amineptine C5 metabolite from Laboratoires Servier (Orleans, 
France). Strychnine and fencamfamine were donated by Merck. Carphedon, 6-OH-
bromantane, crotethamide, cropropamide, cyclazodone and famprofazone were 
bought from NMI (Australia). Dimefline was from Recordate Industria Chemica & 
Farmaceutica (Milan, Italy) and furfenorex and clobenzorex from Roussel Uclaf 
(Romainville, France). Amiphenazole, pholedrine, niketamide, 1-benzylpiperazine 
and octopamine were purchased from Sigma (Bornem, Belgium), while ethamivan 
and benzphetamine were gifts from Sinclair Pharmaceuticals (Godalmings, UK), 
Tropon Werke (Cologne) and Upjohn (Kalamazoo, USA), respectively. 3,3-
diphenylpropylamine and prenylamine were gifts from the World Association of Anti-
Doping Scientists (WAADS). 3,4-Methylenedioxy-N-ethylamphetamine (MDEA) was 
purchased from Cerilliant (Round Rock, Texas). Selegiline was from Orion Pharma 
(Diegem, Belgium) and mefenorex from Roche (Mannheim, Germany). 
2.7 Beta-blockers 
Beta-blockers obtained as reference substances were: acebutolol from Rhone-
Poulenc (Brussels, Belgium), alprenolol from Astra Chemicals (Holstein, Germany), 
propranolol from ICI (Korten- berg, Belgium), betaxolol from Synthelabo (Brussels, 
Belgium), labetolol from Glaxo (Brussels, Belgium), nadolol from Squibb (Braine 
l’Alleud, Belgium), oxprenolol from CIBA (Dilbeek, Belgium), pindolol from Sandoz 
(Vilvoorde, Belgium), timolol from MSD(Brussels, Belgium), bisoprolol from Merck 
(Overijse, Belgium), carvedilol from Roche (Mannheim, Germany). Levobunolol (l-
bunolol), esmolol were a kind gift from the South African Doping Control Laboratory. 
following products were extracted from therapeutical prepa- rations: celiprolol 
(Selectol, Pharmacia, Brussels, Belgium) and metipranolol (Beta-Ophtiole, Tramedic, 
Sint-Niklaas, Belgium). 
2.8 Beta-2-agonists 
Salbutamol, terbutaline and clenbuterol were purchased from RIVM. Salmeterol 
xinafoate was a gift from GlaxoSmithKline (Philadelphia, PA, USA). Fenoterol was a 
gift from Boehringer&Sohn (Ingelheim am Rhein) and formoterol from Novartis 
(Arnhem, The Netherlands). Bambuterol was donated by the Instituto Nacional do 
Desporto (Lisbon, Portugal). 
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2.9 Hormone antagonists and modulators 
Anastrazole, toremifene, exemestane, 17β-hydroxy-6-methylene-androsta-1,4-diene-
3-one (exemestane metab.), were generous gifts from Astra Zeneca (Macclesfield, 
UK), WAADS, Pfizer (Groton, UK) and the Faculty of Pharmacy of the Helsinki 
University (Helsinki, Finland), respectively. 6α-OH-androstenedione, 4-OH-
androstenedione, 4-hydroxycyclofenil (cyclofenyl metab.), 3-hydroxy-4-
methoxytamoxifen and bis-(4-cyanophenyl)methanol (Letrozole metabolite) were 
purchased from NMI. 4-OH-tamoxifen and raloxifene was bought from Sigma–Aldrich. 
2.10 Other substances 
Zilpaterol and zeranol were purchased from NMI, probenecid from Federa (Brussels, 
Belgium) and 5-hydroxypentoxyfylline (5-OH-pentoxyfylline) from Hoechst (Frankfurt, 
Germany). 
2.11 Urine samples 
For the detection of prolintane, sibutramine and metabolites excretion urines were 
used. These urines were collected from healthy people after administration of 10 mg 
oral dose, in accordance with the Helsinki declaration on ethical principles [22].  
For the stability tests concerning the microbiological degradation, urine samples from 
6 healthy volunteers were collected. Each sample was divided in 3 containers and 
each of these was stored under different conditions: refrigerator (2-8°C), room 
temperature (21-24°C) and an incubator at 37°C. Every day during a period of 14 
days, pH and specific gravity was measured and 3 aliquots were collected out of 
every container and stored at -80°C awaiting analysis.  
2.12 Sample preparation 
1 mL of urine was spiked with 25 µL of the internal standard mixture. For hydrolysis 
samples were incubated in an oven at 56°C for 1.5h after adding 1 mL of 0.1M 
phosphate buffer solution (pH = 7) and 50 µL of β-glucuronidase. After adding 2 mL 
NaHCO3/K2CO3 solution (pH = 9.5) the mixture was extracted for 20 min with and 5 
mL diethylether by rolling. The organic phase was centrifuged for 5 min at 
approximately 650g, dried with Na2SO4 and evaporated under OFN at room 
temperature.  
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20 µL of acetonitrile and 50 µL MSTFA was added to the dried residues, followed by 
derivatisation for 30 min at 80°C. Afterwards 50 µL of MSTFA/ethanethiol/NH4I 
(500:4:2) was added for derivatisation at 80°C during another 30 min [9]. 1.3 µL of this 
mixture was injected in the GC. 
2.13 Instrumentation 
An Agilent (Agilent Technologies, Palo Alto, USA) GC 7890 gas chromatograph 
coupled with an Agilent 7000B triple quadrupole mass spectrometer (Agilent 
Technologies) and a MPS2 autosampler and PTV-injector from Gerstel (Mülheim and 
der Ruhr, Germany) were used.  
The GC column – 12.5 m x 200 µm and 0.11 µm film thickness – was a HP-Ultra 1 
from J&W Scientific (Agilent Technologies, USA). The temperature programme was 
as follows: the initial temperature was 80°C (0.2min), increased at 70°C/min to 183°C, 
then at 5.1°C/min to 220°C and at 50°C/min to a final temperature of 310°C (held for 
1.8min). The transfer line was set at 310°C. Helium (Air Liquide) was used as carrier 
gas at a flow rate of 0.8 mL/min.  
In splitless mode 1.3 µL was injected using following PTV-temperature settings: 25°C 
(0.20 min), 12°C/min  310°C.  
In the QqQ collision cell He was used as a quench gas at 2.25 mL/min and N2 as 
collision gas at 1.5 mL/min.  
2.14 Method Validation 
2.14.1 Quantitative 
To construct calibration curves, steroid stripped urine samples were spiked at 6 
concentration levels. The least squares method was used for fitting the calibration 
curves. 
At every level accuracy and precision were tested over 3 replicates. The tolerances 
for precision were calculated following the Horwitz equation (RSDmax= 2(1-0,5logC)). The 
accuracy, expressed as bias, may not exceed 15%.  
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2.14.2 Qualitative 
The limit of detection (LOD) was determined by analyzing 10 different, randomly 
chosen urine samples spiked with the analyte at a range of concentration levels. 
These levels were chosen according the WADA MRPL’s: i.e. 0.05, 0.1, 0.2, 0.5, 1 
and 2 times the MRPL level [18]. The LOD was set at the lowest level where the 
analyte could be detected and complied with WADA’s criteria for identification [23] in 
all samples. 
For every compound precursor ions were selected with mass resolution of the first 
quadrupole set at unity. The collision energy (CE) was optimized, generating 
characteristic product ions. Selectivity and specificity of these transitions were tested 
by the analysis of ten blank urine samples. At least two precursor-product ion 
transitions are monitored and the relative abundance of these transitions are 
determined from the peak area of the integrated selected reaction monitoring (SRM) 
chromatograms. To ensure correct identification, maximum tolerance windows for 
these relative ion intensities (RI) are set by WADA (Table 4.1). 
 
Table 4.1: Maximum tolerance windows for relative ion intensities to ensure 
appropriate confidence in identification [23]. 
Relative abundance (% of base peak) GC-MS/MS 
>50% 10% (absolute) 
25% to 50% 20% (relative) 
5% to <25% 5% (absolute) 
<5% 50% (relative) 
 
3 Results and discussion 
3.1 Method development 
The B-version of the Agilent Triple Quadrupole GC-MS/MS used in this study is 
equipped with a new EI-source. This source has an additional extractor lens, which 
improves sensitivity across the entire mass range resulting in lower limits of detection 
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in comparison to a previous study [24]. The results for several examples from different 
classes are shown in Table 4.2.  
 
Table 4.2: LOD values of some components to illustrate the improving sensitivity 
when using the extractor lens (source B). 
  Source A Source B
Compound LOD (ng/mL) LOD (ng/mL)
Pethidine 4 2
Bolasterone 10 5
Zeranol 10 5
Fenoterol 100 50
Raloxifene 25 5
Oxycodone 200 50
Esmolol 100 25
 
In this method helium is used as a carrier gas. This increases the run time compared 
to hydrogen as a carrier gas [24], but has also some considerable advantages. The 
extended temperature program allows for separation of some more volatile 
compounds. In that way some stimulants could be added to the method. Further the 
system showed to be more robust with the He configuration compared to the one on 
H2. Using the He configuration it is sufficient to clean the source every 1000 
injections, while on the H2 configuration this maintenance needed to be performed 
every 250 injections. So less maintenance was needed for He, resulting in less 
downtime.  
When changing the carrier gas, transitions and corresponding collision energies of all 
compounds were re-evaluated. After performing a full scan analysis the best 
precursor ions - with highest masses and abundances - were selected for every 
component. Next a product ion scan was performed on the selected precursor ions to 
select the most abundant product ions. The resulting transitions were optimized using 
different collision energies (5, 10, 15, 20, 25, 30, 35). Signal to noise was used as a 
criterion for the selection. No differences in fragmentation were observed. However, 
small differences in relative abundances and signal intensities were noticed. 
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added. Since, in general internal standards are dissolved in methanol and it is known 
that the activity of enzymes like β-glucuronidase is reduced in organic solvents [26], it 
is important to minimize the volume of solvent added. When using only 1 mL of urine, 
adding similar amounts of methanolic solutions as in previously described methods 
[6,24], leading to inhibition of hydrolysis could become problematic. Therefore, all 
internal standards solutions were prepared at relatively high concentrations, in order 
to limit the spiked volume to 25 µL. 
The use of both free and glucuronidated steroids as internal standards makes 
evaluation of the hydrolysis efficiency possible. Androsterone-d4 is added in every 
sample as glucuronide conjugate at 486.87 ng in 1 mL of urine (concentration in 
androsteron-d4 equivalents). The degree of deconjugation after the 1.5h hydrolysis 
step with β-glucuronidase allows estimation of the efficiency for each sample 
individually. To correct for variations during sample preparation the area of transition 
423333 (CE 20) for free androsteron-d4 is divided by the area of transition 
424334 (CE 20) for etiocholanolone-d5. This compound is added free (non-
conjugated) at 459 ng/mL. Experiments with both substances spiked as free 
standards in equivalent proportions have shown that the mean ratio of androsterone-
d4 over etiocholanolone-d5 at a theoretical 100% hydrolysis efficiency is 0.85 under 
the given conditions. Analysis of a large number of samples (n > 200) showed that 
minor hydrolysis efficiency causes problems in quantification of compounds from an 
d4-A/d5-Etio ratio below 0.7, i.e. at 80% hydrolysis efficiency.  
The addition of multiple deuterated internal standards (d3-E, d3-T, d5-5βαβ-Adiol, 
d3-5ααβ-Adiol, d3-DHT, d4-A, d5-Etio and d6-DHEA), more similar to the target 
compounds, improves correction for variations caused by sample preparation and 
extraction and also for variations in performance of the used analytical instruments. 
Although this phenomenon is known, most methods do not take this into account 
[8,27,28]. 
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Fig. 4.3 Calibration curves for androsterone using as internal standard 100 ng/mL A-d4 
(dotted line) and 500 ng/mL (solid line). 
 
However, when using deuterated analogues, problems can arise from the natural 
abundances of the heavier isotopes in the target analyte. First of all the degree of 
isotopic substitution in the internal standard should be sufficiently large, making the 
probability of observing the same mass in the analyte as low as possible. Fulfilling 
this condition becomes hard for bigger molecules since for carbon atoms the relative 
abundances (RA) for 13C are 1.11%. In this research all target molecules are silylated 
before analysis. Next to increasing the amount of carbon atoms, the TMS-groups 
introduce a Si atom with 3 different stable isotopes: 28Si, 29Si (RA 4.67%) and 30Si 
(RA 3.10%). The carbon and silicon atoms together are responsible for the higher 
abundances of heavier isotopes. The higher the concentration of the silylated analyte, 
the bigger the contribution of the isotope with the same mass as the internal standard. 
This is the case for the isomers androsterone and etiocholanolone, which can be 
present in relatively large concentrations. For the highest calibration level of 4800 
ng/mL the natural abundance of mass 438 in the bis silylated androsterone 
corresponds already to 12.36 ng/mL (Table 4.3). When spiking the internal standard 
A-d4 at 100 ng/mL this additional presence of mass 438 causes a 12% 
overestimation of the internal standard. This effect can be reduced by using a higher 
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concentration for the deuterated analogue, spiking at 500 ng/mL lowers the error to 
2.4%. Fig. 4.3 shows a deflection in the high concentration range of the calibration 
curve for androsterone when using internal standard A-d4 at 100 ng/mL (dotted line). 
When spiking 500 ng/mL A-d4 for the same concentrations of androsterone this 
deflection does not occur (solid line), additionally the slope of the curve increases, 
making the quantification more sensitive. 
 
Table 4.3: Contribution of natural abundant stable isotopes of analytes 
  Compound Concentration (ng/mL) 
 
Androsterone-bisTMS 48 120 600 1200 2400 4800 
absolute abundance mass 438 0.124 0.309 1.545 3.091 6.182 12.363 
IS
 - 
Lo
w
 
co
nc
Androsterone-d4 -bisTMS 100 100 100 100 100 100 
Total abundance mass 438 100.124 100.309 101.545 103.091 106.182 112.363 
% contribution mass 438 0.123 0.308 1.522 2.998 5.822 11.003 
IS
 - 
H
ig
h 
co
nc
Androsterone-d4 -bisTMS 500 500 500 500 500 500 
Total abundance mass 438 500.124 500.309 501.545 503.091 506.182 512.363 
% contribution mass 438 0.025 0.062 0.308 0.614 1.221 2.413 
 
Also transitions for mono-TMS derivatised androsterone and etiocholanolone were 
included to monitor derivatisation efficiency. Mono-TMS derivatised androsterone 
showed to be more sensitive than the etiocholanolone equivalent and is in that way a 
better parameter for derivatisation efficiency. The cut-off percentage for efficient 
derivatisation was set at 10% mono-TMS. 
3.2.2 Microbiological degradation 
For the stability tests, pH and density were measured every day during 14 days. For 
the density there were no changes observed. There were also no changes in urinary 
pH measured for all samples stored in the refrigerator and at room temperature. 
For samples, stored in the incubator at 37°C, the urinary pH didn’t change for urine 1 
and 2 over the 14 days period of time. However, for urine 3 to 6, pH values increased 
after 4 days of incubation and all reached a steady state at pH 8.9 and 9.2. (Fig. 4.4) 
after 3-6 days. These changes in urinary pH are linked to urease activity of different 
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micro-organisms [19] and provided evidence that the growth of these organisms is 
affected by the urine composition. 
 
 
Fig. 4.4 Urinary pH changes of 6 different urines in function of the number of days 
incubated at 37°C. 
 
Production of 5α-dion and 5β-dion out of androsterone and etiocholanolone, 
respectively, has also been identified as a marker of microbiological degradation. 
Therefore, these steroids were also quantified. 
For aliquots stored in the refrigerator no observations indicating degradation were 
detected, except for urine 4. In this sample, concentrations of 5α-dion and 5β-dion 
were around 10 ng/mL at the beginning of the experiment. After 11 days these 
concentrations had increased to 25 ng/mL. However, no significant changes in the 
steroid profile (T, E, A, Etio) were found. Since absolute concentrations of steroids 
are affected by urinary flow, differences in production, etc, the percentage of 5α-dion 
to androsterone (%5α) and the percentage of 5β-dion to etiocholanolone (%5β) were 
also calculated to evaluate the relative importance of the degradation. In urine 4, 
these percentages were very small, i.e. 0.5 %5α and 2.2 %5β. This illustrates that the 
use of absolute concentrations of these steroids might not be the best indicator to 
monitor alterations of the steroid profile due to microbiological degradation. Hence, it 
can be concluded that although increases in 5α-dion and 5β-dion, indicating 
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microbiological activity, can be noticed, samples can be stored in the refrigerator for 2 
weeks without a significant impact on the steroid profile. pH values for all urines were 
constant during the duration of the experiment. These results also further supports 
previous research showing that storage in fridges as required by WADA’s ISL [29] is a 
sufficient measure to adequately prevent degradation. 
Analysis of urine 1, stored at room temperature, showed no formation of 5α/5β-dion 
and did not result in changes in the steroid profile. In urine 2, no changes neither in 
steroid profile nor in 5α/β-dion concentrations were noticed in the first week . 
However, after ten days significant increases in 5α-dion and 5β-dion (up to 85 ng/mL 
and 630 ng/mL or 2% and 15% of androsterone and etiocholanolone concentrations, 
respectively) were noticed. Concurrently, the T/E ratio increased from 0.05 to 0.1. For 
urine 3, changes in 5α-dion and 5β-dion concentrations were noticed from day 2 
onwards (starting at 30 ng/mL and 20 ng/mL for 5α-dion and 5β-dion, respectively), 
but only after 14 days a change in steroid profile was noticed (T/E ratio decreases 
from 0.8 to 0.45). The %5α and %5β had increased by then to 5 and 15% 
respectively. Storage of urine 5 at room temperature resulted in significant formation 
of 5α-dion and 5β-dion. Indeed, already at day 4 these concentrations were 65 ng/mL 
and 500 ng/mL for 5α-dion and 5β-dion respectively. These values represent 1.5% 
and 15% of androsterone and etiocholanolone. Calculated percentages increase on 
day 7 where 14 %5α and 20 %5β were found. Very similar results were obtained for 
urine 4 and 6. 
In general, when storing samples at room temperature, microbial degradation was 
observed and could be detected by monitoring 5α-dion and 5β-dion concentrations. 
pH values again were constant in function of time, making this an unreliable 
parameter for microbiological degradation. Since endogenous production and urinary 
flow can result in significant differences in basal endogenous steroid concentrations, 
the use of absolute threshold concentrations of 5α-dion and 5β-dion to establish 
significance of the microbial degradation on the steroid profile does not seem to be a 
good parameter. Instead, the use of a % of 5α-dion to androsterone and 5β-dion to 
etiocholanolone seems to be a better indicator. Based upon these preliminary 
experiments a threshold of 1% for 5α-dion and 5% of 5β-dion was established. 
Storing samples in the incubator at 37°C accelerated these degradation processes. 
Concentrations around 30 ng/mL of 5α-dion and 200 ng/mL of 5β-dion were already 
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measured after a few days: from 1 day for urine 5, 2 days for urine 2, 4 and 6 to 4 
days for urine 3. Only urine 1 remained largely unaffected from microbiological 
degradation and only showed increasing 5α/5β-dion concentrations after 12 days. In 
contrast to the pH, which was constant, 5α-dion and 5β-dion were formed in urine 1 
and 2. This indicates again that there is not always a correlation between pH 
elevation and formation of degradation products. Large changes in the 
concentrations of endogenous steroids were observed during the test period. In urine 
4, concentrations of androsterone decreased from 2100 ng/mL at the beginning to 10 
ng/mL after 6 days. For etiocholanolone, the same trend was found: from 1000 ng/mL 
at day 1 to 15 ng/mL after 7 days. In urine 6, the impact of degradation was best 
reflected in the testosterone concentration which decreased from 55 ng/mL at the 
start of the experiment, over 20 ng/mL after 3 days to 5 ng/mL after 10 days. 
Because epitestosterone concentrations remained constant, the T/E ratio decreased 
from 2.3 to 0.6 after 3 days. Evaluation of all samples stored at 37°C also confirmed 
the proposed threshold values of 1% for 5α-dion and 5% of 5β-dion. 
In all samples it was found that Adion concentrations followed the same trend as 
5α/5β-dion concentrations. From constant levels for samples stored in the refrigerator 
to a tenfold increase in concentrations for samples stored at room temperature and at 
37°C. However, Adion concentrations cannot be used as a parameter for 
microbiological degradation because of natural fluctuations. 
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Fig. 4.6 Full scan mass spectrum of the interfering isomer of androsterone. 
 
3.2.3 Quantitative 
All the endogenous steroids traditionally included in the steroid profile used for 
doping control purposes (T, E, A, Etio, DHT, DHEA, Adion, 5ααβ-Adiol and 5βαβ-
Adiol) are included in the quantitative part of the method. However, to improve the 
detection of administration of endogenous steroids, several minor metabolites were 
added to the method; namely 4OH-Adion, 6αOH-Adion, 16αOH-Adion, 7βOH-DHEA 
and 16αOH-DHEA. The endogenous concentrations of these metabolites are lower 
than those of the steroids monitored in the traditional steroid profile. Hence, a small 
increase in concentration after administration of a natural steroid will be more easily 
detected compared to elevations in the concentration of the traditionally monitored 
steroids which can occur in a wide concentration range. In previous research, upper 
reference limits based on population statistics were set for each of these minor and 
major metabolites [30].  
Additionally, several other steroids are also quantified to obtain more information. 
These include 11β-OH-androsteron and 11β-OH-etiocholanolone which are not 
affected by intake of anabolic agents and act as indicators of elevated endogenous 
steroid production and/or urinary flow. 5α-androstande-3,17-dione and 5β-
androstande-3,17-dione were added to monitor microbiological activity in urine during 
the pre-analytical phase. Finally salbutamol, an important beta-2-adrenergic agonist, 
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the major metabolite of cannabis (11-nor-∆9-tetrahydrocannabinol-9-carboxylic acid) 
and norandrosterone were also included. 
The method of least squares has been used to construct the calibration curves over 6 
levels for every quantitative component. All correlation coefficients (R²) were above 
98%. The precision was calculated and evaluated using the RSDmax values 
obtained via the Horwitz equation. All obtained relative standard deviations (RSD) 
were lower than the calculated RSDmax. The accuracy, expressed as bias, was below 
15% for every calibration level.  
3.2.4 Qualitative 
Selectivity of the method was tested by analyzing a blank aliquot of the different 
urines, in order to check for possible naturally occurring interfering substances. 
These results showed that there are no interferences of the urinary matrix with the 
target compounds. 
For every compound screened qualitatively limits of detection (LOD) were 
traditionally determined as the lowest level at which the compound could be detected 
concerning the right retention times and signal to noise ratio (S/N > 3). When using 
tandem mass spectrometry (MSn), other criteria for detection and identification of the 
analyte are specified. This is done by determination of maximum tolerance windows 
for the relative ion intensities. The most abundant transition is taken as reference on 
which the second (and sometimes third) transition is scaled. Traditionally, the allowed 
tolerance windows for the relative abundances are stipulated in technical documents 
by governing bodies in the specified field. In this case the tolerance levels were 
calculated according to the requirements set by WADA in the applicable technical 
document (Table 4.1).  
Although ILAC-G17-2002 specifies that for the time being the application of the 
concept of measurement uncertainty is not a requirement [31], recently criticism has 
been uttered which targeted the use of tolerance windows for relative abundance of 
the mass to charge ratios (m/z) which were not based upon measurement uncertainty 
[32]. Indeed, according to the criticism the regulations set by many fields, but in 
particular the sports drug testing authorities, were ad-hoc. Therefore, in this paper a 
second set of the tolerance levels was calculated using the general principles of 
measurement uncertainty (MU). In general random measurement errors cause 
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statistical variations on the outcome of analytical measurements. The possible 
deviation between the measured value and the true value is expressed in 
measurement uncertainty (MU). This can be expressed as standard deviation or as 
an interval containing the true value with a given certainty. The range of these 
confidence intervals are calculated using a coverage factor (k). The value of this 
factor depends on the desired confidence level: k = 2 for 95% confidence level and k 
= 3 for a 99.7% confidence level. After the calculation of the standard deviation, this 
value will be multiplied by the coverage factor to determine the margins of the 
confidence levels. Both ways of calculating are used to ensure correct identification 
and determine the LOD of all qualitative compounds in this method.  
In general MU is composed of a bias factor and a precision factor. In this study, only 
the influence of precision on the uncertainty of the intensities of mass spectrometric 
signals was evaluated as a first approach to measurement uncertainty in mass 
spectrometry. Hence, when all uncertainty factors would be taken into account, it can 
be expected that the tolerance windows would become larger. In this case the 
intervals are only set by the standard deviation of the relative ion intensities over the 
ten urines multiplied by a coverage factor of 3 (99.7% confidence level is chosen). So 
the maximum tolerance windows for the statistical point of view are given by [x-3sd, 
x+3sd], where x is the mean value and sd the standard deviation.  
In this research both perspectives, explained above, are evaluated as criteria for 
measurement uncertainty in mass spectrometry. 
When following the WADA criteria there are 4 categories in relative ion intensities 
(Table 4.1). In the lowest category, relative intensities (RI) do not exceed 5%. In this 
study, several transitions fall into this category, e.g. for oxprenolol, where the ratio 
between the transitions 22172 (CE 20) and 22156 (CE 10) is 4% (Table 4.4). It 
could be observed that for most of these cases the tolerance levels are slightly tighter 
when calculated with the principles of MU i.e. in the case of oxprenolol [3.11, 4.89], 
compared to the [2, 6] for the WADA criteria. However it is clear that these 
differences are only minor. A similar conclusion can be made for the second category 
(5% < RI < 25%), e.g. benzphetamine (RI 20%) or ethamivan (RI 8%) for given 
transitions and collision energies. In the third category (25% < RI < 50% ) e.g. EDDP 
(RI 46.4%) and mesterolone metabolite (RI 30.5%), in most cases the tolerance 
levels when using the WADA criteria are more strict, but the differences are almost in 
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general neglectable, e.g. bisoprolol. Compounds like amiloride (RI 89%) and 
cyclazodone (RI 92.5%) are situated in the last category (RI > 50%) and show that 
for one compound the WADA rules are slightly stricter while for another the MU 
tolerance levels are smaller, again no big differences between both were found. 
In the past some critics concerning these tolerance windows was published, to point 
out that MU should be used instead of the levels fixed by WADA [32]. This research 
demonstrates that both perspectives are very similar and that practice shows that the 
tolerance levels imposed by WADA are therefore not arbitrary.  
4 Conclusions 
An improved screening method for detecting over 150 compounds from different 
classes in a qualitative way and the complete steroid profile expanded with minor 
metabolites in a quantitative way was developed. During validation, both WADA 
criteria and general principles of measurement uncertainty were used for correct 
identification of compounds in tandem mass spectrometry. It was found that both 
approaches are very similar.  
The addition of both free and glucuronidated (deuterated) internal standards allows 
for quality control in every individual sample i.e. hydrolysis efficiency and 
derivatisation efficiency. Special attention was paid to microbiological degradation 
and the impact on the steroid profile. It was found that samples can be stored in the 
refrigerator for 2 weeks without impact on the steroid profile. Instead of 5α/5β-dion 
concentrations as absolute threshold values, relative threshold values of 1 %5α and 
5 %5β were proposed, better reflecting the real impact on the concentrations of 
endogenous steroids in the steroid profile.  
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Table 4.4: Substance ordered by increasing retention times, all relative to 17α-Methyltestosterone (ISTD, RT=9.59min). 
Compound 
RRT 
(min) 
Quantifier 
Collision 
energy 
(eV) 
LOD 
(ng/mL) 
MRPL 
(ng/mL) 
Relative 
Abundance 
(%) 
Stdev 
MU   
Un_L 
MU   
UP_L 
Wada 
Criterium 
WADA   
UN_L 
WADA   
UP_L 
Methylamphetamine 0.163 
206 -> 59 15 
25 50 
206 -> 88 15 3.8 1.41 -0.43 8.03 1.9 1.9 5.7 
Selegeline 0.168 
96 -> 56 15 
25 50 96 -> 70 15 17.5 1.00 14.51 20.49 5 12.5 22.5 
96 -> 80 15 20.9 6.69 0.84 40.96 5 15.9 25.9 
Phendimetrazine 0.174 
85 -> 42 15 
10 50 85 -> 70 15 23.7 1.61 18.87 28.53 5 18.7 28.7 
85 -> 56 15 20.6 4.92 5.83 35.37 5 15.6 25.6 
Mefenorex 0.196 
120 -> 44 15 
25 50 
120 -> 41 15 18.8 2.90 10.11 27.49 5 13.8 23.8 
Prolintane 0.208 
126 -> 97 15 
5 
 
126 -> 84 15 77 7.47 54.59 99.41 10 67 87 
126 -> 42 15 47.2 5.62 30.35 64.05 9.44 37.76 56.64 
Furfenorex 0.216 
138 -> 81 5 
10 50 
138 -> 53 30 36.6 3.11 27.27 45.93 7.32 29.28 43.92 
Fencamfamine 0.217 
215 -> 186 10 
25 50 
215 -> 198 20 22 1.06 18.83 25.17 5 17 27 
Crothetamide 0.219 
154 -> 86 10 
25 50 
154 -> 69 20 34.1 1.50 29.60 38.60 6.82 27.28 40.92 
  
Compound 
RRT 
(min) 
Quantifier 
Collision 
energy 
(eV) 
LOD 
(ng/mL) 
MRPL 
(ng/mL) 
Relative 
Abundance 
(%) 
Stdev 
MU   
Un_L 
MU   
UP_L 
Wada 
Criterium 
WADA   
UN_L 
WADA   
UP_L 
1-Benzylpiperazine 0.219 
248 -> 102 15 
10 50 248 -> 116 10 24.3 1.51 19.78 28.82 5 19.3 29.3 
248 -> 130 10 24.7 3.14 15.29 34.11 5 19.7 29.7 
Cropropamide 0.225 
168 -> 100 10 
2.5 50 
168 -> 69 15 24 0.19 23.42 24.58 5 19 29 
Pholedrine 0.229 
294 -> 263 15 
25 50 
294 -> 189 15 42.9 6.65 22.95 62.85 8.58 34.32 51.48 
Pethidine 0.234 
247 -> 71 10 
20 200 
247 -> 173 10 11.4 0.73 9.21 13.59 5 6.4 16.4 
Lidocaine 0.242 
220 -> 204 15 
40 200 
220 -> 245 15 44.1 2.43 36.82 51.38 8.82 35.28 52.92 
MDEA 0.249 
264 -> 204 15 
25 50 264 -> 102 15 41.4 4.39 28.23 54.57 8.28 33.12 49.68 
264 -> 219 15 55.1 7.11 33.78 76.42 10 45.1 65.1 
Benzphetamine 0.26 
148 -> 91 20 
2.5 50 
148 -> 65 35 20.1 0.68 18.05 22.15 5 15.1 25.1 
Alprenolol 0.277 
321 -> 72 15 
50 500 
306 -> 203 15 68 3.81 56.58 79.42 10 58 78 
Methylphenidate 0.279 
156 -> 45 10 
25 50 
156 -> 84 10 72.3 5.93 54.51 90.09 10 62.3 82.3 
oxprenolol 0.306 
221 -> 72 20 
50 500 
221 -> 56 10 4 0.30 3.11 4.89 2 2 6 
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Clobenzorex 0.306 
168 -> 125 15 
5 50 
168 -> 89 35 15.5 2.57 7.78 23.22 5 10.5 20.5 
Ethamivan 0.315 
295 -> 223 20 
2.5 50 
295 -> 265 20 8 0.33 7.02 8.98 5 3 13 
Terbutaline 0.318 
356 -> 267 25 
10 100 
356 -> 355 25 70.3 3.37 60.18 80.42 10 60.3 80.3 
Pemoline 0.331 
392 -> 178 15 
2.5 50 392 -> 163 15 25.1 2.33 18.10 32.10 5.02 20.08 30.12 
392 -> 104 15 15.4 1.63 10.50 20.30 5 10.4 20.4 
EDDP 0.344 
277 -> 105 30 
100 200 
277 -> 220 25 46.4 4.50 32.90 59.90 9.28 37.12 55.68 
Carphedon 0.351 
272 -> 104 15 
2.5 50 
272 -> 198 15 25.7 0.69 23.62 27.78 5.14 20.56 30.84 
Octopamine 0.353 
174 -> 86 15 
2.5 50 
174 -> 100 10 55.4 6.09 37.12 73.68 10 45.4 65.4 
Metroprolol 0.373 
324 -> 207 15 
250 500 
324 -> 221 15 21.5 3.05 12.34 30.66 5 16.5 26.5 
Normethadon deriv. 1 0.38 
224 -> 103 35 
40 200 
224 -> 191 35 44.5 5.16 29.01 59.99 8.9 35.6 53.4 
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Clenbuterol 0.394 
335 -> 227 10 
0.2 2 
337 -> 229 15 68.7 3.78 57.36 80.04 10 58.7 78.7 
335 -> 300 10 35.6 1.92 29.83 41.37 7.12 28.48 42.72 
335 -> 262 15 46.4 4.50 32.90 59.90 9.28 37.12 55.68 
Pipradrol 0.407 
239 -> 161 15 
25 50 
239 -> 221 15 52.1 6.62 32.25 71.95 10 42.1 62.1 
Cyclazodone 0.411 
360 -> 178 15 
10 50 
360 -> 247 15 92.5 1.30 88.62 96.39 10 82.5 102.5 
Bupivacaine 0.412 
140 -> 84 15 
10 50 
140 -> 98 15 49.3 3.30 39.39 59.21 9.86 39.44 59.16 
Penbutolol 0.421 
348 -> 70 15 
10 200 348 -> 201 15 57.3 1.03 54.21 60.39 10 47.3 67.3 
348 -> 186 15 29 1.13 25.61 32.39 5.8 23.2 34.8 
3,3-diphenylpropylamine 0.423 
174 -> 86 10 
10 50 
174 -> 100 10 40.1 0.88 37.45 42.75 8.02 32.08 48.12 
Amiphenazole 0.426 
407 -> 187 10 
25 50 407 -> 221 15 21.7 2.86 13.11 30.29 5 16.7 26.7 
407 -> 187 10 75.7 6.43 56.40 95.00 10 65.7 85.7 
Methadone 0.428 
296 -> 191 10 
40 200 
296 -> 281 10 69.4 2.43 62.11 76.69 10 59.4 79.4 
Propanolol 0.432 
316 -> 231 10 
50 500 
316 -> 208 15 30.5 1.86 24.92 36.08 6.1 24.4 36.6 
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cocaine 0.444 
182 -> 82 10 
5 50 182 -> 122 10 17.8 0.46 16.41 19.19 5 12.8 22.8 
182 -> 108 10 15.9 0.64 13.99 17.81 5 10.9 20.9 
Normethadone deriv. 2 0.454 
296 -> 191 20 
10 200 
296 -> 252 20 30.4 0.36 29.31 31.49 6.08 24.32 36.48 
Bisoprolol 0.489 
405 -> 56 25 
100 500 
405 -> 172 15 30.2 1.90 24.49 35.91 6.04 24.16 36.24 
Amiloride 0.491 
388 -> 147 10 
125 250 
388 -> 298 10 89 7.57 66.31 111.70 10 79 99 
Metipranolol 0.502 
366 -> 281 10 
100 500 
366 -> 239 15 74.1 2.22 67.43 80.77 10 64.1 84.1 
Anastrazole 0.505 
209 -> 141 30 
10 50 209 -> 194 15 76.1 3.65 65.14 87.06 10 66.1 86.1 
209 -> 115 30 44 1.19 40.44 47.56 8.8 35.2 52.8 
Benzoylecgonine 0.506 
240 -> 82 20 
25 50 
361 -> 82 20 22.3 3.55 11.66 32.94 5 17.3 27.3 
Bupivacaine deriv. 2 0.512 
140 -> 84 15 
10 50 140 -> 98 15 38.7 5.81 21.29 56.12 7.74 30.96 46.44 
140 -> 41 15 23.7 1.61 18.87 28.53 5 18.7 28.7 
Pentazocine 0.515 
289 -> 45 10 
10 200 
289 -> 110 15 22.4 0.22 21.73 23.07 5 17.4 27.4 
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Letrozole metab. 0.521 
291 -> 160 20 
2.5 50 
291 -> 217 20 51.3 3.08 42.07 60.53 10 41.3 61.3 
Timolol 0.525 
373 -> 186 10 
25 500 
373 -> 70 35 65.6 1.97 59.70 71.50 10 55.6 75.6 
Probenecid 0.527 
328 -> 103 25 
12.5 250 
328 -> 193 15 47.3 1.80 41.91 52.69 9.46 37.84 56.76 
Zilpaterol 0.567 
308 -> 218 15 
5 10 308 -> 235 15 24.6 2.44 17.29 31.91 5 19.6 29.6 
308 -> 203 25 4.5 1.17 1.00 8.00 2.25 2.25 6.75 
Celiprolol 0.581 
200 -> 128 15 
100 500 
200 -> 144 15 20.7 1.97 14.80 26.60 5 15.7 25.7 
Aminogluthetimide deriv. 
1 
0.608 
361 -> 206 30 
5 50 
361 -> 221 10 75 3.38 64.88 85.13 10 65 85 
Betaxolol 0.611 
364 -> 209 10 
50 500 
364 -> 172 10 42.2 3.21 32.58 51.82 8.44 33.76 50.64 
Pindolol 0.619 
205 -> 130 10 
100 500 
292 -> 218 15 48.5 3.93 36.71 60.29 9.7 38.8 58.2 
Codeine 0.672 
371 -> 229 15 
10 200 
371 -> 234 10 75.7 0.98 72.75 78.65 10 65.7 85.7 
5-OH-pentoxyfylline 0.703 
337 -> 237 15 
5 50 
337 -> 193 15 8.5 0.50 7.00 10.00 5 3.5 13.5 
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Levobunolol 0.703 
234 -> 233 5 
25 500 
234 -> 217 10 101.6 0.20 100.99 102.21 10 91.6 111.6 
Boldenone metab. 0.705 
194 -> 179 10 
0.5 10 
194 -> 105 15 57.6 0.63 55.70 59.50 10 47.6 67.6 
Epimethenediol 0.706 
358 -> 301 15 
1 2 
358 -> 196 20 9.5 1.65 4.54 14.46 5 4.5 14.5 
Ethylmorphine 0.713 
385 -> 214 35 
10 200 
385 -> 234 10 60.6 1.21 56.96 64.24 10 50.6 70.6 
Fenspiride 0.715 
241 -> 96 20 
2.5 50 241 -> 154 15 71.1 1.14 67.69 74.51 10 61.1 81.1 
241 -> 108 15 32.1 0.61 30.27 33.93 6.42 25.68 38.52 
Hydromorphone 0.735 
429 -> 234 25 
20 200 
429 -> 357 15 61.6 0.86 59.01 64.19 10 51.6 71.6 
Oxycodone 0.745 
459 -> 368 15 
50 500 
459 -> 312 15 88.2 0.53 86.61 89.79 10 78.2 98.2 
Amineptine metab. 0.764 
192 -> 191 20 
5 50 
192 -> 165 35 20.9 1.71 15.76 26.04 5 15.9 25.9 
Nadolol 0.782 
510 -> 70 35 
25 500 
510 -> 186 20 67.9 6.31 48.96 86.84 10 57.9 77.9 
Prenylamine 0.792 
238 -> 58 20 
10 50 238 -> 167 10 12.6 2.36 5.53 19.67 5 7.6 17.6 
238 -> 91 20 1.1 0.35 0.04 2.16 0.55 0.55 1.65 
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MAM 0.797 
399 -> 287 15 
20 200 
399 -> 340 10 77.1 1.46 72.71 81.49 10 67.1 87.1 
Oxymorphone 0.816 
502 -> 70 30 
40 200 
517 -> 355 15 97 4.95 82.16 111.84 10 87 107 
Norethisteron metab. 0.82 
431 -> 167 20 
1 10 
431 -> 193 20 68.4 1.98 62.45 74.35 10 58.4 78.4 
Drostanolone metab. 0.822 
448 -> 433 10 
5 10 448 -> 343 25 39.4 2.05 33.25 45.55 7.88 31.52 47.28 
448 -> 253 25 23.9 3.35 13.86 33.94 5 18.9 28.9 
Heroin 0.843 
327 -> 215 15 
2.5 50 
327 -> 268 15 30.6 1.90 24.91 36.29 6.12 24.48 36.72 
Metenolone metab. 0.849 
446 -> 341 15 
5 10 
446 -> 195 20 31 3.35 20.96 41.04 6.2 24.8 37.2 
1-Androstenedion 0.851 
415 -> 221 20 
5 10 
415 -> 193 20 13.7 1.96 7.82 19.58 5 8.7 18.7 
6-OH-Bromantane 0.861 
395 -> 91 30 
2.5 50 
393 -> 91 30 96.9 0.97 93.99 99.81 10 86.9 106.9 
Fluoxy-18-nor 0.869 
462 -> 208 15 
2 10 
462 -> 337 15 25.9 1.40 21.70 30.10 5.18 20.72 31.08 
Bambuterol 0.872 
354 -> 72 25 
5 100 
354 -> 282 10 21.2 0.40 19.99 22.41 5 16.2 26.2 
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1-testosterone 0.873 
194 -> 179 5 
2 10 206 -> 191 10 28.7 2.96 19.83 37.57 5.74 22.96 34.44 
194 -> 105 10 63.7 3.89 52.04 75.36 10 53.7 73.7 
Mesterolone metab. 0.874 
448 -> 433 10 
1 10 
448 -> 253 20 30.5 2.41 23.27 37.73 6.1 24.4 36.6 
1-Androstenediol 0.883 
434 -> 195 10 
2 10 434 -> 377 10 35.1 2.42 27.83 42.37 7.02 28.08 42.12 
434 -> 143 10 27.7 2.96 18.81 36.59 5.54 22.16 33.24 
β-Methyltestosterone 
metab. 
0.884 
270 -> 213 15 
1 2 
255 -> 245 15 18.6 1.58 13.86 23.34 5 13.6 23.6 
α-Methyltestosterone 
metab. 
0.892 
270 -> 199 20 
1 2 
255 -> 105 20 79.5 6.44 60.18 98.82 10 69.5 89.5 
17α-Trenbolone 0.906 
412 -> 322 15 
5 10 412 -> 307 15 79.8 5.91 62.08 97.52 10 69.8 89.8 
412 -> 296 15 29.9 3.56 19.23 40.57 5.98 23.92 35.88 
Dimefline 0.909 
279 -> 163 15 
25 50 279 -> 133 15 27 3.29 17.12 36.88 5.4 21.6 32.4 
279 -> 105 15 17.4 1.91 11.66 23.14 5 12.4 22.4 
Fenbutrazate 0.912 
261 -> 103 35 
2.5 50 
261 -> 175 15 53 3.18 43.46 62.54 10 43 63 
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Boldenone 0.926 
206 -> 191 10 
0.5 10 430 -> 206 15 10.2 1.14 6.77 13.63 5 5.2 15.2 
206 -> 165 15 23.6 0.87 20.98 26.22 5 18.6 28.6 
Tibolone metab. 0.937 
443 -> 193 35 
2 10 
443 -> 167 30 58.1 2.73 49.91 66.29 10 48.1 68.1 
Norethandrolone metab. 0.938 
421 -> 241 15 
1 10 
421 -> 145 25 77.8 7.08 56.56 99.04 10 67.8 87.8 
Epioxandrolone 0.946 
363 -> 161 20 
5 10 363 -> 213 25 54.2 5.15 38.75 69.65 10 44.2 64.2 
363 -> 273 5 76.5 6.12 58.14 94.86 10 66.5 86.5 
Calusterone metab. 0.949 
374 -> 269 15 
5 10 
374 -> 229 15 67.6 4.60 53.81 81.39 10 57.6 77.6 
Fentanyl 0.956 
245 -> 146 20 
0.5 10 
245 -> 189 10 48.7 1.07 45.49 51.91 9.74 38.96 58.44 
Me-1-Testosterone 0.967 
356 -> 231 20 
5 10 356 -> 206 5 77.4 5.96 59.52 95.28 10 67.4 87.4 
356 -> 192 5 54.3 4.67 40.29 68.31 10 44.3 64.3 
Bolasterone metab. 0.969 
269 -> 213 15 
5 10 
269 -> 173 15 45.1 5.46 28.73 61.47 9.02 36.08 54.12 
Norethandrolone 0.969 
421 -> 331 10 
5 10 
421 -> 241 15 77.8 7.08 56.56 99.04 10 67.8 87.8 
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Metenolone 0.971 
446 -> 208 10 
0.5 10 
446 -> 195 25 69.2 3.60 58.40 80.00 10 59.2 79.2 
Clostebol metab. 0.972 
466 -> 431 15 
5 10 
0 0 0 
466 -> 181 25 66.2 4.37 53.09 79.31 10 56.2 76.2 
7βOH-DHEA 0.984 430 -> 299 15 5 10 
430 -> 325 15 76.1 3.42 65.83 86.37 10 66.1 86.1 
Mibolerone 0.984 
431 -> 341 15 
1 10 
431 -> 431 15 27 1.38 22.87 31.13 5.4 21.6 32.4 
Butorphanol 0.997 
416 -> 326 15 
25 50 
416 -> 103 15 69.4 5.48 52.95 85.85 10 59.4 79.4 
Methyldienolone 0.997 
430 -> 285 20 
5 10 
430 -> 340 15 38.7 3.99 26.74 50.66 7.74 30.96 46.44 
Norbolethone metab. 1 
435 -> 255 10 
1 10 
435 -> 345 5 36.1 3.61 25.27 46.93 7.22 28.88 43.32 
Fenethylline deriv. 1 1.001 
250 -> 207 15 
25 50 
250 -> 70 15 11.4 1.28 7.57 15.23 5 6.4 16.4 
THCA 1.004 
371 -> 289 20 
7.5 15 
371 -> 265 15 92.9 1.95 87.05 98.75 10 82.9 102.9 
Bolasterone 1.007 
460 -> 355 15 
5 10 
460 -> 315 20 60.3 4.22 47.64 72.96 10 50.3 70.3 
Calusterone 1.007 
460 -> 355 15 
5 10 
460 -> 315 20 65.8 4.34 52.77 78.83 10 55.8 75.8 
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Oxandrolone 1.01 
363 -> 273 10 
5 10 363 -> 213 15 18.1 2.70 10.01 26.19 5 13.1 23.1 
363 -> 161 20 35.1 3.47 24.68 45.52 7.02 28.08 42.12 
Ethisteron 1.01 
456 -> 316 15 
0.5 10 
456 -> 301 20 90.8 4.63 76.91 104.69 10 80.8 100.8 
Acebutolol 1.015 
278 -> 208 20 
250 500 278 -> 236 15 69.7 6.27 50.88 88.52 10 59.7 79.7 
278 -> 166 20 14.1 1.93 8.30 19.90 5 9.1 19.1 
4-OH-Nandrolone 1.022 
506 -> 147 25 
5 10 506 -> 195 20 20.4 1.67 15.38 25.42 5 15.4 25.4 
506 -> 93 20 17.1 2.50 9.61 24.59 5 12.1 22.1 
Norbolethone metab. 1 1.022 
435 -> 255 20 
0.5 10 
435 -> 345 5 36.1 3.61 25.27 46.93 7.22 28.88 43.32 
6α-OH-Androstenedione 1.027 518 -> 319 25 5 10 
518 -> 413 15 54.2 6.29 35.34 73.06 10 44.2 64.2 
Triamterene 1.031 
454 -> 340 15 
125 250 
454 -> 171 15 15.9 1.32 11.94 19.86 5 10.9 20.9 
Zeranol 1.034 
433 -> 295 20 
5 10 
433 -> 309 20 58.3 2.39 51.13 65.47 10 48.3 68.3 
Formebolone metab. 2 1.036 
534 -> 389 15 
5 10 
534 -> 339 25 28.2 2.57 20.50 35.90 5.64 22.56 33.84 
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4-OH-Androstenedione 1.038 
518 -> 147 30 
0.5 10 518 -> 169 30 23.9 1.48 19.45 28.35 5 18.9 28.9 
518 -> 107 30 57 4.39 43.83 70.17 10 47 67 
Norclostebol 1.041 
452 -> 216 15 
5 10 
452 -> 321 5 28.7 1.69 23.62 33.78 5.74 22.96 34.44 
Amineptine 1.042 
192 -> 191 15 
10 50 
192 -> 165 15 2.7 0.15 2.26 3.14 1.35 1.35 4.05 
4-OH-Testosteron 1.043 
520 -> 225 25 
5 10 
520 -> 431 15 65.3 7.51 42.77 87.83 10 55.3 75.3 
Cyclofenil metab. 1.053 
512 -> 422 15 
2.5 50 
512 -> 343 20 10.9 0.24 10.18 11.62 5 5.9 15.9 
Toremifene 1.053 
405 -> 58 15 
25 50 
405 -> 72 5 71.7 3.01 62.67 80.73 10 61.7 81.7 
6β-OH-methandienone 1.055 517 -> 229 25 5 10 
517 -> 337 15 8.9 0.80 6.50 11.30 5 3.9 13.9 
Dextromoramide 1.055 
265 -> 166 20 
100 200 
265 -> 98 20 78.4 1.88 72.76 84.04 10 68.4 88.4 
Labetolol 1.064 
383 -> 265 15 
50 500 383 -> 251 15 52.5 6.67 32.50 72.50 10 42.5 62.5 
383 -> 223 15 28.7 3.10 19.40 38.00 5.74 22.96 34.44 
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Fluoxymesterone 1.065 
552 -> 407 15 
5 10 552 -> 357 20 36.9 4.72 22.73 51.07 7.38 29.52 44.28 
552 -> 319 25 40.9 4.34 27.89 53.91 8.18 32.72 49.08 
Oral-Turinabol 1.065 
240 -> 225 5 
5 10 240 -> 189 20 22.7 1.93 16.91 28.49 5 17.7 27.7 
240 -> 93 15 29.2 1.28 25.35 33.05 5.84 23.36 35.04 
Oxymesterone 1.069 
534 -> 389 25 
5 10 
534 -> 444 20 13.8 2.79 5.44 22.16 5 8.8 18.8 
Formoterol 1.07 
277 -> 216 10 
50 100 
277 -> 233 10 49.3 6.80 28.89 69.71 9.86 39.44 59.16 
Fenethylline deriv. 2 1.076 
322 -> 207 15 
25 50 322 -> 253 15 32.1 1.38 27.96 36.24 6.42 25.68 38.52 
322 -> 45 15 32.9 2.04 26.78 39.02 6.58 26.32 39.48 
4-OH-Tamoxifen 1.077 
459 -> 72 10 
25 50 
459 -> 58 20 40.1 0.88 37.45 42.75 8.02 32.08 48.12 
Fenoterol 1.078 
308 -> 207 25 
50 100 308 -> 179 30 21.1 2.15 14.64 27.56 5 16.1 26.1 
308 -> 116 30 15.8 3.13 6.41 25.19 5 10.8 20.8 
Famprofazone 1.082 
286 -> 72 20 
25 50 
286 -> 214 15 18 2.45 10.66 25.34 5 13 23 
  
  
Compound 
RRT 
(min) 
Quantifier 
Collision 
energy 
(eV) 
LOD 
(ng/mL) 
MRPL 
(ng/mL) 
Relative 
Abundance 
(%) 
Stdev 
MU   
Un_L 
MU   
UP_L 
Wada 
Criterium 
WADA   
UN_L 
WADA   
UP_L 
Oral-Turinabol metab. 1.086 
315 -> 227 15 
5 10 317 -> 243 15 52.2 6.99 31.22 73.18 10 42.2 62.2 
315 -> 241 15 23 4.12 10.65 35.35 5 18 28 
Exemestane metab. 1.098 
443 -> 207 20 
25 50 
443 -> 353 10 33.8 3.45 23.46 44.14 6.76 27.04 40.56 
Fencamine deriv. 1 1.098 
365 -> 308 15 
10 50 365 -> 251 15 12.4 1.98 6.45 18.35 5 7.4 17.4 
365 -> 84 15 3.6 0.74 1.39 5.81 1.8 1.8 5.4 
Danazol 1.1 
466 -> 167 20 
5 10 
466 -> 193 20 41.1 3.29 31.24 50.96 8.22 32.88 49.32 
Canrenone 1.113 
412 -> 397 15 
25 250 
412 -> 383 15 15.7 1.70 10.61 20.79 5 10.7 20.7 
16-OH-furazabol 1.117 
490 -> 231 15 
1 10 
490 -> 143 35 47.8 2.10 41.49 54.11 9.56 38.24 57.36 
Strychnine 1.123 
316 -> 220 15 
10 50 316 -> 144 15 23.1 2.82 14.65 31.55 5 18.1 28.1 
316 -> 115 25 15.5 1.07 12.29 18.71 5 10.5 20.5 
3’-OH-Stanozolol 1.128 
545 -> 147 25 
10 2 
488 -> 182 15 33.2 3.35 23.14 43.26 6.64 26.56 39.84 
16-OH-Stanozolol 1.128 
560 -> 143 15 
10 2 
560 -> 231 15 10 2.86 1.42 18.58 5 5 15 
  
  
Compound 
RRT 
(min) 
Quantifier 
Collision 
energy 
(eV) 
LOD 
(ng/mL) 
MRPL 
(ng/mL) 
Relative 
Abundance 
(%) 
Stdev 
MU   
Un_L 
MU   
UP_L 
Wada 
Criterium 
WADA   
UN_L 
WADA   
UP_L 
Fencamine deriv. 2 1.146 
293 -> 236 15 
25 50 293 -> 84 15 2.7 0.83 0.21 5.19 1.35 1.35 4.05 
293 -> 58 15 23 2.02 16.93 29.07 5 18 28 
Fluticasone 1.162 
644 -> 224 15 
15 30 644 -> 461 15 44.9 3.19 35.34 54.46 8.98 35.92 53.88 
644 -> 371 15 14.9 2.37 7.79 22.01 5 9.9 19.9 
Buprenorfine 1.172 
506 -> 84 25 
0.5 10 
506 -> 55 30 39.8 0.72 37.65 41.95 7.96 31.84 47.76 
Raloxifene 1.216 
578 -> 193 35 
5 50 
578 -> 413 30 30.9 2.69 22.84 38.96 6.18 24.72 37.08 
Carvedilol 1.224 
183 -> 154 15 
250 500 
183 -> 155 20 90.9 5.27 75.08 106.72 10 80.9 100.9 
Salmeterol 1.227 
311 -> 149 15 
20 100 
311 -> 121 25 22.6 0.95 19.75 25.45 5 17.6 27.6 
  
  
Internal standard 
RRT 
(min) 
Quantifier 
Collision 
energy 
(eV) 
LOD 
(ng/mL) 
MRPL 
(ng/mL) 
Relative 
Abundance 
(%) 
Stdev 
MU   
Un_L 
MU   
UP_L 
Wada 
Criterium 
WADA   
UN_L 
WADA   
UP_L 
Salbutamol-d3 0.3629 
372 -> 210 20 
  372 -> 193 20 20 1.28 16.16 23.84 5 15 25 
Androsterone-d4 0.7789 
423 -> 333 20 
  423 -> 243 20 100 3.30 90.10 109.90 10 90 110 
Etiocholanolone-d5 0.7894 
424 -> 334 20 
  424 -> 244 20 65 1.82 59.54 70.46 10 55 75 
5α-And-3α,17β-diol-d3 0.8029 
244 -> 188 15 
  
244 -> 202 15 96.8 0.00 96.80 96.80 10 86.8 106.8 
244 -> 145 15 55 0.00 55.00 55.00 10 45 65 
5β-And-3α,17β-diol-d5 0.8081 
246 -> 164 15 
  
246 -> 190 15 62.1 0.62 60.24 63.96 10 52.1 72.1 
246 -> 176 15 47.3 1.37 43.18 51.42 9.46 37.84 56.76 
DHEA-d6 0.8571 
438 -> 333 20 
  
438 -> 307 20 7.8 0.00 7.80 7.80 5 2.8 12.8 
438 -> 243 20 68.9 0.00 68.90 68.90 10 58.9 78.9 
Epitestosterone-d3 0.8895 
435 -> 209 15 
  435 -> 330 15 50 1.60 45.20 54.80 10 40 60 
DHT-d3 0.902 
437 -> 195 15 
  
437 -> 143 15 73.9 5.03 58.82 88.98 10 63.9 83.9 
437 -> 205 15 30.5 1.95 24.64 36.36 6.1 24.4 36.6 
Testosterone-d3 0.9397 
435 -> 209 20 
  435 -> 330 20 35 0.74 32.80 37.21 7 28 42 
  
 
Internal standard 
RRT 
(min) 
Quantifier 
Collision 
energy 
(eV) 
LOD 
(ng/mL) 
MRPL 
(ng/mL) 
Relative 
Abundance 
(%) 
Stdev 
MU   
Un_L 
MU   
UP_L 
Wada 
Criterium 
WADA   
UN_L 
WADA   
UP_L 
17α-Methyltestosterone 1 446 -> 301 15 
  446 -> 198 20 7.9 0.70 5.81 9.99 5 2.9 12.9 
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Abstract 
A rapid and sensitive determination of cannabinoids in urine is important in many 
fields, from workplace drug testing over toxicology to the fight against doping. The 
detection of cannabis abuse is normally based on the quantification of the most 
important metabolite 11-nor-∆9-tetrahydrocannabinol-9-carboxylic acid (THCA) in 
urine. In most fields THCA needs to be present at a concentration exceeding 15 
ng/mL before a positive result can be reported.  
In this paper a fast confirmation method is described to quantify THCA in 1 mL of 
urine. This method combines a 4 min GC-QqQ-MS method with a fast sample 
preparation procedure using microwave assisted derivatisation in order to complete 
the quantification of THCA in urine in 30 min.  
The method is selective, linear over the range 5 – 100 ng/mL and shows excellent 
precision and trueness and hence, the estimated measurement uncertainty at the 
threshold level is small. The method also complies with applicable criteria for mass 
spectrometry and chromatography. Therefore, the method can be used for rapid 
screening and confirmatory purposes. 
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1 Introduction 
The psychoactive substances from Cannabis sativa are amongst the most widely 
used illicit drugs in the world. Considering the various effects of cannabis [1], there is 
a need for rapid and sensitive detection methods in many fields: workplace drug 
testing [2], clinical and forensic toxicology [3], and the fight against doping [4]. Although 
they do not improve athletic performance, cannabinoids allow the athlete to relax and 
escape from pressure. Additionally, the use of cannabis reduces alertness and quick 
reflexes, making it dangerous in motor and team sports [5,6]. Therefore, natural (e.g. 
cannabis, hashish, marijuana) or synthetic ∆9-tetrahydrocannabinol (THC) are also 
prohibited in competition by the World Anti-Doping Agency (WADA) [7].  
According to the guidelines of various scientific organizations, a two-step approach is 
applied: after detecting the substance or its metabolites in a screening method, a 
confirmation procedure is performed in order to obtain additional information to 
support a possible positive result. This confirmation procedure needs to have equal 
(in case a hyphenated mass spectrometry method was used in the screening) or 
greater selectivity than the initial screening method [8,9]. 
In most fields, immunoassays are used as screening methods for the detection of 
cannabis metabolites in biological matrices. However, since these techniques 
measure the total amount of cannabis metabolites [10] and can eventually show cross-
reactivity, any positive result must be confirmed by a chromatographic technique, 
combined with mass spectral identification [11,12]. In general chromatography-mass 
spectrometry needs to be used to comply with the stringent requirements to 
unequivocally identify a compound in most fields.  
To differentiate active from passive users [13], a threshold concentration of 15 ng/mL 
for 11-nor-∆9-tetrahydrocannabinol-9-carboxylic acid (THCA), the major metabolite of 
THC (Fig. 5.1), in urine is set by WADA [14]. Similar as for the WADA-regulations, a 
threshold of 15 ng/ml is also commonly used in the fields of toxicology and in drugs at 
the workplace testing [9,15]. Of course any conclusion, whether or not a threshold 
concentration is exceeded, should take into account the measurement uncertainty 
associated with the result. 
Both the limited reporting period and the limited amount of urine available are 
important factors in the development of a confirmation procedure. Traditionally, 
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confirmatory methods for THCA use multiple sample preparation steps and are time-
consuming [16].  
In this work a fast confirmation method is presented for the quantification of ∆9-
tetrahydrocannabinol in urine that not only fulfills all legal requirements (MS criteria, 
uncertainty, etc.), but which by using an accelerated sample pretreatment and a fast 
chromatographic method allows to quantify this metabolite rapidly and accurately in a 
low volume of urine.  
 
 
Fig. 5.1 Formation of THCA, the marker for detection of cannabis use in urine. 
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2 Experimental 
2.1 Instrumentation 
An Agilent (Agilent Technologies, Palo Alto, USA) GC 7890 gas chromatograph 
coupled to an Agilent 7000B triple quadrupole mass spectrometer (Agilent 
Technologies) and a MPS2 autosampler and PTV-injector from Gerstel (Mülheim and 
der Ruhr, Germany) were used.  
The GC column – 12 m x 250 µm and 0.25 µm film thickness – was a HP-1MS from 
J&W Scientific (Agilent Technologies, USA). The temperature program was as 
follows: the initial temperature was 110°C (0.15min), increased at 70°C/min to 310°C 
(held for 1min). The transfer line was set at 310°C. Helium (Air Liquide, Desteldonk, 
Belgium) was used as carrier gas at a flow rate of 3 mL/min.  
Injection was performed using the following PTV setting: in the solvent vent mode 10 
µL was injected (0.5 µL/s injection speed) and the PTV-temperature settings were: 
110°C (0.15 min), 12°C/min to 310°C (2 min) and 12°C/min to 380°C (1 min). The 
vent flow was 60 ml/min and the vent pressure 5 psi until 0.1 min. 
In the QqQ collision cell He was used as a quench gas at 2.25 mL/min and N2 as 
collision gas at 1.5 mL/min. 
Quantification and confirmation were performed in selected reaction monitoring (SRM) 
mode. The monitored transitions and corresponding collision energies are given in 
Table 5.1. 
For derivatisation a domestic microwave oven (Samsung M643) was used in this 
study, which has a total capacity of 750W. The effective capacity was verified with 
every batch. 
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Table 5.1. Monitored transitions for THCA and THCA-d9 (internal standard), 
corresponding collision energies and transition ratios (tested against WADA criteria 
for identification). 
        WADA Max. tolerance window 
Compound 
name 
Transition Collision 
energy (eV) 
Transition 
ratio (%) 
Identification 
criterium Under limit Upper limit 
THCA 371 -> 305 10 
    THCA 371 -> 289 10 98.8 10 88.8 108.8 
THCA 371 -> 265 10 86.8 10 76.8 96.8 
THCA 371 -> 95 10 78.4 10 68.4 88.4 
THCA-d9 380 -> 67 25 
    THCA-d9 380 -> 101 25 35.2 7.04 28.16 42.24 
THCA-d9 380 -> 84 25 50.5 10 40.5 60.5 
THCA-d9 380 -> 292 25 43.2 8.64 34.56 51.84 
 
2.2 Reagents 
11-nor-∆9-tetrahydrocannabinol-9-carboxylic acid (THCA) and d9-11-nor-∆9-
tetrahydrocannabinol-9-carboxylic acid (THCA-d9) were purchased from Cerriliant 
(Round Rock, Texas, USA). NaOH and acetic acid were from Merck (Overijse, 
Belgium). N-methy-N-(trimethylsilyl)-trifluoroacetamide (MSTFA) was obtained from 
Chem. Fabrik Karl Bucher (Waldstedt, Germany). Ethanethiol and ethylacetate were 
purchased from Acros (Geel, Belgium) and acetonitrile (ACN) was from Biosolve 
(The Netherlands). Ammoniumiodide (NH4I) from Sigma Aldrich (Bornem, Belgium) 
and n-hexane from Biosolve (Valkenswaard, The Netherlands). All reagents were 
analytical grade. 
2.3 Sample preparation 
1 mL of urine was spiked with 50 µL of the internal standard containing 0.5 µg/mL 
THCA-d9. Hydrolysis was performed by incubation for 7 min in an oven at 56°C ± 
5°C after addition of 100 µL of 6M NaOH solution. After briefly cooling 1.5 mL acetic 
acid and 3 mL n-hexane/ethyl acetate (9/1) were added and the mixture was 
extracted by vortexing for 1 min. The organic phase was evaporated under oxygen 
free nitrogen at 40°C ± 5°C. The dried residue was derivatised using 20 µL 
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acetonitrile, 50 µL MSTFA and 50 µL of MSTFA/ethanethiol/NH4I (500:4:2) in a 
microwave reactor at 750 W during 1.5 min.  
2.4 Validation 
2.4.1 Microwave calibration 
The microwave calibration procedure was based upon a calorimetric methodology. In 
a glass beaker, 1L distilled water was heated in the microwave for 90 s at 100% 
power. The microwave power absorbed by the water that was used for heating the 
volume was calculated on the measured temperature rise ∆T [17]. 
   
    
        
 
In this formula P is the microwave power in Watt (W), t the time of heating in seconds, 
V the volume of heated water (m³), CP the heat capacity (J/kg.K) and ρ the density 
(kg/m³).  
2.4.2 Quantitative 
To construct calibration curves, blank urine samples were spiked at 6 concentration 
levels. The least squares method was used for fitting the calibration curves and 
controlling linearity of the method. At every level accuracy and precision were tested 
over 3 replicates. The tolerances for precision were calculated following the Horwitz 
equation (RSDmax= 2(1-0,5logC)) and should not exceed 2/3 RSDmax. The 
accuracy, expressed as bias, may not exceed 15%.  
For correct identification of the compound, WADA criteria state that retention times 
(RT) of the analyt shall not differ more than ±0.1 min or 2% from that of the same 
substance in a spiked urine sample. Further, the transition ratios are calculated by 
dividing the area of the given qualifier by the quantifier. Maximum tolerance windows 
for these relative ion intensities are determined by WADA [18]. For the least intense 
diagnostic transition, signal-to-noise (S/N) ratio shall be greater than 3.  
To verify to what extent the method can determine THCA and THCA-d9 in matrices 
without interferences from other compounds, several mixtures of possible interfering 
compounds (narcotics, anabolic steroids, beta-blockers, diuretics and stimulants) 
were analysed.  
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The limit of detection (LOD) and limit of quantification (LOQ) were determined by 
using the IUPAC standard approach SA1, which uses the mean blank signal as the 
basis for the calculation of the LOD and LOQ values [19]. 
The standard deviation, calculated in 40 control samples, was used to determine 
tolerance windows for quality control and measurement uncertainty for THCA. 
2.4.3 Cross validation 
To verify the applicability of the method for the analysis of routine samples, the 
method was compared to the GC-MS method which was formerly used in our lab [16]. 
Therefore, 20 urines, positive for THCA, were analysed with both methods and the 
obtained concentrations were compared. 
3 Results and discussion 
3.1 Sample preparation procedure 
In previous described methods using gas chromatography-mass spectrometry, the 
quantity of urine used per analysis varied between 2 and 3 mL [10,11,16,20–23]. Since the 
amount of urine available is limited and for confirmation procedures usually 3 aliquots 
are analysed, it is important to lower the volume of urine consumed per analysis. The 
combination of large volume injection using a PTV injector and tandem mass 
spectrometry for higher selectivity and sensitivity (Fig. 5.2), allowed for using only 1 
mL of urine. 
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Fig. 5.2 THCA and THCA-d9 ion traces in a urine sample, spiked with THCA at 15 ng/ml 
(left) and THCA-d9 at 50 ng/ml (right). 
 
Since THCA is mostly excreted in urine in a conjugated form (Fig. 5.1), first a 
hydrolysis step is performed. In previously described methods this is either done with 
an enzymatic hydrolysis using β-glucuronidase (incubation up to 60min) [23] or an 
alkaline hydrolysis using NaOH or KOH (usually between 15min and 30 min 
incubation) [10,11,20]. THCA however is connected to the glucuronide using an ester 
bond, which allows the use of a faster alkaline hydrolysis. Indeed, previous research 
showed that incubation for 7 min provides complete hydrolysis [24]. Hence, after 
verification of this procedure the hydrolysis time in this study was set to 7 min as well. 
While in the past, when using single MS technology, a preliminary extraction was 
needed for sample clean-up in order to obtain sufficient selectivity [16], this is not 
necessary when using MS/MS. The elimination of this step reduces the sample 
preparation time. Hence, sample pretreatment for GC-MS/MS is less time-consuming 
and becomes comparable to the fastest recently published LC-MS procedures [24–27]. 
Subsequently, the free compound is usually isolated out of the urine matrix using 
labor-intensive solid-phase extraction (SPE) [21] or time consuming liquid-liquid 
extraction (up to 20min mixing/rolling) [16,22,23]. This step is optimized by analyzing 
blank urine samples spiked at 15 ng/mL THCA using different extraction times (3 
replicates each). From the recoveries given in Fig. 5.3 it can be concluded that the 
extraction can be shortened to 1 min of vortexing without compromising on efficiency, 
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resulting in a drastic reduction of analysis time. This can be explained by the addition 
of the deuterated internal standard THCA-d9 which compensates very well for any 
losses during this and other sample preparation steps. Further, the changes in peak 
area of THCA in this experiment are showing that the equilibrium is quickly set. 
Indeed, compared to the traditional 20 min of rolling where an average peak area of 
30877 with a RSD of 4.33% was found (n = 3), all other peak areas did not differ 
more than 0.14% from this value. 
 
 
Fig. 5.3 Optimization extraction procedure: recoveries as a function of the mixing time 
for samples spiked at 15 ng/mL THCA (n=3). 
 
Recently, most of the fast quantification methods for THCA have been based on LC-
MS analysis. One of the primary reasons for this is that GC-MS requires a time-
consuming derivatisation step to improve the compounds characteristics in terms of 
chromatography. This derivatisation is usually performed with silylation reagents and 
the energy needed to complete the silylation reaction is traditionally added by 
conventional heating, which requires long reactions times up to 1h [28,29]. Supplying 
the energy transfer by microwave irradiation instead of thermal heating can reduce 
this derivatisation time to a few minutes [30]. When using microwave-assisted 
derivatisation (MAD), the reaction mixture is heated rapidly from the inside, in 
contrast to conventional heating which is slow and enters the sample from the 
surface, heating also the reaction tube [31]. Reducing the time required for this and 
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other sample preparation steps prior to GC analysis greatly improves the 
competitiveness of GC-MS. Indeed, GC-MS is less costly than LC-MS and shows 
better separation power. 
The GC-MS method described here allows for a perfect separation of the target 
compound from any matrix interferences in less than 4 min. To the best of our 
knowledge, this is faster than previously described GC [16,22,23,32] and LC [24–26] 
method run times, greatly improving sample turn-around and throughput. 
Hence, the optimized sample preparation procedure together with a GC run of only 4 
min allows for a quantification of THCA in 1 mL of urine in less than 30 minutes. 
3.2 Derivatisation procedure 
The domestic microwave system used in this experiment has a nominal power of 
750W. Since quality control is of great importance in doping control, a procedure is 
needed to monitor the performance of the microwave through time. When using the 
absorbed power as a parameter, the stability of the microwave can easily be 
monitored on a daily base [33]. Therefore, 1 L of distilled water is heated for 90 s at 
100% nominal power. Using the abovementioned formula, one can calculate the 
effective absorbed power from the temperature rise of the water. From different 
measurements over a period of 2 months, an absorbed power of 576 ± 39 W was 
found. 
When using microwave assisted derivatisation, reaction solvent, microwave power 
and reaction time are important parameters [34,35]. 
In contrast to conventional heating, the amount of heat transferred to the reaction 
mixture depends on the dielectric properties of the molecules [31]. Because polar 
molecules have a permanent dipole moment, they can absorb the microwave energy 
and convert it into heat. ACN has a high polarity and is therefore very suitable for 
absorbing electromagnetic energy [36]. This means that the derivatisation mixture for 
silylation commonly known in the doping control field [37] can still be used, only an 
easy addition of ACN is required. 
To investigate the yield of the derivatisation reaction when using microwave energy, 
comparison was made with conventional heating in an oven. Therefore, 2 calibration 
curves were made by spiking 6 blank urines with THCA at different concentration 
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levels (5, 10, 20, 50, 75 and 100 ng/mL). The samples of the first calibration curve 
were heated for 90 s in the microwave for derivatisation, while the samples of the 
second calibration curve were heated for 30 min at 80°C in a conventional oven. The 
equations of both calibration curves are showed in Table 5.2, coefficients of 
determination were both higher than 99%. 
 
Table 5.2: Comparing microwave assisted derivatisation (90 s at 750 W) to 
derivatisation using conventional heating (30min at 80°C), control samples spiked at 
25 ng/mL THCA. 
 Oven Microwave 
Calibration curve eq. 
y = 0.128580 x – 0.020451 
R² = 0.99880 
y = 0.129871 x – 0.028104 
R² = 0.99953 
Mean concentration control 
samples (ng/mL) 
24.3 24.41 
Standard deviation on 
concentration control samples 
0.392 0.493 
T-Test 0.7716 
 
Subsequently, 2 sets of 6 THCA control samples spiked at 25 ng/mL were prepared 
using both heating methods to compare their performance. A t-test was used to 
determine whether there is a significant difference between the means of both groups. 
The calculated P-value was 0.7716, which indicates no difference between both 
groups. 
This proves that the derivatisation yield after 90 s of irradiation at 750 W is 
comparable to the yield of the derivatisation with 30 min of conventional heating at 
80°C. 
Chapter 5: Confirmatory quantification of threshold substances: THCA 
121 
 
3.3 Validation 
3.3.1 Quantitative 
For the quantification of THCA, calibration curves over 6 concentration levels (5, 10, 
20, 50, 75 and 100 ng/mL) were constructed, using the method of least squares. The 
coefficient of determination r² was above 99%.  
At each level, precision and bias were determined in 3 replicates. The Horwitz 
equation was used to calculate the tolerance levels for precision. For every 
calibration level the obtained relative standard deviations (RSD) were lower than 2/3rd 
of the calculated RSDmax. The bias was always below 15% (Table 5.3).  
 
Table 5.3: Relative standard deviation and bias for each calibration level. 
Conc.(ng/mL) 5 10 20 50 75 100 
2/3RSDmax 23.68 21.33 19.22 16.75 15.75 15.09 
RSD % 11.21 6.59 1.32 1.3 5.19 3.75 
Bias % 6.87 -1.73 -6.83 -3.93 0.60 0.92 
 
Retention times did not differ more than 2% between all samples, thereby complying 
with WADA’s criteria [18]. 
To ensure correct identification in tandem mass spectrometric detection, two or more 
precursor-product ion transitions are monitored. The relative abundance of each 
transition is calculated relative to the most abundant transition (quantifier). The 
allowed tolerance windows for the relative abundances are traditionally imposed by 
governing bodies in the given field. Here the tolerance levels were calculated 
according to the WADA technical document [18]. For THCA all calculated transition 
ratios are between the calculated lower and upper limits (Table 5.1). Additionally the 
S/N ratio of the least intense diagnostic transition is calculated. On each 
concentration level of the calibration curve, this ratio was higher than 3 to 1 for the 
least abundant transition. 
Selectivity of the method was tested by analyzing ten blank urines and urines spiked 
with mixtures of other WADA prohibited drugs and/or metabolites (50 anabolic 
steroids, 15 beta-blockers, 30 diuretics, 17 narcotics and 35 stimulants). These 
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results showed that there are no interferences of the urine matrix and spiked 
compounds with the target analytes.  
The calculation of the LOD, described by IUPAC, is based on the mean value of the 
blank signal [19]. Therefore, 10 blank urine samples were analysed and the standard 
deviation on the blank signal was calculated as 0.0178. With a slope of the 
calibration curve of 0.9399 and a coverage factor k of 3 for a 99.9% probability, the 
calculated LOD was 0.1 ng/mL. For the quantification limit IUPAC uses a coverage 
factor of 10. Using the same calculation the LOQ was found at 0.2 ng/mL. Although 
this is a low detection limit, it is of little importance in doping control since THCA is a 
threshold substance, but it does show the possibility to detect trace amounts of this 
compound in a biological matrix with limited sample preparation using GC-MS/MS.  
In an effort to harmonize the results amongst all laboratories world-wide, WADA has 
defined the maximum combined uncertainties (uc max) for all threshold compounds 
and calculated a decision limit (DL) that needs to be used when reporting results. 
This DL is the sum of the original threshold value and a guard band. The guard band 
is based upon the maximum acceptable value of the combined standard uncertainty 
(uc max) multiplied by an appropriate expansion factor k (1.645; representing a 95% 
one-sided confidence level). In the case of THCA, a urine sample can be reported as 
‘positive’ if the concentration of THCA exceeds the DL of 18 ng/ml. Consequently, the 
standard uncertainty uc of any methodology used should be less than the uc max of 1.5 
ng/ml. This protocol is in agreement with the Eurachem guidelines on the use of 
uncertainty data in compliance testing [38]. 
Over 40 quality control samples, spiked at 15 ng/mL THCA, the RSD and bias were 
found to be 5.88% and 2.50% respectively. Using these values the calculation of the 
combined standard uncertainty uc (by taking the square root out of the sum of 
squares of both parameters) resulted in 0.6 ng/mL. This is well below the maximal 
combined standard uncertainty uc Max of 1.5 ng/mL imposed by WADA. The expanded 
uncertainty for a 95% confidence level based on a 2-tailed distribution is calculated 
using a coverage factor k of 2.  
3.3.2 Application to routine samples 
20 urine samples, with concentrations of THCA above the WADA decision limit of 18 
ng/mL, were analysed. The results were compared with concentrations obtained 
Chapter 5: Confirmatory quantification of threshold substances: THCA 
123 
 
when analyzing these urine samples with the GC-MS quantification method of De 
Cock et al [16]. To check the correlation between the 2 methods a Bland-Altman plot is 
used. As showed in Fig. 5.4 all values are in the 95% confidence interval, which 
proves the agreement between the GC-MS and the newly developed GC-QqQ-MS 
method. 
 
 
Fig. 5.4 Bland-Altman plot for the correlation between the GC-MS method of De Cock 
et al. [16] and the developed GC-QqQ-MS method for 20 urine samples positive for 
THCA. The 95% confidence interval (dotted lines) around the mean difference (solid 
line) is showed. 
 
3.4 Additional considerations 
Sample preparation is probably the most polluting part of an analytical method 
because of the high quantities of organic solvents used. Special attention was paid to 
the impact on the environment and the associated overall cost per analysis. 
In order to speed up the sample preparation time, methods using (automated) SPE 
for the extraction of THCA in urine were developed [20,26]. The SPE protocol normally 
requires a conditioning step using 2 to 4 mL of solvent [25,32]. After loading the sample, 
-20
-15
-10
-5
0
5
10
15
0 20 40 60 80 100 120 140 160 180 200
D
if
fe
re
n
ce
 
Mean 
Chapter 5: Confirmatory quantification of threshold substances: THCA 
124 
unwanted interferences are removed by successive washes using several mL of 
solvent like methanol, acetic acid and ACN[20,25,26]. Finally more MeOH and ACN is 
added to elute the compounds of interest from the cartridge. 
The LLE methodology proposed here only consumes 3 mL of organic solvents to 
extract the free THCA in urine and there is no need for SPE cartridges. Such 
procedure is environmentally friendlier and reduces the overall cost of the procedure. 
4 Conclusions 
A selective method for the quantification of THCA in urine was developed and 
validated. Special attention was paid to the limited volume of urine available and the 
total analysis time.  
The use of microwave assisted derivatisation allows for a fast and complete silylation 
of THCA in 90 s, whereas this step would take at least 30 min using conventional 
heating in an oven. In order to monitor the performance of the domestic microwave a 
calorimetric methodology was used.  
This method can be applied as a confirmation procedure after a positive finding of 
THCA in a screening method and allows for the quantification in less than 30 min. 
5 Note: Implementation of the new Technical Document 
TD2013 DL 
On 11 May 2013, WADA announced an update on the technical document on 
decision limits for the confirmatory quantification of threshold substances (TD2013 
DL [39]). This document contains a new directive for the confirmation of THCA in urine, 
as an answer to the submissions received from stakeholders during the review 
process of the Code [40].  
Concrete, this new document contains an increase of the threshold for THCA in urine 
from 15 ng/mL – as described in this chapter – to 150 ng/mL. This new threshold 
aims at reducing the chances for a positive test in competition after the (allowed) out 
of competition use of cannabis. Very likely, this will lead to a decrease in the number 
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of Adverse Analytical Findings for THCA in the future (cfr. Statistics in Chapter 1, 
paragraph 4.1). 
This new technical document necessitates a revision of the method described in this 
chapter. Indeed, both the range of the calibration curve (currently the highest level is 
100 ng/mL) as the estimation of the measurement uncertainty need an update. 
However, since sample preparation and both chromatographic and mass 
spectrometric conditions are still applicable, the method in general, can be 
maintained.  
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Abstract 
Around 2008, synthetic cannabinoids were found to be present in and responsible for 
the psychoactive effects of herbal mixtures with names like ‘Spice’ or ‘K2’. In 
response to the increased popularity of these products, (inter)national organizations 
and governments started banning these cannabimimetics gradually. However, the 
lack of a uniform and international regulation makes it hard to control this issue.  
For the different types of synthetic cannabinoids the scientific knowledge in terms of 
pharmacokinetics and pharmacodynamics is limited. This also means that little is 
known on the health of users, both on short and long term.  
In the last years effort has been made to make detection of these products possible 
in different biological matrices. However, since the number of cannabimimetic 
compounds on the market appears to grow every month, both scientist and 
legislators run after a moving target.  
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1 Introduction 
Starting from 2004, a new generation of psychoactive substances appeared on the 
market. These products, with brand names like ‘Spice’ or ‘K2’, are sold as herbal 
mixtures and are available in many European countries [1]. Packed as ‘natural herbal 
incense’ or ‘room odorizers’, these products can be traded legally in head shops and 
online stores [2,3]. After smoking these mixtures, users reported cannabis-like effects 
on internet forums. These effects were first explained in 2008 by the detection of 
synthetic cannabinoids like JWH-018 as active ingredient [4], although not mentioned 
on the package. 
Throughout the years, more of these products were identified as additives in these 
packages of herbal material. As a response to the rising popularity of these 
compounds, several countries started monitoring and even banning these products 
[5]. 
The search for compounds with THC-like properties in the human body, i.e. synthetic 
cannabinoid receptor agonists or briefly cannabimimetics, started in the 
pharmaceutical industry. In a way to separate the wanted pain-relieving effects from 
the unwanted psychotropic effects, several categories of products were synthesized 
and subjected to SAR (structure activity relationship) tests. The academic and/or 
pharmaceutical origin of these compounds is often reflected in the name of the 
product. In the best known class of JWH-compounds, these initials stands for the 
name of the organic chemistry professor John W. Huffman, who first synthesized 
these products in the 1990s. In a similar way AM (e.g. in AM-630) refers to professor 
Alexandros Makriyannis from Northeastern University and HU (e.g. from HU-210) to 
Hebrew University. Also, the pharmaceutical industry realized the potential value of 
these products, leading to the synthesis of the CP-family (e.g. CP-47,497) by Pfizer 
and the WIN-group (e.g. WIN 55,212-2) by the former Sterling Winthrop 
Pharmaceuticals. 
In general, they are lipid soluble, non-polar molecules, containing 20 to 26 carbon 
atoms [6]. Based upon this chemical structure, synthetic cannabinoids can be divided 
into different classes (Table 6.1) [1]. 
 
Chapter 6: General considerations 
134 
 Classical cannabinoids: structurally related to THC from Cannabis sativa. 
 Non-classical cannabinoids: cyclohexylphenols or 3-arylcyclohexanols 
 Hybrid cannabinoids: structural combinations of both classical and non-
classical cannabinoids.  
 Aminoalkylindoles; 
o Naphthoylindoles 
o Phenylacetylindoles 
o Naphthylmethylindoles 
o Benzoylindoles 
 Eicosanoids: endocannabinoids and synthetic analogs 
 Others: diarylpyrazoles, naphthoylpyrroles, etc. 
It should be noted that, depending on the source, the classifications can vary. In the 
light of an internationally uniformed approach, referring to the (abovementioned) 
classification of a leading institution as the United Nations Office on Drugs and Crime 
(UNODC) is recommended. 
 
Table 6.1. Classification of synthetic cannabinoids according to the UNODC [1], with 
some typical examples. The underlined compound is illustrated in the right column. 
Classical cannabinoids 
e.g. THC, HU-210, AM906, … 
 
Non-classical cannabinoids 
e.g. CP-47,497-C8, CP-55,940, HU-308, … 
 
O
OH
OH
OH
OH
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Hybrid cannabinoids 
e.g. AM-4030 
 
 
 
Naphthoylindoles 
e.g. JWH-018, JWH-073, JWH-122, JWH-200, 
… 
 
Phenylacetylindoles 
e.g. JWH-250, RCS-8, JWH-203, … 
 
Naphthylmethylindoles 
e.g. JWH-175, JWH-184, JWH-185, … 
 
Benzoylindoles 
e.g. AM-630, AM-2233, RCS-4, … 
 
Eicosanoids 
e.g. anandamide, methanandamide, … 
 
O
OH
OH
H
OH
O
N
O
N
O
N
O
N
O
NH
OH
O
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Others 
e.g. JWH-307, CRA-13, … 
 
 
2 Abuse of synthetic cannabinoids 
Packages of ‘Spice’ usually contain approximately 3g of herbal material and are often 
sold in head shops, gas stations or via internet shops. The price varies around €10/g, 
which is considered expensive compared to traditional cannabis [4]. It is promised that 
the inhalation of the blends of psychoactive plants gives the user a similar experience 
as marijuana, only using legal alternatives. A survey in the US showed that ‘Spice’ 
products were primarily smoked, but also administration via vaporization, oral and 
rectal ingestion were reported [7]. 
Little is known on the exact composition and the properties of the used plants and in 
many cases the ingredients listed on the package do not cover the content either [8,9]. 
The manufacturers of these blends make users believe the effects are caused by the 
mix of plant material used. However, research on the botanical material showed that 
most of the plant species do not have psychoactive properties and are therefore only 
used to dilute the added cannabimimetics [9]. Moreover, the producers try to present 
their products as natural and safe in order to circumvent the marijuana policy of 
governments. The UNODC concluded that producers respond very fast to changes in 
legislations by making small modifications to the new products launched [1].  
The success of this ‘legal-highs’ business is reflected in the increasing number of 
web shops selling these products online. In 2009, the European Monitoring Centre 
for Drugs and Drugs Addiction (EMCDDA) found 115 online shops offering 
psychoactive substances in Europe, in 48% of these ‘Spice’ products were offered. In 
a recent report mention is made of an increase to 314 online shops in 2011 and 690 
in January 2012 [10]. Moreover, an investigation via Google® performed by the 
Belgian Monitoring Centre for Drugs and Drug Addiction (BMCDDA), showed that all 
new products reported in 2010 were already offered for sale online even before their 
O
N
F
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existence was picked up by the Belgium Early Warning System for Drugs (BEWSD) 
[11]. Also the list of products with names like ‘Spice gold’, ‘Yucatan Fire’ and ‘Lava 
Red’ continued to rise [8]. Furthermore, recent investigation in Poland demonstrated 
that many herbal blends contained more than one psychoactive ingredient [12]. 
A survey of the member states of the European Union by the EMCDDA showed that 
in 2009, ‘Spice’ products were identified in 21 out of the 30 countries. At that time no 
products containing synthetic cannabinoids were found in Belgium. In 2011 however, 
Belgian laboratories reported 11 synthetic cannabinoids to the European Early 
Warning System (EWS) and for the first time a complete laboratory capable of 
producing and packing synthetic cannabinoids was dismantled in Belgium. Similar 
facilities were reported in Ireland and the Netherlands and are the link between the 
producers – mainly located in China and India – and the customers in Europe. Since 
these substances can be produced cheaply, it is clear that these businesses are very 
lucrative [10]. During the production process, the synthesized synthetic cannabinoids 
are distributed over the dried plant material. This is usually done by homogenization 
with cannabinoids in the crystalline form or by spraying the products dissolved in an 
organic solvent. However, recently also the starting materials are being sold as 
‘research chemicals’ via online shops or traders [13]. 
The rate at which a specific product is spreading, is also noteworthy. In Europe, 
JWH-018 was first reported by Austria in December 2008. Only in the first year after 
this detection, eight more neighboring countries confirmed this finding, followed by 
ten more in the next months. Similar developments were reported for other 
compounds like JWH-073 (13 countries), CP47, 497 (10 countries), JWH-122 (14 
countries), JWH-081 (10 countries) and AM-2201 (11 countries) [11]. In 2011, already 
23 new synthetic cannabimimetics were reported through the European Early 
Warning System (EWS), in 2012 another 30 followed. With a current total of 84 
compounds (May 2013), the synthetic cannabinoid receptor agonists are, despite 
their recent introduction, already the largest drug family monitored by the EMCDDA 
[14]. 
An internet search learned that mostly young people - especially men - aged 
between 25 and 40 are using Spice-like products. The reasons are various; ranging 
from previous cannabis users looking for a substitute over people in search of legal 
drugs to experimental users seeking sensation [8]. In 2008, German authorities found 
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a strong increase in the interest for these products after a period of biased media 
attention in which their use as legal cannabis substitutes was announced. Once the 
presence of synthetic compounds was demonstrated and some of these products 
were banned, the opposite trend was observed, leaving only the users looking for a 
cannabis substitute to avoid positive testing [1]. 
Even in sport drug testing, the first cannabimimetics were reported in the statistics of 
the World Anti-Doping Agency (WADA). However, with only 3 positive cases in 2011, 
the number remains small compared to the traditional THC abuse in sport 
competitions (n = 442 in 2011) [15]. 
3 Legislation 
Since synthetic cannabinoids are currently not controlled under the UN Drug control 
conventions, the legal status of these compounds depends on the drug laws of 
individual countries [1].  
In Europe, the first actions by governments were taken in 2009. The first discovered 
compounds JWH-018, HU-210 and CP47,479 and its homologues were included in 
national drug laws in Austria, Germany, France, Luxembourg, Sweden, Estonia, 
Poland, Hungary and the United Kingdom. A recent report on the evolution of the 
situation in Poland over the last few years, showed that both the compounds and the 
way of trading changed in response to the successive actions of the Polish 
government [12]. As mentioned earlier, it is sufficient to make a small change in the 
drug structure to stay one step ahead of the legislator. Therefore, the UK and Ireland 
started using generic definitions to include products which will appear in the future [8]. 
Recently, other European countries also adopted this strategy in substitution for the 
earlier used approach of individual listing of already identified synthetic cannabinoids 
[10]. 
In Belgium the first legislative actions were taken in 2011, by adding the first seven 
compounds to the list of prohibited psychotropic substances. In 2013 six more 
cannabimimetics were listed (Table 6.2). Unfortunately, to this day, no generic 
definitions have come into force. 
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In the United States, the Synthetic Drug Abuse Prevention Act of 2012 placed 
cannabimimetic agents in Schedule I, making manufacturing, distributing, or 
possessing these products illegal. Besides this federal law, several states and even 
individual cities have taken additional measures to control ‘Spice’ abuse [16]. 
Since, similar to classical cannabis, the synthetic analogues are predominantly 
smoked, it is not inconceivable that passive inhalation of the smoke can result in 
positive testing. Once this was observed for cannabis [17], threshold concentrations 
were installed to distinguish active from passive use [18]. However, up to now, this 
possibility has not been studied for the cannabimimetics currently flooding the 
market. 
In general, legislation, both within and outside Europe, is too diverse and therefore 
not efficient to tackle international issues as ‘legal highs’. 
 
Table 6.2. Synthetic cannabinoids present on the list of prohibited psychotropic 
substances in Belgium. 
KB 2011-09-26/16, art. 1,011 
Effective date: 23/10/2011 
KB 2013-03-20/08, art. 1,012 
Effective date: 22/04/2013 
JWH-018 AM-694 
JWH-073 AM-2233 
JWH-250 WIN 48,098 
JWH-398 JWH-307 
CP-47,497 A-796,260 
HU-210 XLR-11 (5F-UR144) 
JWH-210  
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4 Pharmacokinetics 
Contrary to the classical THC for which the pharmacokinetics have been investigated 
[19,20], no such data are available for the synthetic analogues. 
As described in several reports on the experiences of ‘Spice’ users, the effect is 
quickly noticeable after smoking a few grams of herbal material [2,6,16]. These 
observations are supported by a recent study on the quantification of JWH-018 in 
blood after smoking the incense ‘Smoke’ [21]; the maximum concentrations were 
found 5 min post-smoking. This shows that after inhalation, the absorption via the 
lungs and the distribution over organs like the brain takes place in a few minutes [1]. It 
was found that the measured maximum blood concentrations of JWH-018 were 
already decimated after 3h and the parent compound was detectable until 48h after 
administration [21]. 
Investigation of the metabolisation of cannabimimetics is not as straightforward as for 
pharmaceutically approved agents. Since there are little or no pharmacological data 
available for these compounds, human administration in order to perform excretion 
studies is ethically questionable. Therefore, most studies use models to reveal the 
metabolic pathways in the human body. In one of the most common approaches 
human liver microsomes are used to investigate the metabolisation in vitro [22–25], in 
the search for a more complete model with higher complexity also in vivo mice 
experiments are performed [26]. In some cases, human urine samples are available 
from caught users [27–29] or conducted self-experiments [30].  
In general, these compounds are excessively metabolized in the human body. In all 
metabolic studies on compounds of the aminoalkylindole family described up to now 
a similar series of modifications were found: single or multiple hydroxylations, 
carboxylation, dehydrogenation, dealkylation and dihydrodiol formation. From the 
data obtained using in vivo models or positive urine samples, it was found that these 
metabolites are mainly excreted as glucuronide and/or sulphate conjugates in urine 
[26]. The monohydroxylated [31] and carboxylated [28] metabolites are mainly found in 
the highest quantities in urine. 
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5 Pharmacodynamics 
Although the effects of Cannabis sativa and derivates are known for centuries, it was 
only in the last twenty years that the interactions in the human body were revealed 
[6,32]. 
Today, two cannabinoid receptors are described in the human body. Both CB1 and 
CB2 are G-protein coupled receptors with an important function in intercellular 
signaling. The CB1 receptor is distributed in the brain and the central nervous 
system, mainly expressed presynaptically, and decreases the release of 
neurotransmitters like dopamine [33]. Activation of the CB1 receptor is responsible for 
the psychotropic effects assigned to cannabis use. 
CB2 receptors are located in immune cells and interfere in the regulation of the 
inflammatory process [19]. Therefore in the medical field, research has focused on 
receptor agonists selective for this CB2 receptor aiming for the therapeutic effects 
and hereby avoiding the psychotropic effects induced by the interaction with the CB1 
receptor. 
Next to endocannabinoids [33], plant derived and other exogenous cannabinoids act 
as agonists of both receptors with varying affinity. Classical cannabinoids like THC 
have comparable affinity for both receptors, about 40 nM, without a major selectivity 
for a particular receptor [34]. As shown in Table 6.3, this is different for synthetic 
cannabinoids. The affinity of the most prevalent cannabimimetic compounds is 
significantly higher, especially towards the CB1 receptor. With this in mind, it can be 
expected that compounds with lower potency (i.e. lower affinity for the CB1 receptor) 
than classical THC will not be used in ‘Spice’-like products. Nevertheless JWH-015 
was recently detected in a herbal blend in Latvia [1]. 
When using data on receptor affinities, one should be careful when using exact 
numbers. Indeed, depending on the experimental set-up, variation in the values is 
possible [34]. In short, the receptor affinity (Ki) is determined as the ability of the given 
compound to displace a potent radio labeled cannabinoid (usually tritiated CP-55,940 
or tritiated WIN-55,512-2) from their binding sites [35]. For a potent cannabinoid, low 
concentrations will be sufficient to achieve this. Since this concentration (IC50) is 
proportional to the receptor affinity Ki, the more potent the cannabinoid, the lower Ki 
(Table 6.3). 
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Table 6.3. Receptor affinities for both cannabinoid receptors for some common 
cannabimimetics. 
 
 
6 Health risks 
Although there are case reports describing the effects experienced immediately after 
the use of ‘Spice’ [2,3,16], little or no information is available on the long term effects or 
the consequences of regular use.  
In 2009, Zimmermann et al. reported on a patient who showed symptoms of a 
physical withdrawal syndrome after using ‘Spice Gold’ on a daily basis for about 8 
months. While the patient initially used only 1g of product every day, the decreasing 
effect experienced made him increase the dose up to 3g daily. Both physical 
(sweating, tremor, insomnia, nausea, etc.) as psychological (depression, desperation, 
desire for ‘Spice Gold’) effects were observed the first days of treatment in hospital 
[40]. In another paper, psychosis was diagnosed in ten patients after smoking herbal 
blends containing synthetic cannabinoids, which lasted months after the final use [41]. 
Recently, compound specific data related to harm assessment have been included in 
the European Database on New Drugs (EDND). For two compounds, chronic 
physical damage after use is mentioned. It is related to learning difficulties and 
cognitive ailment for HU-210 and JWH-018, respectively. Moreover, for both 
Compound  Ki - CB1 (nM) Ki - CB2 (nM) 
HU-210 0.06 [34] 0.52 [34] 
JWH-122 0.7 [36] 1.2 [36] 
JWH-073 8.9 [35,37] 27 [35], 38 [37] 
JWH-018 9 [35] 2.9 [35] 
CP47,497 9.54 [38]  
JWH-250 11[39] 33[39] 
Δ9-THC 39.5 [34] 40 [34] 
JWH-015 383 [34], 164[35] 13.8 [34,35] 
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compounds physical dependence (withdrawal symptoms) was reported, together with 
psychological dependence for JWH-018 and JWH-122 [11].  
Predicting the possible effects of a particular herbal blend is almost impossible. It was 
shown that the content of these packages varies significantly and is often not in 
accordance with the indications on the package. Toxicological data on the used plant 
material are not available and then again, mostly the indications on the packages 
with regard to the herbal material are not reliable [9]. Concerning the added synthetic 
cannabinoids, it was shown that concentrations can vary [5] and that some blends 
may contain two or more active compounds [42]. Although research showed that the 
used chemicals are of high purity [43], the presence of impurities with unknown toxicity 
cannot be ruled out. In that way, it is not possible to estimate the impact when 
smoking a few grams of a given mixture. In general, the observed effects are very 
diverse and highly dependent on the type of herbal blend or synthetic cannabinoid(s) 
used. Most described psychoactive effects are: alterations in mood (from euphoria to 
anxiety) [5], hallucinations, agitated behavior and hyperreflexia [16]. Medical 
investigation showed symptoms like increased pulse rates [6] and blood pressure, 
flushed skin, dilated pupils and nausea [16]. It was reported that the major 
psychotropic and physical effects disappear after 6h to 8h [5,6]. 
Together with the fact that these cannabimimetics have stronger affinities for the 
cannabinoid receptors compared to THC, it is not unlikely that overdosing would lead 
to life-threatening intoxications. This is confirmed in case studies [44] and reflected in 
the increasing statistics of Poison Control Centers in the US: in 2011 there were 
reports of over 4000 synthetic marijuana exposures in a period of 8 months, which is 
an increase of 52% compared to 2010 [45].  
7 Detection of synthetic cannabinoids abuse  
In the past, several screening procedures – both via immunological and 
chromatographic techniques – have been developed to screen for the use of 
products from Cannabis sativa in different matrices [18,46–49]. The abuse of the growing 
group of cannabimimetics, synthesized over the last years, however, cannot be 
detected with these methods.  
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For the identification of spiked substances in the herbal material in particular, a more 
or less standard strategy is used. The herbal material is extracted and subsequently 
analyzed by means of a chromatographic technique mostly combined with mass 
spectrometric detection [50]. Next, the outcome is compared with databases 
containing the already known synthetic cannabinoids [51]. If it turns out to be an 
unknown compound, the structure is elucidated by using high resolution mass 
spectrometry (HRMS) or NMR (Nuclear Magnetic Resonance) technology [52–54]. 
When it comes to detection in the human body, different approaches can be used 
depending on the type of biological sample available. In serum or whole blood, both 
the unchanged target compound and its metabolites are present and can be 
extracted and analyzed by means of liquid chromatography (LC) [55,56]. The methods 
developed up till now mostly target the parent compounds, since this eliminates the 
need for the time-consuming search for metabolites and allows the quick update of 
the method after the release of a new compound in the future [57,58]. For oral fluid 
testing, detection of this parent compound is possible, even via direct injection on the 
LC system [59]. However, it should be noted that detection in the latter matrix is limited 
to a few hours after consumption [60]. 
If urine is the matrix of choice, knowledge on the metabolisation is essential, since no 
unchanged parent compound is found to be excreted. To detect these metabolites, 
an enzymatic hydrolysis is usually performed, followed by an extraction and analysis 
by means of liquid chromatography coupled to mass spectrometry (LC-MS) [61]. For 
JWH-018 it was found that monohydroxylated [31] and carboxy metabolites [28,62] are 
excreted in the highest concentrations, which makes these the metabolites of choice 
to implement in routine screening methods. Similar results are found for other indole-
based cannabimimetics [26,29,63,64]. Based upon these findings, chromatographic 
methods are developed and validated to screen for synthetic cannabinoid 
metabolites in urine [65,66]. Also commercial tests for synthetic cannabinoids became 
available, promising a detection window of 72 h after a single use. Peer-reviewed 
data on detection times - although rare - indicate similar ranges [30,67]. No information 
is available on the accumulation in the body of chronic users. However, in those 
cases detection in urine would be possible up to 3 weeks [67].  
Immunochemical-based detection methods have the advantage of being cheaper 
and faster than the chromatographic procedures referred to above, but the 
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development and implementation was long in coming. Indeed, developing such 
immunoassays is a challenging task given the great structural variety between the 
compounds of the cannabimimetics family. Only recently, the first screening method, 
using enzyme linked immunosorbent assays (ELISA) for the detection of metabolites 
of the naphthoylindole group in urine, has been described in literature [68]. Gradually, 
also commercial kits for high-throughput screening of synthetic cannabinoids have 
become available [69,70]. For any positive outcome however, a confirmatory analysis 
by means of the more selective chromatographic techniques remains essential. 
It should be noted that correct identification of these products remains a difficult task 
since the availability of reference material is lagging behind on the rapid release of 
new products on the market [6]. The latter makes it also difficult to keep screening 
methods up to date, since the existing methods are not able to detect non-target (i.e. 
currently unknown) compounds. To close this gap, an open screening approach 
whereby the method is capable of detecting a class of cannabinoids in a non-
targeted way could be a solution. 
8 Perspectives - Conclusions 
Despite the increasing number of actions taken by governments and other 
(inter)national institutions, the ‘Spice’ issue is still expanding. The list of synthetic 
cannabinoids detected continues to grow and the statistics on hospitalizations due to 
the use of these herbal blends do follow the same trend.  
Although effective interventions of the authorities are necessary to tackle these 
problems, strict legislation also has a downside. The total ban on these products 
takes away the opportunity to investigate the therapeutic properties. Taking into 
account the successful use of plant derived cannabis in medicine, there is a demand 
to provide the possibility to do research that leads towards the medicinal use of these 
synthetic analogues [71]. 
It is clear that further research in this field is necessary. When it comes to 
pharmacodynamics, so far only the properties of the parent compound are 
investigated. However, recent data show that also the formed metabolites remain 
active in the human body by binding to both cannabinoid receptors [72]. 
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For routine testing, methods should be developed to improve detection in different 
biological matrices. Given the rapidly growing number of products appearing on the 
market, an open-screening approach could be a big step forward. When routine 
screening becomes more common, there will be a need for uniform regulations taking 
also into account the problem of passive inhalation, as known for THC smoke.  
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Abstract  
1-Pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122) is an agonist of the 
cannabinoid receptors CB 1 and CB 2. In this study, the phase I and phase II 
metabolism of JWH-122 were investigated using two models. In vitro studies 
using incubations of JWH-122 with human liver microsomes were performed to 
obtain metabolites of the drug at the first step; 11 classes of metabolites were 
found and analysed by liquid chromatography-mass spectrometry (LC-MS) and 
liquid chromatography-tandem mass spectrometry (LC-MS-MS). 
Hydroxylation(s) on the naphthalene moiety and/or the indole moiety of the 
molecule took place as such or in combination with dehydrogenation or 
cleavage of the N-pentyl side chain. Furthermore also dihydrodiol metabolites 
are probably formed via epoxide formation on the naphthalene moiety, 
irrespective of the combination with hydroxylation(s). A metabolite carrying a 
carboxylgroup on the N-pentyl side chain was also detected. In the second step 
of the study, in vivo experiments, using chimeric mice were performed; the mice 
were orally administered JWH-122, and the urine samples were collected to be 
subjected to enzymatic hydrolysis, followed by LC-MS and LC-MS/MS. The 
urine samples without hydrolysis were also analysed for their molecular 
formulae in the conjugated forms by LC-high resolution MS. The in vivo model 
using chimeric mice could confirm most metabolite classes and clarify the 
phase II metabolism of JWH-122. From these results, it can be concluded that 
all metabolites formed in vivo are excreted conjugated as glucuronide or 
sulphate, with conjugation rates above 50%.   
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1 Introduction 
With the discovery of the cannabinoid receptors CB 1 and CB 2 in humans in 
the 1980s, the search for synthetic cannabinoid receptor agonists started. CB 1 
is mainly located in the brain and is responsible for the psychoactive effects, 
while CB 2, found in the immune cells, is involved in pain perception. Therefore, 
pharmaceutical research has been directed to novel compounds with high-
affinity binding for CB 2 and low-affinity for CB 1 to separate the desired 
properties from the unwanted psychoactive effects [1,2]. This has led to the 
synthesis and the study of structure-activity relationships of a wide range of 
synthetic cannabinoids receptor agonists, including a series of 
aminoalkylindoles known as JWH-compounds [3]. However, unfortunately, these 
JWH-cannabinoids have found their way to the black market, and many of these 
have been found in herbal smoking mixtures [4]. Products like Spice Gold, Spice 
Silver and Spice Diamond are abused like cannabis and produce similar effects 
[5].  
To cope with this problem, the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA) and Europol organized a conference on the ‘spice’ topic in 
2009. Based upon this report [2], most European countries started banning the 
use of some of these compounds. This report also pointed out the problem on 
the screening for these JWH-compounds: the variety of these products is large 
and still growing in the world [6–10]. Moreover little is known on the metabolism of 
these substances, making an adequate detection in biological specimens 
difficult. In a recent briefing paper [11] the EMCDDA describes a strong increase 
in the number of shops selling these products online. Beside the well-known 
JWH-018, of which the metabolism has already been investigated [12,13], 1-
pentyl-3-(4-methyl-1-naphthoyl)indole (JWH-122) appeared also high on the list. 
This JWH-class compound was reported as an active ingredient in illegal 
products in Germany and Japan [14,15]. 
To allow for the development of detection methods for this compound, the 
metabolism of JWH-122 have been investigated in this study. In vitro studies 
using human liver microsomes were initially conducted to identify possible 
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metabolites. Although in vitro metabolism via human liver microsomes has 
shown to be a valuable tool for the elucidation of drug metabolism [16], the exact 
mimicking of human metabolism is not always true [17,18]. Therefore, in the 
second step, the urinary detectability of the metabolites was investigated in 
vivo. Urine allows long term detection of cannabinoids [19] and is the preferred 
matrix in drugs of abuse and anti-doping analysis. Since administration to 
humans is ethically questionable, a more complex model, namely the chimeric 
mouse model was applied. This has shown to be an excellent model for the 
study of the metabolism of several substances, including steroids [20,21], where a 
wide variety of human metabolic pathways were shown to be present, including 
phase II metabolic pathways [22]. The parent compound was administered to 
both chimeric and non-chimeric mice, to verify the metabolism of JWH-122. 
2 Materials and methods 
2.1 Reagents 
The enzyme β-glucuronidase (140 U/mg at 37°C) from E. coli, used for 
hydrolysis, was purchased from Roche Diagnostics GmbH (Mannheim, 
Germany); methanol from Fisher Scientific (Loughborough, UK); disodium 
hydrogen phosphate (Na2HPO4) and sodium dihydrogen phosphate (NaH2PO4) 
from Merck (Darmstadt, Germany); phosphate buffer solution, pH 7.2 from 
Invitrogen (Merelbeke, Belgium); the internal standard (IS), deuterated 11-nor-
∆9-tetrahydrocannabinol-9-carboxylic acid (THCA-d9) was from Cerriliant 
(Round Rock, TX, USA); JWH-122 from Bio-Connect (Te Huissen, 
Netherlands). All reagents were of the analytical grade. For microsomal 
incubations, all reagents such as NADPH generating system, phosphate buffer 
(pH 7.4) and pooled human liver microsomes were from BD Bioscience 
(Erembodegem, Belgium). The gas used for the mass spectrometer was 
nitrogen (Alphagaz2-grade), from Air Liquide (Desteldonk, Belgium). 
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2.2 In vivo model with chimeric mice 
The project was approved by the Animal Ethics Committee of the Faculty of 
Medicine of the Ghent University (ECD 06/09). The production and 
maintenance of the chimeric uPA+/+-SCID mice were done according to a 
previously described protocol [23]. 
The administration experiments were performed in metabolic cages (Tecniplast, 
Casale Litta, Italy), allowing unlimited access to water and food for the mice and 
easy collection of the urine, separated from the faeces. The excretion studies 
were performed by oral administration of 50 µl of PBS containing the synthetic 
cannabinoid JWH-122 (0.1 mg drug dissolved in 2 ml of ethanol/PBS (20:80, 
v/v) ) to both chimeric (human albumin 3.8 mg/ml) and non-chimeric mice. 
Non-transplanted uPA+/−-SCID mice, i. e. without human hepatocytes, were 
included in the administration study as a control group for the interspecies 
differences. Urine was collected prior to and 24 h after a single dose 
administration (2.5 µg). All samples were stored at -20ºC until analysis. 
A 100 µl aliquot of mouse urine was spiked with 50 µl of IS solution containing 
0.5 µg/mL THCA-d9. For hydrolysis, samples were incubated in an oven at 
56°C for 1.5 h after adding 1 ml of 0.1 M phosphate buffer solution (pH = 7) and 
50 μl of β-glucuronidase. Solid-phase extraction (SPE) was used for further 
purification and concentration of the compounds of interest; Oasis® HLB 3cc 
(60 mg) extraction cartridges from Waters (Milford, MA, USA) were used. The 
cartridge was first activated with 2 ml of methanol and was subsequently rinsed 
with 2 ml of water. Before loading, the sample was first diluted up to 2 ml with 
water. After loading, the column was washed twice with 2 ml of water. Then 2 
ml of methanol was used to elute the compounds from the column. After 
evaporation of the methanol under a stream of oxygen-free nitrogen, the 
residue was redissolved in 100 µl of water/methanol (95:5, V/V) for liquid 
chromatography-mass spectrometry (LC-MS) analysis. 
A part of each urine sample collected from the chimeric and non-chimeric mice 
after administration of JWH-122 was purified by the SPE without the enzymatic 
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hydrolysis for detection of metabolites in their conjugated forms by LC-high 
resolution (HR)-MS. 
2.3 In vitro model with human liver microsomes 
For microsomal incubation, a solution of 4 mg/ml JWH-122 in dimethyl sulfoxide 
was prepared. A volume of 250 µl reaction medium was prepared containing 
226 µl 0.1 M phosphate buffer (pH 7.4) and 15 µl of a 10 mM NADPH 
generating system. This contained 12.5 µl of a mixture of NADP+ (1.3 mM), 
glucose-6-phosphate (3.3 mM) and MgCl2 (3.3 mM) and 2.5 µl glucose-6-
phosphate dehydrogenase (0.4 U/ml) in sodium citrate solution (0.05 mM). To 
this, 2.5 µl of the JWH-122 solution was added, and the mixture was incubated 
at 37ºC. The reaction was initiated by adding 6.5 µl microsomal protein (20 
mg/ml). The mixture was vortexed briefly and incubated at 37ºC for 4 h. To stop 
the incubation, 250 µl of ice-cold methanol was added, and the samples were 
centrifuged for 5 min at 12,000g at 4ºC. Then the mixture was evaporated under 
oxygen-free nitrogen at room temperature. The dry residue was redissolved in 2 
ml of distilled water prior to further purification by SPE with the Oasis® HLB (60 
mg) cartridges. The procedure used was the same as described before for the 
in vivo experiments. 
2.4 Instrumentation 
All experiments were performed under the same LC conditions, using a MS 
Pump Plus coupled with a Surveyor Plus autosampler (Thermo Scientific, 
Bremen, Germany). Separation was performed with a Sunfire™ C18 column 
(50 x 2.1 mm i.d., particle size 3.5 µm) from Waters (AH Etten-Leur, 
Netherlands). The volume for injection was 20 µl. The mobile phase A was 
0.1% acetic acid plus 1 mM ammonium acetate in water, mobile phase B was 
0.1% acetic acid plus 1 mM ammonium acetate in methanol. Gradient elution 
was: 95% A / 5% B for 1.5 min, then linearly changed to 0% A / 100% B in 25 
min and held for 3 min. This was followed by the return to the initial conditions in 
0.1 min and an equilibration for 2.9 min before the next injection (total run time 
31 min). The flow rate was constant at 250 μl/min. 
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Both low-resolution and HR-MS(-MS)-based strategies were used to detect and 
characterize JWH-122 metabolites. Low resolution MS experiments were 
performed on a Finnigan TSQ Quantum mass spectrometer (Thermo Scientific). 
The MS conditions were: interface, electrospray ionization (ESI); capillary 
voltage, 3.5 kV; source temperature, 350 °C; sheath gas pressure, 50 (arbitrary 
units); auxiliary gas pressure, 20 (arbitrary units); tube lens offset, 100 V; 
collision energy 25 to 40 eV; scan range, m/z 50 – 800; scan time, 0.5 s. 
For HRMS experiments, an Exactive Mass spectrometer (Orbitrap-based mass 
spectrometer) from Thermo Scientific was operated in both positive and 
negative polarity modes. The conditions were: sheath gas, 60 (arbitrary units); 
the auxiliary gas, 30 (arbitrary units); capillary temperature, 350 °C; capillary 
voltage, 30V; spray voltage, 4 kV; full-scan range, m/z 50-1,000; high-collision 
dissociation energy, 30 eV; resolving power, 100,000 at m/z 200; data 
acquisition rate, 1 Hz. 
3 Results and discussion 
3.1 Product ion scanning for precursor JWH-122 to obtain 
clues for estimation of its metabolite structures.  
Identification and revealing of unknown metabolites for a given parent 
substance are often a challenging task. On the basis of the knowledge of 
microsomal transformations [16] and the metabolism of synthetic cannabinoids of 
the aminoalkylindole type investigated earlier [1,12,24], a list of theoretically 
possible metabolites can be composed. To check their presence and study their 
fragmentation, LC-MS-MS is the technique of choice [13]. Due to the presence of 
an amino group in the molecule, abundant protonated molecular ions were 
observed in the positive ionization mode. Full scans were performed on the 
protonated molecular ions of each of the 12 predicted categories (M1 – M12, 
Table 7.1) of metabolites using collision energies at 25 and 40 eV. Initially, the 
product ion formation pattern of JWH-122 was investigated. As shown in Fig. 
7.1, the protonated molecular ion at m/z 356 (M+H) fragmented into 2 main 
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parts; the complete naphthalene moiety (m/z 169) and the indole moiety 
containing the N-pentyl side chain (m/z 214), both containing the central 
carbonyl functional group. The observed fragmentation was in agreement with 
the previous described work on naphthoylindoles [1,12,25]. The former ion was 
further fragmented to form an ion at m/z 141, which is 28 amu less than that at 
m/z 169 (loss of CO). For the latter ion, the alkyl side chain was cleaved from 
the indole moiety, leaving a fragment at m/z 144. The origin of the fragment at 
m/z 115, formed at higher collision energies, was investigated using HRMS. 
From the accurate mass number of 115.0543 found by the high collision 
dissociation experiment, the structural formula of C9H7+ (theoretic mass number 
of 115.0542 with Δ=0.78 ppm) was obtained. This is in accordance with a 
fragmentation pathway suggested earlier for the naphthalene moiety of 
naphthoylindoles [25]. 
 
 
Fig. 7.1 Product ion mass spectrum obtained from the protonated precursor 
JWH-122 molecular ion at m/z 356.5 using collision energy at 40 eV, and the 
probable fragmentation pathways. 
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Modifications in one part of the molecule (the indole or naphthalene side) 
without simultaneous changes in the other moiety should leave detectable ions 
at m/z 144 and 214 or ions at m/z 115 and 141 respectively. Therefore, these 
product ions will be used to estimate the structure of metabolites produced by in 
vitro incubation of JWH-122 with human liver microsomes. 
3.1.1 Monohydroxylation (M1) 
The protonated molecular ions of the monohydroxylated JWH-122, if present, 
should show peaks on the channel at m/z 372 of the mass chromatograms. As 
shown on the chromatogram at m/z 372 (Fig. 7.2 M1), at least 7 
monohydroxylated metabolites could be identified after the in vitro incubation of 
JWH-122 with human liver microsomes. The location of the hydroxylation can 
be estimated from each product ion mass spectrum. For metabolites A, B and 
C, the presence of peaks at m/z 141, 144 and 169 (same as the parent 
compound, Fig. 7.1) showed that neither the naphthalene nor the indole moiety 
was modified. Therefore, the hydroxylation should be situated on the alkyl side 
chain of the indole moiety. Attribution of the exact position of the hydroxylation 
on the alkyl side chain, however, was not possible for these metabolites. 
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Fig. 7.3 Product ion mass spectrum obtained from the monohydroxylated 
metabolite M1 D shown in Table 7.1 and Fig. 7.2 using collision energy at 40 eV, 
and the probable fragmentation pathways. 
 
3.1.2 Dihydroxylation (M2) 
The protonated molecular ions of the dihydroxylated JWH-122 metabolites 
should show peaks at m/z 388 of the mass chromatograms. As shown in Fig. 
7.2 M2, 7 peaks appeared for these metabolites. At least one hydroxyl group 
can be found on the naphthalene moiety, because of the appearance of a 
product ion at m/z 185 ([169-H+OH]+) in the product ion mass spectra for all 
peaks (Table 7.1, M2). The second hydroxyl-group was placed on the indole 
moiety of the molecule including the alkyl side chain, yielding a product ion at 
m/z 230, which could be explained as the sum of fragment at m/z 214 (cf. Fig. 
7.1) and a hydroxyl group. To allow unequivocal distinction between 
hydroxylation at the indole ring and the N-pentyl chain, the interpretation of the 
origin of additional fragments was necessary. For metabolites A and C, the 
fragment ion appearing at m/z 144, representing an unchanged indole ring (cf. 
Fig. 7.1), indicated that the hydroxylation was located on the alkyl side chain. 
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More accurate location of the hydroxylation in the side chain could be found for 
metabolites B and G. Fragments at m/z 314 and 342 (cfr. molecular weight of 
JWH-122 = 355) appeared showing product ions including the 
monohydroxylated naphthalene moiety, which lacked only a part of the N-pentyl 
side chain. For the ion at m/z 314, there was a loss of 73 amu from the 
molecular ion at m/z 388, according to the loss of a hydroxyl group together with 
an n-butyl group. Similarly, the fragment ion at m/z 342 originated from a loss of 
45 amu; i.e., a hydroxyl group and the peripheral 2 carbons of the side chain. 
Therefore, it can be concluded that a hydroxyl group is located at the end part 
of the N-pentyl side chain, probably on the 4th or 5th carbon. The same ion at 
m/z 342 appeared in metabolite D, leading to the same conclusion. However, 
distinction between the indole ring and the alkyl chain could not be made for 
metabolite F; it was possible for metabolite E, where the ion at m/z 160 proved 
the hydroxylation on the indole ring (Table 7.1, M2). 
3.1.3 Trihydroxylation (M3) 
In the mass chromatogram at m/z 404, evidence for two kinds of trihydroxylated 
metabolites was found (Fig. 7.2, M3). For both metabolites, the appearance of a 
product ion at m/z 185 indicated a single hydroxylation on the naphthalene 
moiety. Therefore the other two hydroxyl groups were probably located on the 
N-alkylated indole. However, evidence for this assumption could not be found in 
the product ions. The difficulty to detect these trihydroxylated metabolites, 
produced in low amounts in vitro, has already been encountered in another 
study on a similar compound [12]. 
3.1.4 Dehydrogenation (M4) 
In the mass chromatogram at m/z 354, 3 different metabolites appeared (Fig. 
7.2 M4), which were deprotonated molecular ions of JWH-122. Although the 
exact position of the double bond in the N-pentyl chain could not be located 
using the MS-MS experiments, the product ions at m/z 141 and 144 indicated 
an unchanged naphthalene moiety and an indole moiety, respectively. The 
appearance of the product ion at m/z 212 – i.e. the ion 2 amu less than the 
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corresponding product ion at m/z 214 of JWH-122 (Fig. 7.1) - provides further 
evidence that the dehydrogenation is located in the alkyl part of the molecule. 
3.1.5 Dehydrogenation + hydroxylation(s) (M5 and M6) 
The above described modification in the N-pentyl chain was also found together 
with hydroxylation(s). Two monohydroxylated variants were found (Fig. 7.2 M5, 
Table 7.1 M5). In metabolite M5A, the product ion at m/z 212 was absent. 
However, a product ion at m/z 228 appeared, which can be explained by the 
addition of a hydroxyl group to the dehydrogenated N-alkylated indole (m/z 
212). Because the product ion at m/z 144, showing the unchanged indole ring 
(cf. Fig. 7.1) was still present, it can be concluded that the hydroxylation took 
place on the alkyl side chain. This was not the case for metabolite M5B (Fig. 7.2 
M5, Table 7.1 M5), where the product ion at m/z 212 was still present. This, 
together with the appearance of a product ion at m/z 185 (cf. Fig. 7.3), indicates 
a single hydroxylation on the naphthalene part of the structure. 
Additionally, one metabolite bearing 2 hydroxyl groups (Table 7.1, M6) was 
found in combination with dehydrogenation. The simultaneous occurrence of 
both m/z 185 and 228 indicates that one hydroxyl group is located on the 
naphthalene moiety and the other on the dehydrogenated N-pentyl side chain. 
3.1.6 Dihydrodiol formation (M7) 
As shown in the previous studies on the in vitro metabolism of similar 
compounds [1,12], some metabolites can be formed via epoxide formation on the 
naphthalene moiety. This epoxide then undergoes enzymatic hydrolysis to give 
dihydrodiol metabolites. For JWH-122, two such metabolites were found in the 
mass chromatogram at m/z 390 (Fig. 7.2 M7). Because in the fragmentation 
pattern for both substances a product ion at m/z 214 was found (Fig. 7.4), the 
N-alkylated indole part seems to be intact. The presence of a product ion at m/z 
203 proved that a modification took place at the naphthalene ring structure. This 
is confirmed by the presence of product ions at m/z 157 and 185, both 
originating from a monohydroxylated naphthalene moiety formed by a loss of 
H2O (Fig. 7.4). Although the exact locations of these diols on the ring cannot be 
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clarified by the MS-MS experiments, only 2 possible locations were found and 
characterized in the previous study using NMR technology [26]. In comparison 
with the unmodified naphthalene ring of the investigated WIN55212-2 [26], JWH-
122 bears an extra methyl group on the naphthalene ring, which limits the 
possible hydroxylation positions. Therefore, it can be assumed that the 
dihydrodiol group for JWH-122 is estimated to be located in positions 1 and 2, 3 
and 4, respectively (Fig. 7.4). 
 
 
Fig. 7.4 Product ion mass spectrum obtained from the peak M7 B shown in Fig. 
7.2 using collision energy at 25 eV. It was estimated to be a dihydrodiol 
metabolite of JWH-122 showing its protonated molecular ion at m/z 390. Only 
one possible structure with two hydroxyl groups on the naphthalene moiety is 
shown. The probable fragmentation pathways are also shown. 
 
3.1.7 Dihydrodiol formation + hydroxylations (M8) 
Some metabolites were found combining the dihydrodiol formation with one 
hydroxylation. In metabolite A (Fig. 7.2 M8), the proof for the dihydoxylation via 
epoxide hydrolysis on the naphthalene moiety was again given by ions at m/z 
203, 185 and 157, as described for M7 (Fig. 7.4). The product ion at m/z 214, 
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however, was replaced by the ion at m/z 230, which is the indication of 
hydroxylation on the N-alkylated indole. 
In metabolite B, the product ion at m/z 203 was not observed, but an ion at m/z 
219 appeared. Because the ion at m/z 214 was also present, it can be 
concluded that the extra hydroxylation took place on the naphthalene part of the 
molecule. 
3.1.8 N-Dealkylation(s) (M10 and M11) 
The M10 metabolite, with protonated molecular ion at m/z 286, was formed by 
the cleavage of the N-pentyl side chain (Table 7.1 M10). In the product ion 
spectra, both unchanged naphthalene (m/z 169 and 141) and indole moiety 
(m/z 144) were present. The product ion at m/z 214 for the N-alkylated indole 
did not appear. 
Additionally, two monohydroxylated plus N-dealkylated metabolites were 
detected (Fig.7.2 M11). In metabolite A, the hydroxylation occurred on the 
naphthalene moiety, because product ions at m/z 185 and 157 were present (cf. 
Fig. 7.3), and the ion at m/z 144 shows that the indole moiety remained 
unchanged. For metabolite B, the product ions at m/z 169, 160 and 141 
appeared. The ions at m/z 169 and 141 (cf. Fig. 7.1) indicate that the 
naphthalene structure was not modified, while the ion at m/z 160 was formed by 
hydroxylation on the indole ring. 
3.1.9 Carboxylation (M12) 
In the positive ionization mode, a metabolite with a carboxyl group could be 
detected (Table 7.1 M12). The fragmentation pattern of the molecular ion at m/z 
386 shows product ions similar to those of the parent drug with respect to both 
the naphthalene moiety (m/z 169, 141 and 115) as well as the indole ring (m/z 
144). However, the product ion corresponding to the indole moiety containing 
the alkyl side chain showed a change from m/z 214 for the parent drug to m/z 
244 for the metabolite. This may indicate that the carboxyl-group was formed on 
the N-pentyl side chain. Because compounds containing a carboxyl group can 
easily be deprotonated using ESI [13], additional evidence for the presence of 
Chapter 7: JWH-122 
168 
this metabolite is found when analyzing the sample in the negative ionization 
mode. 
 
Table 7.1 JWH-122 metabolites found in the in vitro model experiments. 
Class   Nr. Location of modification 
M1 Monohydroxylation A N-Pentyl side chain 
  B N-Pentyl side chain 
  C N-Pentyl side chain 
  D Naphthalene moiety  
  E Indole/alkyl moiety 
  F Naphthalene moiety  
    G Naphthalene moiety  
M2 Dihydroxylation A Naphthalene moiety + N-pentyl side chain 
  B Naphthalene moiety + N-pentyl side chain 
  C Naphthalene moiety + N-pentyl side chain 
  D Naphthalene moiety + N-pentyl side chain 
  E Naphthalene moiety + indole ring 
  F Naphthalene moiety + indole/alkyl moiety 
  G Naphthalene moiety + N-pentyl side chain 
M3 Trihydroxylation A 
1 x Naphthalene moiety, 2x indole/alkyl 
moiety
    B 
1 x Naphthalene moiety, 2x indole/alkyl 
moiety
M4 Dehydrogenation A N-Pentyl side chain 
  B N-Pentyl side chain 
  C N-Pentyl side chain 
M5 
Dehydrogenation + 
monohydroxylation A N-Pentyl side chain 
    B Naphthalene moiety 
M6 
Dehydrogenation + 
dihydroxylation A N-Pentyl side chain + naphthalene moiety 
M7 Dihydrodiol formation A Naphthalene moiety 
    B Naphthalene moiety 
M8 
Dihydrodiol formation + 
Monohydroxylation A 
Naphthalene moiety (dihydrodiol) + indole 
moiety (hydroxyl)
  B Naphthalene moiety (dihydrodiol + hydroxyl)
M10 N-Dealkylation A N-Pentyl side chain 
M11 
N-Dealkylation + 
monohydroxylation A Naphthalene moiety 
  B Indole ring 
M12 Carboxylation A N-Pentyl side chain 
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3.2 In vivo metabolism using the chimeric mouse model 
For detection of the metabolites, an LC-MS-MS method was used. On the basis 
of the results from the in vitro experiments, two transitions per compound were 
selected and programmed in the selected reaction monitoring (SRM) mode for 
every metabolite. In the first experiments, all mouse urine samples were 
hydrolyzed prior to analysis. In this way all metabolites could be investigated, 
originating from both free and conjugated excreted metabolites. 
Then the samples without the hydrolysis step were investigated for the phase II 
metabolism, using LC-HRMS, which could check the presence of both 
glucuronide and sulphate conjugates for all metabolites already discovered in 
the in vitro study. Finally these samples were also analysed using the SRM 
method to check the compounds excreted free into urine. 
Twenty-four hours after the administration, no parent compound was found for 
all mouse urine samples. Hence, it can be concluded that there was a complete 
biotransformation and excretion within this period. This result was supported by 
similar findings for JWH-018 [27]. However, faecal excretion cannot be excluded. 
Among the 7 monohydroxylated metabolites identified by the in vitro study 
(Table 7.1 M1), only 3 could be detected in the mouse model (Fig. 7.5, Fig. 7.2 
M1 A, D, E). One extra peak named H, was detected at 23.3 min, which showed 
the presence of an additional monohydroxylated metabolite (Fig. 7.5 H). These 
4 metabolites were produced in both the chimeric mouse and the non-chimeric 
control group. As shown in Fig. 7.5, production of metabolites M1A, D and E in 
the chimeric mice was much higher than that in the non-chimeric mice which 
can only originate from the contribution of the humanized liver. This is in 
contrast to metabolite H, for which the intensities of the peaks were similar for 
both mouse types, suggesting it is a murine-specific metabolite. 
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Fig. 7.5 Selected reaction monitoring (SRM) chromatogram for 
monohydroxylated metabolites of JWH-122 obtained from urine extracts of 
chimeric (top) and non-chimeric mice after hydrolysis. The used transitions for 
SRM were m/z 372  214, 372  185, 372  169, 372  141. 
 
For these M1-class substances, their conjugated forms were carefully analysed 
by LC-HRMS as shown in Table 7.2; three glucuronides and one sulphate 
conjugate could be detected. Because almost no free monohydroxylated 
metabolites could be detected without enzymatic hydrolysis, it can be concluded 
that these metabolites are excreted almost exclusively as conjugates. Similar 
results could be obtained for the multiple hydoxylated metabolites. For the class 
of M2, only three metabolites could be detected (Fig. 7.2, M2 A, B, D) after 
hydrolysis in the in vivo experiments. However, four conjugates were found in 
the LC-HRMS experiments without hydrolysis: three glucuronides and one 
sulphate (Table 7.2). Also for the M2 metabolites no significant amounts of 
compounds were detected in the free forms. Therefore it can be assumed that 
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one metabolite partially appeared as a glucuronide and partially as a sulphate, 
while the others appeared only as glucuronides. Only one metabolite containing 
three hydroxyl groups was found in the hydrolyzed mouse urine (Fig.7.2 M3 B), 
originating from a sulphate conjugate (Table 7.2). From the comparison of the 
M3 peak areas, the amount excreted in the free form in the non-hydrolyzed 
urine was about 50%; the comparable ratio was found to be excreted in the 
conjugated form. In the chimeric mouse urine, no metabolites with 
dehydrogenation (M4) or the combination of dehydrogenation and 
monohydroxylation (M5) were detected. However, only the dihydroxylated 
metabolite M6 was found in combination with the dehydrogenation in the N-
pentyl side chain. Without hydrolysis for M6, one glucuronide and one sulphate 
metabolite could be detected in the LC-HRMS experiments. The conjugation 
reaction was complete for the M6 metabolites. In terms of the peak areas, the 
M6 glucuronide conjugate concentration was higher than the sulphate 
concentration. Only one metabolite carrying a dihydrodiol group on the 
naphthalene moiety could be found in vivo for M7 metabolite (Table 7.2 M7), 
which was identified as metabolite B (Fig. 7.2 M7) formed by microsomal 
incubation. This metabolite was present in urine as a glucuronide conjugate. 
The M7 B is only found in the chimeric mice and not in the non-chimeric control 
mice, indicating that the M7 metabolite is of human origin. A few combinations 
of this dihydrodiol group with other modifications were found. One metabolite 
with the dihydrodiol and monohydroxyl groups (M8 A) was excreted both in the 
free and glucuronidated forms in approximately equal amounts. One metabolite 
with the dihydrodiol and dihydroxyl groups, which was completely sulphated 
(Table 7.2 M9), was found in the in vivo study. The N-dealkylation was only 
seen in combination with monohydroxylation in the mouse model. After 
enzymatic hydrolysis both metabolites A and B (M11) could be identified by LC-
MS-MS, one of which is excreted as sulphate and the other as glucuronide 
(Table 7.2 M11). 
  
Table 7.2 JWH-122 conjugated metabolites found with the in vivo model experiments analysed by liquid chromatography-high 
resolution mass spectrometry. The deviation of theoretical and experimental mass number is calculated (RT = retention time). 
Class Metabolite Conjugation 
Structure 
formula 
RT 
(min) 
Mode
Theoretic 
mass (m/z) 
Experimental 
mass (m/z) 
Δ 
ppm 
M1 Monohydroxylation Glucuronide C31H33NO8 21.7 + 548.2279 548.2272 1.295 
M1 Monohydroxylation Glucuronide C31H33NO8 23.0 + 548.2279 548.2273 1.113 
M1 Monohydroxylation Glucuronide C31H33NO8 23.4 + 548.2279 548.2271 1.496 
M1 Monohydroxylation Sulphate C25H25NO5S 24.4 - 450.1381 450.1390 2.155 
M2 Dihydroxylation Glucuronide C31H33NO9 19.8 + 564.2228 564.2222 1.028 
M2 Dihydroxylation Glucuronide C31H33NO9 20.2 + 564.2228 564.2222 1.134 
M2 Dihydroxylation Glucuronide C31H33NO9 21.0 + 564.2228 564.2225 0.638 
M2 Dihydroxylation Sulphate C25H25NO6S 21.0 - 466.1330 466.1334 0.901 
M3 Trihydroxylation Sulphate C25H25NO7S 19.5 - 482.1279 482.1281 0.436 
M6 Dehydrogenation + dihydroxylation Glucuronide C31H31NO9 19.6 + 562.2072 562.2063 1.511 
M6 Dehydrogenation + dihydroxylation Sulphate C25H25NO6S 21.0 - 466.1330 466.1335 1.094 
M7 Dihydrodiol formation Glucuronide C31H35NO9 21,8 + 566.2385 566.2378 1.236 
M8 
Dihydrodiol formation + 
monohydroxylation Glucuronide C31H35NO10 17.1 
+ 582.2334 582.2326 1.305 
M9 Dihydrodiol formation + dihydroxylation Sulphate C25H27NO8S 9.6 + 502.1530 502.1546 3.067 
M11 N-Dealkylation + monohydroxylation Glucuronide C26H23NO8 19.6 + 478.1496 478.1493 0.648 
M11 N-Dealkylation + monohydroxylation Sulphate C20H15NO5S 20.2 - 380.0598 380.0603 1.210 
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4 Conclusions 
In this study, the metabolism of a synthetic cannabinoid JWH-122 was 
investigated using two experimental models; in vitro incubation of JWH-122 with 
human liver microsomes, and in vivo chimeric mouse experiments collecting 
their urine. Eleven classes of metabolites were detected in vitro by LC-MS and 
each chemical structure was estimated by LC-MS-MS. Secondly, the urine 
samples obtained by the in vivo experiments were subjected to enzymatic 
hydrolysis to clarify their structure by LC-MS and LC-MS-MS; the urine samples 
without hydrolysis were also analysed for their molecular formulae in the 
conjugated forms by LC-HRMS.  
Comparison of the metabolism of both models showed that the classes found in 
the in vitro model are mostly present in the in vivo model as well. However, 
there are a few exceptions. Both dehydrogenation (M4) and dehydrogenation 
plus monohydroxylation (M5) were not detected in the chimeric mouse (Tables 
7.1, 7.2). Nevertheless these modifications seem possible in vivo because the 
dehydrogenation was present in combination with dihydroxylation (Table 7.2 
M6). This is not the case for carboxylation (M12), which was not detected at all 
in the in vivo model. The opposite is true for the combination of dihydrodiol 
formation and dihydroxylation (M9), because this is only observed in the in vivo 
mouse model (Table 7.2 M9). 
Even though there was a high similarity between the classes of metabolites 
detected in both models, it is clear that the number of metabolites produced in a 
given class was limited in in vivo experiments compared to in vitro experiments. 
This is due to the higher complexity of the in vivo model, where a number of 
factors influencing the metabolic clearance exist. One of these factors is phase 
II metabolism, which is present in the chimeric mouse model. All metabolites 
detected in the mouse urine are at least partially excreted as conjugates (both 
glucuronide and sulphate), with conjugation rates between 50 and 100%. 
The results seem to have great consequences for detection of JWH-122 abuse 
using urine samples. Because no parent compound was excreted, it seems 
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advisable to look for the best detectable metabolites. From the results of the 
SRM method applied to the mouse urine samples, it was clear that hydroxylated 
metabolites are excreted in the highest amounts. This amount decreased from 
monohydroxylated over dihydroxylated to trihydroxylated compounds. 
Moreover, all these metabolites are excreted exclusively as conjugates. This 
means that screening of urine samples for the phase II metabolites is necessary 
for adequate detection of JWH-122 abuse.  
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Abstract 
The synthetic cannabinoid JWH-200 (1-[2-(4-morpholinyl)ethyl]-3-(1-
naphthoyl)-indole) appeared on the market around 2009. In order to identify 
markers for misuse of this compound and allow for the development of 
adequate routine methods, the metabolism of this compound was investigated 
using two models. 
In vitro and in vivo (both with and without enzymatic hydrolysis) samples were 
purified by solid-phase extraction and analyzed using liquid chromatography. 
For the identification of the metabolites electrospray ionization was used in 
combination with high resolution mass spectrometry detection powered by 
Orbitrap™ technology. To confirm the results in vivo, triple-quadrupole mass 
spectrometry was applied.  
In the in vitro model, using human liver microsomes, 22 metabolites were 
detected which could be divided into 11 metabolite classes. 
By using the chimeric mouse model with humanized liver, most of these 
metabolites were confirmed in vivo. It was found that all metabolites are 
excreted in urine as conjugates, mostly as glucuronides with varying 
conjugation rates.  
The metabolite formed by consecutive morpholine cleavage and oxidation of 
the remaining side chain to a carboxylic group, was detected in the highest 
amounts with the longest detection time. Therefore it is the best candidate 
metabolite to detect JWH-200 abuse in urine. 
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1 Introduction 
The products of Cannabis sativa and corresponding derivates are considered 
the most frequently used illicit drugs for several hundreds of years. [1] While 
between 1990 and 2000 cannabis use increased in many countries, European 
statistics show a stabilization and even a small decrease in these numbers in 
the last years [2]. This can be seen as a positive trend in the traditional 
cannabis abuse. However the opposite evolution is observed for synthetic 
analogues of Δ9-tetrahydrocannabinol (THC) [3]. According to the annual 
report of Europol and the European Monitoring Centre for Drugs and Drug 
Addiction (EMCDDA), 23 new synthetic cannabinoids were reported via the 
EU early-warning system (EWS) in 2011, making these synthetic analogues 
of THC one of the largest drug groups monitored by the EWS [4]. 
These new psychoactive substances – also named ‘’legal highs’’ – are usually 
sold via internet, presented as room odors, herbal incenses or other deceptive 
names [5]. However, forensic investigation by German and Austrian authorities 
demonstrated in 2008 that synthetic cannabinoids were present in these 
blends of herbal material, causing the cannabis-like effects experienced by 
users [6]. From that moment on, the list of these compounds detected in 
products with names like ‘Spice’ [7], continued to grow. It started with JWH-
018 and CP 47,497 [6],[8], but until now more variants are found almost every 
month [9,10], which can be divided in different classes [5]. 
The reasons for the growing popularity of these drugs vary. The synthetic 
analogues mimic the effect of cannabis and avoid a positive outcome on the 
current screening tests for THC [7]. In many countries legislation is based 
upon individual named substances, therefore these laws are quickly outdated 
when a new product is brought on the market. Indeed, previous research 
showed that as soon as the product appears on a prohibited list, a new 
generation is created and launched on the market in a few weeks. This clearly 
shows that the producers of these drugs have both legal and scientific 
background [11]. 
Further these products are readily available, they are - often falsely - sold as 
‘legal’ alternatives for cannabis via internet shops and this online selling is still 
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expanding at high speed [3]. The frequently seen indication ‘not for human 
consumption’ can be taken seriously, since little is known on the toxicology of 
the synthetic cannabinoids which has already resulted in some cases of 
severe overdosing [8,12]. 
In 2009 a new compound, 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)-indole 
(JWH-200) was detected by the EWS [13] and was at the end of 2010 
scheduled by the American Drug Enforcement Agency (DEA) [14] and several 
European countries [15]. This has led to the development of screening 
methods to detect JWH-200 in herbal mixtures [16,17], oral fluids [18], serum 
[19,20] and recently urine [21]. However, due to the lack of data on the 
metabolism of this new compound, optimized detection in urine was up to now 
not possible. Indeed, as described for other naphthoylindoles, the unchanged 
parent compound is not excreted in urine. [15,22] With the knowledge of the 
metabolism, long term detection via routine screening in urine becomes 
possible [23]. 
In this work both the in vitro and in vivo metabolism of JWH-200 is described. 
2 Experimental 
2.1  Reagents 
The enzyme β-glucuronidase from E. coli, used for hydrolysis, was purchased 
from Roche Diagnostics GmbH (Mannheim, Germany). 
Methanol was obtained from Fisher Scientific (Loughborough, UK). Disodium 
hydrogen phosphate (Na2HPO4) and sodium dihydrogen phosphate 
(NaH2PO4) were purchased from Merck (Darmstadt, Germany). Phosphate-
buffered saline (PBS) solution, pH 7.2, was purchased from Invitrogen 
(Merelbeke, Belgium). The internal standard, deuterated 11-nor-∆9-
tetrahydrocannabinol-9-carboxylic acid (THCA-d9) was from Cerilliant (Texas, 
USA). JWH-200, JWH 200 5-hydroxyindole metabolite and JWH 200 6-
hydroxyindole metabolite were purchased from Bio-Connect (Te Huissen, 
Netherlands). All reagents were of analytical grade. 
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The phosphate buffer solution used for hydrolysis was prepared by dissolving 
7.1 g Na2HPO4·2H2O and 1.4 g NaH2PO4·H2O in 100 mL of water. 
For microsomal incubations, all reagents were purchased from BD Bioscience 
(Erembodegem, Belgium): NAPDH generating system, phosphate buffer (pH 
7.4) and pooled Human Liver Microsomes. 
LC–MS grade methanol and LC–MS grade water were purchased from 
Biosolve (Valkenswaard, Netherlands), respectively. Ammonium acetate 
(NH4OAc) was obtained from Sigma (St. Louis, MO, USA). Acetic acid 
(HOAc) was purchased from Merck (Darmstadt, Germany). 
The gases used for the mass spectrometer were nitrogen (Alphagaz2-grade) 
and argon (Alphagaz1-grade), from Air Liquide (Desteldonk, Belgium).  
2.2 Chimeric mice – in vivo model 
The project was approved by the Animal Ethics Committee of the Faculty of 
Medicine of Ghent University (ECD 06/09). The production and maintenance 
of the chimeric uPA+/+-SCID mouse was done according to a previously 
described protocol [24]. 
For the administration studies metabolic cages (Tecniplast, Varese, Italy) 
were used, designed for giving the mice unlimited access to water and food 
and making an easy collection of the urine, separated from the faeces, 
possible. 
Via oral gavation 50 µL of a PBS solution containing the synthetic 
cannabinoid JWH-200 (0.1 mg JWH-200 dissolved in 2 mL of ethanol/PBS 
20/80 (v/v)) was administered to both chimeric (HuAlb 2.6 mg/mL, 2.1 mg/mL 
and 2.4 mg/mL) and non-chimeric mice. 
Non-transplanted uPA+/−-SCID mice, i.e. without human hepatocytes, were 
included in the administration study as a control group for the interspecies 
differences. Urine was collected prior to administration and 24 h and 48 h 
after a single dose of 2.5 µg. All samples were stored at -20°C until analysis. 
100 µL of the mouse urine was spiked with 25 µL of the internal standard 
containing 0.5 µg/mL THCA-d9. For hydrolysis 1 mL of 0.1 M phosphate 
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buffer solution (pH = 7) and 50 μL of β-glucuronidase were added and the 
samples were incubated at 56°C for 1.5 h. 
For purification solid-phase extraction (SPE) was applied, using Oasis® HLB 
3cc (60 mg) extraction cartridges from Waters (Milford, Massachusetts, USA). 
The following protocol was used: 2 mL of MeOH and 2 mL of water were used 
for activating and rinsing the column, respectively. Then the sample was 
diluted with 2 mL of water prior to loading. The column was washed twice with 
2 mL of water and eluted with 2 mL of MeOH. After evaporation of the MeOH, 
the residue was redissolved in 100 µL of H2O/MeOH (95/5) for LC-MS 
analysis. 
2.3 Human liver microsomes – in vitro model 
To study the in vitro metabolism of JWH-200, microsomal incubations were 
performed using a stock solution of the parent compound in DMSO (4 
mg/mL). The reaction medium (250 µL in total) contains 226 µL phosphate 
buffer (pH 7.4) and 15 µL of a 10 mM NADPH generating system. The latter 
consists of 12.5 µL of a mixture of NADP+ (1.3 mM), glucose-6-phosphate 
(3.3 mM) and MgCl2 (3.3 mM) and 2.5 µL glucose-6-phosphate 
dehydrogenase (0.4 U/mL) in sodium citrate (0.05 mM). After adding 2.5 µL of 
the JWH-200 stock solution, the reaction was initiated by adding 6.5 µL 
protein (20 mg/mL). The mixture was vortexed briefly and incubated at 37°C. 
After 4 h, the incubation was stopped by adding 250 µL of ice-cold MeOH and 
samples were centrifuged for 5 min at 12.000 g at 4°C. Subsequently the 
mixture was evaporated under oxygen free nitrogen (OFN) at room 
temperature. The dry residue was redissolved in 2 mL of distilled water prior 
to further purification by solid-phase extraction (SPE) with Oasis® HLB (60 
mg) cartridges. The procedure is the same as described earlier for the in vivo 
experiments. 
2.4  Instrumentation 
The same chromatographic conditions were used for all experiments. A MS 
Pump Plus was coupled with a Surveyor Plus autosampler (both from Thermo 
Scientific, Bremen, Germany). 20 µL was injected using a Sunfire™ C18 3.5 
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µm, 2.1 x 50 mm column from Waters (AH Etten-Leur, Netherlands). The 
mobile phase A consisted of 1mM NH4OAc in H2O, 0.1% HOAc, mobile phase 
B consisted of 1mM NH4OAc in MeOH, 0.1% HOAc. 
The gradient used was as follows: 95% mobile phase A for 1.5 min, then 
decreased linearly to 0% mobile phase A in 25 min, hold for 3 min. This was 
followed by an increase to initial conditions in 0.1 min and an equilibration for 
2.9 min before the next injection (total run time 31 min). A constant flow rate 
of 250 μL/min was used. 
Both low-resolution and high-resolution mass spectrometry-based strategies 
were used to detect and characterize JWH-200 metabolites. 
For high-resolution experiments, an Exactive mass spectrometer powered by 
Orbitrap™ technology from Thermo Scientific was operated in both positive 
and negative polarity switching modes and was equipped with an electrospray 
ionization (ESI) source. The sheath gas (nitrogen) flow rate was set at 60 
(arbitrary units) and for the auxiliary gas (nitrogen) at 30 (arbitrary units). The 
temperature of the capillary was 350 °C. The capillary voltage and spray 
voltage were set to 30 V and 4 kV, respectively. The instrument was operated 
in full-scan mode from m/z 50 to m/z 1,000 and high-collision energy 
dissociation (HCD) mode at 10, 20, 50 and 100 eV from m/z 50 to m/z 1,000, 
at 100,000 resolving power (at m/z 200). The data acquisition rate was 1 Hz. 
The Orbitrap™ performance in both positive and negative ionization modes 
was evaluated daily and when failed, external calibration was realized with 
Exactive Calibration Kit solutions (Sigma-Aldrich, St. Louis, USA and ABCR 
GmbH & Co. KG, Karlsruhe, Germany). 
Low resolution product ion scan experiments were performed on a Finnigan 
TSQ Quantum triple quadrupole mass spectrometer, from Thermo Scientific, 
using the electrospray source. The following ESI–MS parameters were used: 
capillary voltage 3.5 kV; source temperature 350 °C; sheath gas pressure, 50 
(arbitrary units); auxiliary gas pressure, 20 (arbitrary units); tube lens offset, 
100 V. 
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3 Results and discussion 
In analogy with the metabolic pathways reported for similar compounds like 
JWH-015 [25], JWH-018 [22,26] and JWH-122 [27], the in vitro metabolism of 
JWH-200 was investigated. Therefore HRMS experiments were performed. 
Identification and structure elucidation of the metabolites was based on the 
occurrence of diagnostic product ions, related to the parent compound. Using 
all ion fragmentation in the HCD-cell [28], the fragmentation pattern of JWH-
200 was investigated. As shown in Fig. 8.1 the protonated molecule 
generates two main product ions. The first ion with an accurate mass of m/z 
155.0489 was found to be the naphthalene moiety containing the carbonyl 
function (mass error: 1.2 ppm). The second originates from the morpholine 
ring containing the alkyl side-chain with m/z 114.0912 (mass error: 1.7 ppm). 
The presence of both ions, called F1 and F2 respectively (Table 8.1), was 
used to prove the unchanged appearance of this part of the molecule in the 
metabolites. Also a product ion with m/z 145.0645 is found (F3), however with 
a lower abundance. This is formed from F1 after the loss of CO and the 
addition of water as previously described [29] and shown in Fig. 8.1 (mass 
error: 1.7 ppm). Product ions proving the presence of the indole ring however, 
were not found.  
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Fig. 8.1 The mass spectrum of the protonated JWH-200 with proposed 
structures for the formed product ions. 
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Table 8.1. Common product ions of the protonated JWH-200 and its 
metabolites formed after HCD fragmentation. 
Fragment Nr. Structure Theoretical m/z detected in metabolites 
F1 155.0491 P, M1A, M1C, M2A, 
M2B, M2C, M3, M7, M8 
M9A, M9B, M9D, M10A, 
M10B, M11 
F2 114.0913 P, M1A, M1B, M4A, M4B 
F3 145.0648 P, M7, M10A, M10B 
F4 171.0441 M1B, M4A, M4B, M5A, 
M5B, M6A, M6B 
F5 112.0757 M1C, M2A, M3 
F6 100.0752 M2B, M2C 
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F7 189.0544 M4A, M5A, M6A 
F8 143.0489 M4A, M4B, M5A, M5B, 
M6A, M6B 
F9  188.0706 M6A, M6B, M7 
F10 160.0393 M9A, M9B 
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3.1 Phase I metabolism of JWH-200 
For the detection of metabolites in the in vitro experiments, accurate masses 
were calculated for theoretically possible metabolites. A mass tolerance 
window of 5 ppm was applied for identification of the metabolites. An overview 
of the metabolites described below is shown in Table 8.2. 
 
 
Fig. 8.2 HRMS chromatograms for the protonated molecules of the metabolites 
of JWH-200 obtained using the in vitro model with human liver microsomes. 
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3.2 Hydroxylation and dehydrogenation 
Four monohydroxylated metabolites were detected as protonated molecules 
[M+H]+ m/z 401.1860 (Fig. 8.2 M1). After HCD experiments, both ions F1 and 
F2 (Table 8.1) were found in metabolites M1A and M1B. This indicates an 
unchanged naphthalene and morpholine moiety, respectively (cf. JWH-200 in 
Fig. 8.1). Consequently it can be assumed that the hydroxylation is located on 
the indole ring for both metabolites. Even though a product ion proving this 
assumption could not be found, both metabolites could be identified by means 
of reference standards. As shown in Fig. 8.3, M1A corresponds to the 5-
hydroxyindole metabolite, while M1B turns out to be the 6-hydroxyindole 
metabolite of JWH-200. While ion F2 is also detected in metabolite C, F1 is 
missing. This points towards a modification in the naphthalene moiety. 
Indeed, as shown by the presence of a product ion with m/z 171.0441 (F4 in 
Table 8.1) the hydroxylation is located on the naphthalene ring. For metabolite 
D, the opposite is true: ion F1 is still present, but F2 was not observed. 
Instead, two other ions were found proving the hydroxylation on the 
morpholine ring: m/z 130.0863 (i.e. F2 + OH) and m/z 112.0757. The latter is 
formed via the loss of water from the original ion m/z 130.0863 (F5, Table 
8.1). 
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Fig. 8.5 HRMS mass spectrum of the protonated metabolite M3, using HCD at 
50 eV. 
 
3.3 Dihydrodiol metabolites 
As known for naphthoylindoles, dihydrodiol metabolites are formed [22,25]. This 
loss of aromaticity in combination with two hydroxylations on vicinal positions, 
is most likely initiated through epoxidation and consecutive hydrolysis on the 
naphthalene ring [30]. As shown in Fig. 8.6 for metabolite M4 A, the unaltered 
morpholine ring is represented by ion F2 (Table 8.1). The modifications on the 
other part of the molecule are reflected in three product ions: m/z 189.0544 
(Table 8.1, F7) corresponds to the dihydrodiol present on the naphthalene 
ring; m/z 171.0438 (Table 8.1, F4) and m/z 143.0489 (Table 8.1, F8) are 
formed after the loss of water and CO, respectively. The second metabolite 
with protonated mass m/z 419.1965 (M4 B, Fig.8.2) shows a similar 
fragmentation pattern, although the ion F7 is missing. The explanation for this 
can be found in the different location of the dihydrodiol in both isomeric 
metabolites as observed by Zhang et al. [30]. Because of the similar properties 
in terms of metabolism for both compounds, it can be assumed that also for 
JWH-200 the dihydrodiol functionalities are located on the same positions. For 
the metabolite carrying this functionality in ring a of the naphthalene, the 
{ } p @ [ ]
60 80 100 120 140 160 180 200 220 240 260 280 300 320 340 360 380 400
m/z
0
5
10
15
20
25
30
35
40
45
50
55
60
65
70
75
80
85
90
95
100
R
el
at
iv
e 
A
bu
nd
an
ce
155,06011
188,07036
144,04415
112,05398
N
N
O
O
OH
O
+
N
O
+
OH
N
H
O
+
CH3
N
+
O
316,13243
F1
F5
Chapter 8: JWH-200 
195 
aromaticity of the indole-naphthalene system is lost. Therefore the loss of 
water is favorable to restore the aromaticity, meaning that ion m/z 189.0544 
(F7) is not formed. This would mean that the other metabolite carries the 
dihydrodiol functionality in the b ring. 
 
 
Fig. 8.6 Proposed fragmentation pattern (HCD, 50 eV) of the protonated 
metabolite M4 A. Only one possible configuration is shown. 
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ion corresponds to the complete metabolite after cleavage of the morpholine 
ring. Therefore it can be assumed that the latter was hydroxylated, however 
no additional proof in terms of product ions was found. 
3.4 Morpholine ring cleavage 
The dihydrodiol functionality is also detected together with the loss of the 
morpholine ring (M6, Fig. 8.2). After cleavage of the C-N bond, the alkyl side 
chain is hydroxylated at the end position [31]. This is the case for both 
metabolites M6 A and M6 B, since a product ion with m/z 188.0706 is 
detected (Table 8.1, F9). Since this morpholine-cleavage is identical, the 
difference between both metabolites is found in the location of the dihydrodiol 
on the naphthalene ring, similar as was proposed earlier: ring b for M6 A (F7, 
F4, F8) and ring a for M6 B (F4, F8). 
Two metabolites are the result of a morpholine cleavage from the parent 
compound. In the first (M7) - with m/z 316.1332 and a retention time of 17.2 
min – the end position of the alkyl side chain is again hydroxylated as for the 
M6 metabolites. Indeed, while the presence of F1 and F3 proved that the 
naphthalene moiety remained unchanged, the presence of F9 showed the 
modifications on the alkyl chain. In the second metabolite (M8 with m/z 
330.1125 for the [M+H]+ ion and retention time 20.0 min), the hydroxylation is 
replaced by a carboxylic group at the end of the alkyl chain. This is reflected 
in the mass spectrum by the presence of a product ion with m/z 202.0499, 
replacing F9. As a confirmation, this metabolite was also detected in negative 
mode with m/z 328.0979 for the [M-H]- ion. This metabolic transformation can 
be explained using the successive hydroxylation-hydrolysis pathway 
described by Denissen et al. [32]. 
As shown in Fig. 8.2, four metabolites were detected with m/z 332.1281 (M9). 
This corresponds to an increase of m/z 15.9944 compared to the 
abovementioned metabolite M7 (m/z 316.1332), pointing towards one extra 
hydroxylation in addition to the morpholine cleavage. For metabolites M9 A 
and D, the fragmentation is comparable to that of M7 but ion F9 is missing. 
This is replaced by a product ion with m/z 204.0655 (i.e. 15.9944 higher) in 
both metabolites. Upon further fragmentation the alkyl side chain is also 
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cleaved, leading to a product ion with m/z 160.0393 (Table 8.2, F10). This 
allows locating the hydroxylation on the indole ring. Metabolite B differs from 
the previous two by the absence of ion F10, so it can be assumed the 
hydroxylation is located on the alkyl side chain instead of the indole ring. The 
low abundance of metabolite M9 C makes correct identification of the product 
ions difficult, therefore again low resolution MS/MS experiments were used. 
After conducting product ion scans at m/z 332, ions m/z 171 (cf. F4) and m/z 
143 (cfr. F8) were found, proving the hydroxylation on the naphthalene ring. 
3.5 Morpholine ring opening 
The different metabolic pathways for the opening of the morpholine ring are 
well known. One of the described options is the cleavage of the C-O bond 
yielding a metabolite with a mass increased by 2 Da [31]. This transformation 
explained two metabolites for JWH-200 using liquid chromatography low 
resolution mass spectrometry by the presence of 2 peaks with m/z 387 for the 
[M+H]+ ion (i.e. formula C25H26N2O2, compared to C25H24N2O2 for the parent 
molecule). However, in order to confirm this finding using HRMS technology, 
the accurate masses measured for both peaks (Fig. 8.2, M10) were found not 
to correspond to the proposed chemical formula. Indeed, when using a 5 ppm 
tolerance window the experimental protonated mass of m/z 387.1694 
appeared to be the protonated form of C24H22N2O3. To obtain a metabolite 
with this formula, other modifications than cleaving the ether bond should 
occur. By performing experiments using all ion fragmentation in the HCD cell  
diagnostic ions were detected (Fig. 8.6): ion F1 showed the unaltered 
naphthalene ring, while a product ion with m/z 116.0704 could explain the 
modifications in the morpholine ring. To the best of our knowledge this 
pathway has not been previously described but can be explained by the two 
earlier proposed pathways for N-substituted morpholine rings. [32] In the first 
Denissen et al. propose an intermediate formed after a hydroxylation on the 
morpholine ring vicinal to the nitrogen, a ring opening via hydrolysis and a 
consecutive hydroxylation. When this product is further oxidized, a 
decarboxylation would lead to the ion proposed in Fig. 8.7. The second 
pathway is similar, although the initial hydroxylation is located next to the 
oxygen of the morpholine ring, leading to a different metabolite. This may 
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explain the presence of 2 metabolites with identical fragmentation patterns but 
different retention times (Fig 2, M10). It should be noted that by only using low 
resolution techniques no distinction can be made between these metabolites 
and the metabolite as described by Zhang et al. [31]. 
 
 
Fig. 8.7 Proposed fragmentation pathway (HCD, 20 eV) of the protonated ring 
opening metabolite M10. Only one possible configuration is shown. 
 
One step further in the metabolic process the original morpholine ring is 
transformed to an ethanolamine moiety, via hydrolysis of the abovementioned 
intermediates [32]. In the metabolite formed via this pathway, a loss of C2H2 is 
seen compared to the parent molecule. Accordingly, one metabolite (M11) 
was detected at a retention time of 11.1 min with protonated mass m/z 
359.1746. After HCD fragmentation, a product ion with m/z 88.0755 was 
detected. This corresponds to the loss of ethylene from ion F2 in the parent 
molecule. When applying low energies (10 to 20 eV) in the HCD cell, a 
product ion with m/z 315.1486 is also found. This is the cleavage of ethanol 
from the M11 metabolite, proving again the morpholine ring opening with the 
loss of ethylene. 
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Table 8.2. Proposed metabolite structures for JWH-200. Only one possible 
configuration is shown. 
Category Modification Example 
M1 Monohydroxylation 
m/z 401.1860 
 
M2 Dehydrogenation 
m/z 383.1754 
 
M3 Monohydroxylation + 
Dehydrogenation 
m/z 399.1703 
 
OH
N
N
O
O
N
N
O
O
N
N
O
O
OH
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M4 Dihydrodiol functionality 
m/z 419.1965 
 
M5 Dihydrodiol functionality + 
monohydroxylation 
m/z 435.1914 
 
M6 Dihydrodiol functionality + 
cleavage morpholine ring 
m/z 350.1387 
 
M7 Cleavage morpholine ring 
(OH) 
m/z 316.1332 
 
N
N
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O
OH
OH
OH
N
N
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O
OH
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N
OH
O
OH
OH
N
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O
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M8 Cleavage morpholine ring 
(COOH) 
m/z 330.1125 
 
M9 Cleavage morpholine ring 
(OH) + monohydroxylation 
 
m/z 332.1281 
 
M10 Morpholine ring opening 
 
m/z 387.1703 
 
M11 Morpholine ring opening – 
loss of ethylene 
m/z 359.1746 
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3.6 Analysis of mouse urine samples – chimeric mouse 
model 
In the second part of this study uPA+/+-SCID mice with humanized liver were 
used as a model for the in vivo metabolism of JWH-200. This model proved to 
be an efficient alternative for human administration studies for the 
investigation of steroid metabolism [33] and was recently used to reveal both 
phase I and phase II metabolism of synthetic cannabinoids [27].  
Briefly this chimeric mouse model is based on the transplantation of human 
hepatocytes to uPA+/+-SCID mice. Therefore mice suffering from a chronic 
liver disease caused by overexpression of the urokinase plasminogen 
activator (uPA) were used. This situation is beneficial for liver regeneration by 
transplanted hepatocytes. However, to avoid graft rejection when 
transplanting human hepatocytes, these mice were backcrossed with 
genetically immunodefficient (i.e. carrying a severe combined immune 
deficiency syndrome or SCID) mice. In the obtained uPA+/+-SCID successful 
transplantation of human hepatocytes is possible [24,33]. 
For the following discussion a two-step approach was used. The phase I 
metabolism was investigated after performing a hydrolysis step on the mouse 
urine samples. Therefore the LC-MS/MS was operated in selected reaction 
monitoring mode (SRM). This method, containing two transitions for every 
metabolite detected in vitro, was used to confirm the previously described 
metabolites in vivo. Then the non-hydrolyzed urine was screened for 
glucuronide and sulphate conjugates by LC-HRMS and subsequently 
analyzed using the SRM method for the detection of potential free excreted 
metabolites.  
Besides a small amount in one chimeric mouse urine, no parent compound 
was detected in the urines collected 24h after administration. The four in vitro 
monohydroxylated metabolites, M1A and M1C are also present in the mouse 
urine. Although metabolite M1D is not detected, one extra metabolite was 
found where the hydroxylation is also located on the naphthalene ring (M1E in 
Fig. 8.8). This finding was also reflected in the phase II metabolism, since 
three glucuronide conjugates were detected. When comparing the peak areas 
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of the metabolites found in the hydrolyzed urine to those detected free in the 
non-hydrolyzed urine, it was possible to estimate the conjugation rate. 
Metabolite M1A was not detected free, while for both other monohydroxylated 
metabolites the conjugation rates were estimated around 50%.  
 
Fig. 8.8 Relative peak areas (corrected by the internal standard THCA-d9) of the 
metabolites detected using 3 chimeric mice for hydrolyzed urines collected 
24h after administration. 
 
In the chimeric mice, both metabolites with a dihydrodiol functionality (M4) 
were detected. From the HRMS experiments, two corresponding glucuronide 
conjugates were found. While for metabolite M4A the conjugation rate was 
estimated 80%, free M4B was not detected. It should be noted that only M4A 
was detected in the non-chimeric mouse (Fig. 8.9). Since metabolite M4B is 
absent in normal mice and only one glucuronide conjugate was detected in 
this control group, it can be considered an exclusive human metabolite.  
Also the metabolites carrying a combination of the dihydrodiol and a 
morpholine cleavage (M6) seemed to be of human origin, since those were 
not detected in the non-chimeric control group either. In the hydrolyzed urine 
of the mice with humanized liver both metabolites M6A and M6B were 
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detected, together with two glucuronide conjugates in the non-hydrolyzed 
urine. Since no free excreted metabolites were detected, the conjugation 
reaction was considered complete. A similar result was found for metabolite 
M7. This metabolite, with the alkyl side chain hydroxylated after the cleavage 
of the morpholine ring, is only found in the chimeric mouse urine and is 
completely excreted as glucuronide conjugate. 
Not all metabolites are that extensively conjugated. Indeed, although 
metabolite M8 is detected in large amounts in the hydrolyzed urine (Fig. 8.8), 
only a small amount of the M8-glucuronide is detected. Taking into account 
the amount detected in the free fraction, the conjugation rate is estimated to 
be below 30%. However being excreted mostly non-conjugated, this 
metabolite could be detected in all hydrolyzed urines collected 48 h after 
administration using the SRM method. 
Two metabolites from the M9-class could be confirmed in vivo, being M9A 
and M9B. Although only low amounts of these metabolites were present, two 
corresponding glucuronides were found but no significant amount could be 
detected in the free fraction.  
Both types of morpholine ring opening detected in the in vitro model are 
confirmed in the chimeric mouse model. For the M10-class, were the ring 
opening is presumably followed by a decarboxylation, both metabolites M10A 
and M10B are detected in the hydrolyzed urine using the SRM method. In 
contrast to all other metabolites, no glucuronide but two sulphate conjugates 
were formed in vivo. Since sulphates easily undergo deprotonation, this 
finding could be confirmed by operating the HRMS in negative ionization 
mode. The metabolite formed after the loss of ethylene from the morpholine 
ring (M11) was also detected in the total fraction, excreted almost completely 
as glucuronide conjugate. 
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Fig. 8.9 In vivo metabolism of JWH-200: HRMS chromatograms for the 
protonated dihydrodiol metabolites (M4 – m/z 419.1965) and corresponding 
glucuronide conjugates (M4-gluc – m/z 595.2256) for mouse urine samples 
analyzed both with (total fraction) and without hydrolysis (phase II and free 
fraction). 
 
4 Conclusion 
Although the structure of JWH-200 shows similarities to other earlier 
described naphthoylindoles, the addition of the morpholine ring to the 
structure has a large impact on the metabolism. As shown in the in vitro 
research, this ring structure was modified in different ways. After cleavage of 
the complete ring, the remaining alkyl chain was hydroxylated (M7 and M9) or 
further oxidized towards a carboxylic acid on the end position (M8). In 
addition, the ring can also be opened in two different ways: via a new 
proposed pathway including a decarboxylation (M10) or via the known loss of 
ethylene (M11).  
The chimeric mouse model allowed to confirm most of the metabolites 
discovered in vitro, including the mentioned modifications at the level of the 
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morpholine ring. However the dehydrogenation pathway – as seen in 
metabolites M2 and M3 – could not be confirmed in vivo. Also the metabolites 
with the combination of the dihydrodiol functionality and a single hydroxylation 
(M5) were not found in the mouse urine. 
By analyzing the non-hydrolyzed urine using HRMS, information was obtained 
on the phase II metabolism of JWH-200. Even though varied conjugation 
rates were observed, most metabolites were excreted as glucuronide 
conjugates. Only for the metabolites of the M10-class, two sulphate 
conjugates could be detected.  
Using the information obtained from the in vivo model, it was possible to make 
conclusions towards routine screening of JWH-200 in urine. The relative 
abundances of the excreted metabolites in Fig. 8.8 clearly indicate that 
metabolite M8 is detected in the highest amounts in the in vivo model. 
Moreover, this metabolite was still detectable 48 hours after the dose was 
administered, which indicates that it is the metabolite of choice to monitor 
JWH-200 abuse. This can be done both on the free metabolite, after 
performing hydrolysis, and on the glucuronide conjugate, using non-
hydrolyzed urine.  
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Over the last years the aim of DoCoLab has been to improve the existing analytical 
procedures in several ways. To raise the overall efficiency of the laboratory – both 
with respect to time and costs – it was also tried to reduce the number of screening 
procedures.  
This goal could be achieved although simultaneously more stringent requirements 
were imposed by WADA. Indeed, the number of compounds and/or corresponding 
metabolites is increasing while the corresponding MRPL’s follow the opposite trend. 
Research projects - focused on metabolomics – yielded more and better target 
metabolites to screen for known compounds and allowed to implement newly 
discovered compounds in these improved screening methods. 
This thesis describes some of the efforts made both in the development of a new 
screening method as in the implementation of a new class of compounds. 
Part II: The implementation of GC-QqQ-MS 
In the first part the evolutions in the GC-screening methods are described. Before the 
installation of the GC-MS/MS system in 2009, two GC-MS methods [1,2] were in use: 
one method to detect anabolic steroids and quantify the endogenous steroids and 
another to screen for narcotics and stimulants. This required two different sample 
preparation procedures and corresponding chromatographic runs of approximately 
20-26 minutes each. It is self-evident that the implementation of a single GC-MS/MS 
method capable of detecting all these compounds, in a run of 15 minutes, improved 
the sample turn-around time strongly. 
In chapter 3 the first fast GC-MS/MS method is described. This method – using 
hydrogen as a carrier gas – is built up in two parts. In the quantitative part the 
steroids of the traditional steroid profile are included together with endogenous 
steroids, which are not affected by the intake of natural AAS (11β-OH-androsterone 
and 11β-OH-etiocholanolone) and markers to monitor microbiological degradation 
(5a-androstanedione and 5b-androstanedione) of the urine samples. Additionally, the 
method is also capable of quantifying salbutamol and the major metabolite of 
cannabis (THCA). Compared to the former methods, this quantification was not only 
improved due to the higher selectivity and specificity of the new technique but also by 
using 6-point calibration curves and deuterated internal standards instead of one-
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point calibration and use of a single internal standard. In the qualitative part of the 
method, over 140 substances can be detected at or below the required MRPL’s. 
Although only 1 mL of urine was used, low detection limits could be reached by the 
combination of tandem MS detection and the injection of large volumes with the PTV-
system. 
While in the past, monitoring of the sample preparation was principally limited to 
verification of extraction recovery and derivatisation efficiency, in the new method 
measures were taken to monitor all major sample preparation steps in every single 
sample. The hydrolysis and extraction efficiency are evaluated by the addition of both 
free and glucuronidated deuterated internal standards, the yield of the derivatisation 
reaction is measured by including transitions for the mono-TMS derivatised 
androsterone and etiocholanolone and two markers are quantified to monitor 
possible microbiological sample degradation. 
Technically it was possible to limit the run time to only 8 min by the combination of a 
short HP-Ultra 1 column and hydrogen as carrier gas  
This GC-MS/MS screening method was subject of further research in order to further 
improve it (according to the at that time statutory WADA technical document [3]) . 
Chapter 4 describes in detail both the research and the adjustments made to the 
method. 
With daily use, it was found that the system showed stability problems when using 
hydrogen as a carrier gas, this was solved by switching back to the previously used 
helium. Although this increased the runtime to about 12 min, the extended 
temperature program had the advantage that the separation of some more volatile 
compounds became possible.  
Indeed, qualitatively, the method was extended to over 150 compounds from different 
classes. In the quantitative part the traditional steroid profile was expanded with 6 
minor metabolites, which can enlarge the distinctive power of the steroid profile in the 
detection of endogenous steroid abuse. The addition of these markers could allow 
the use of this method in the framework of the adaptive model [4] on a routine basis. 
Currently population based reference ranges must be exceeded before a 
confirmation procedure by IRMS is recommended [5]. When – by analogy with the 
already used hematological markers – endogenous steroid data will be included in 
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the Athlete Biological Passport [6], individual reference ranges will decrease the 
margins for detection of endogenous steroid abuse [7]. 
The quality measurements implemented to monitor the complete sample preparation 
procedure were further investigated and improved. To check the hydrolysis efficiency, 
the ratio of androsterone-d4 glucuronide over etiocholanolone-d5 was used. Further 
the ratio of mono-TMS derivatised androsterone to bis-TMS derivatised androsterone 
proved to be the parameter of choice to monitor the derivatisation reaction. Stability 
experiments were performed to investigate the response and reliability of the steroid 
profile under harsh conditions and to identify reliable markers for microbiological 
degradation. Therefrom, it could be concluded that relative concentration ratios (like 
5α-androstane-3,17-dion over androsterone) are the obvious parameters to estimate 
the effect of microbiological degradation on the concentrations of the steroid profile. 
In chapter 5, a fast GC-MS/MS confirmation procedure for THCA is described. 
Therefore both the sample preparation procedure and the GC-methodology were 
optimized. Starting from only 1 mL of urine, the alkaline hydrolysis proved to be 
complete in 7 min. Compared to previously used methods, only a single extraction 
was needed to obtain sufficient selectivity in the MS/MS system, which was 
performed by 1 minute of vortexing. Microwave-assisted-derivatisation was applied to 
speed up the otherwise time-consuming derivatisation step. Finally the GC-runtime 
was reduced to 4 minutes. 
In that way the combination of a simplified sample preparation procedure, large 
volume injection using the PTV-injector and tandem mass spectrometry allows to 
quantify THCA in urine in only 30 minutes. 
Part III: Synthetic cannabinoids 
The class S8 of the prohibited list [8] contains both natural as well as synthetic 
substances binding to the cannabinoid receptors. In addition to the optimization of 
the confirmation procedure for cannabis, this thesis also focused on other 
cannabinoids. It should be noted that synthetic cannabinoids are not only a doping 
related problem. Indeed, the introduction of a wide-range of new psychoactive 
substances, constitutes a growing drug problem in general. The increasing use of 
these products, among which the group of synthetic cannabinoids is studied in this 
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work, should therefore be seen in a wider perspective. Although the number of 
positive cases in sport drugs testing are rather limited up to now [9], the popularity of 
these cannabimimetics is growing all over the world [10–12]. Reversing this evolution is 
only possible when a broad, international approach is applied. So, dissemination of 
correct information, a sound and uniform legislation, interception of 
production/dealing units and efficient detection of abuse are essential. 
Chapter 6 summarizes some general considerations on these synthetic 
cannabinoids. An overview is given on the situation of the abuse and the current 
legislation. Further attention is paid to the interactions which occur in the human 
body, the possible health risk of (long-term) use and the current state of affairs in the 
field of detection is outlined. 
In the doping control area as well as in many other fields, urine is the matrix of choice 
to detect drugs of abuse. Still, this is not straightforward since it necessitates the 
knowledge of the metabolic modifications to which the compound of interest is 
submitted prior to excretion. Synthetic cannabinoids are known to be heavily 
metabolized in the human body, even to such extent that the unchanged parent 
compound is usually not detectable in urine. This makes metabolic studies an 
absolute prerequisite for development of screening methods using urine. As 
explained in chapter 6, it is unethical to carry out human administration studies for 
metabolic investigation of these types of compounds. Therefore in this work a 
strategy - based upon the consecutive use of two models - is presented as 
alternative. 
The application of this strategy to reveal the metabolism of JWH-122 is described in 
chapter 7. In a first step, the phase I metabolism is investigated by means of an in 
vitro model using human liver microsomes. This model has the advantage that it is 
easy to carry out in a standard analytical laboratory. In this work, it was found that for 
the cannabimimetics studied, an incubation time of 4h showed the best results, which 
makes it a fast procedure as well. Further, the limited amount of matrix interferences 
allows identifying the formed metabolites more easily than in real urine samples. 
Using LC-MS, 11 classes of metabolites were identified. The JWH-122 parent 
compound was metabolized via hydroxylations, dehydrogenations or cleavage of the 
N-pentyl side chain. Further also dihydrodiol functionalities were introduced on some 
metabolites and one metabolite was found carrying a carboxyl group on the N-pentyl 
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side chain. Information on the location of the metabolic modifications on a given 
metabolite was obtained from fragmentation experiments using CID on the LC-
MS/MS system. 
Consecutively the presence of these metabolites was checked in an in vivo model, 
developed in cooperation with the Centre for Vaccinology, via oral administration to 
chimeric uPA+/+-SCID mice. LC-MS analysis of the mouse urine allowed confirming 
most abovementioned metabolic modifications. Furthermore, the urine samples were 
analysed a second time, without enzymatic hydrolysis. From these experiments, it 
could be concluded that all detected metabolites were excreted as glucuronide or 
sulphate conjugate, with conjugation rates above 50%. By comparing the relative 
peak areas, it was found that the monohydroxylated JWH-122 metabolites were 
excreted in the highest amounts. Therefore these metabolites were selected as target 
compounds to screen for JWH-122 abuse. 
The same strategy was also followed for JWH-200 as explained in chapter 8. The 
presence of the morpholine ring on the alkyl side chain of this naphthoylindole had a 
large impact on the metabolism. Indeed, next to the modifications described for JWH-
122, the presence of the morpholine ring was responsible for the formation of several 
ring-opening metabolites. To locate these metabolic modifications both CID (LC-
MS/MS) and HCD (LC-HRMS) experiments were performed. Although high resolution 
data acquisition makes unambiguous identification of the fragment possible, the all-
ion-fragmentation technique, used in the HCD-cell, sometimes makes it difficult to 
distinguish compound-related fragments from others, especially in the lower 
concentration ranges. For the latter the more specific product ion scans on the LC-
MS/MS system can offer a solution. 
Although less metabolites were found via the in vivo model compared to in vitro, most 
metabolic modifications could be confirmed. As for JWH-122, also the JWH-200 
metabolites were excreted as glucuronide or sulphate conjugates. For these 
experiments the strength of the HRMS detection should be highlighted. By combining 
the full scan high resolution data acquisition with fast polarity switching between 
positive and negative scan modes, all data can be collected in one single run. 
Afterwards it is a matter of data processing to confirm whether or not a theoretically 
possible phase II metabolite is present. This is particularly of interest if there is a 
limited volume of sample available, as for the mouse urine.  
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The JWH-200 metabolite, formed after consecutive morpholine cleavage and 
oxidation of the remaining side chain to a carboxylic group, appeared to be present in 
the highest amounts. In general, with this mouse model metabolites are cleared 
within 24h whereas this metabolite was detectable even 48h after administration. 
This indicates that this metabolite might be useful for prolonged detection of misuse. 
It is clear that the research described in this work, which could lead to the urinary 
detection of both JWH-compounds, is only a small step in the whole synthetic 
cannabinoid story. As mentioned earlier, this problem requires a global and 
comprehensive approach, in which different areas of expertise will need to contribute.  
Today it is impossible to estimate how the situation will evolve, so continuously 
improving the detection strategies of the currently known compounds and these 
which will – without any doubt – enter the market in the (near) future, will be 
necessary. Concerning the detection in urine, both research toward metabolism and 
method development will be essential. As can be derived from their scientific output 
in this area over the last years, doping control laboratories play an important part in 
this. 
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Het streven naar hogere efficiëntie was de laatste jaren één van de drijfveren voor 
het onderzoek rond methodeontwikkeling in DoCoLab. Enerzijds betekenen 
efficiëntere methodes een winst in zowel tijd als kosten, anderzijds is continue 
verbetering noodzakelijk om te blijven voldoen aan de steeds strenger wordende 
eisen. Zo wordt het aantal te bepalen componenten steeds groter, terwijl de minimaal 
vereiste detectielimieten hiervoor steeds worden verlaagd. 
Naast het ontwikkelen van nieuwe methodes wordt veel geïnvesteerd in metabolisme 
onderzoek. Dit is een noodzakelijke tussenstap om tot detectie van nieuwe 
componenten in urine te komen. Wanneer het gaat over reeds gekende 
componenten verschuift de nadruk naar beter en langer detecteerbare metabolieten. 
In dit werk wordt zowel de ontwikkeling van een nieuwe screeningsmethode als de 
implementatie van een nieuwe klasse van verboden producten besproken. 
Deel II: De implementatie van GC-QqQ-MS 
In het eerste deel van deze thesis wordt de evolutie op het gebied van 
gaschromatografie beschreven. Voor de installatie van het GC-MS/MS systeem in 
2009 werd gebruikt gemaakt van twee GC-methodes [1,2], de ene voor de detectie 
van anabole steroïden en de kwantificering van de endogene steroïden en de andere 
voor het screenen op narcotica en stimulantia. Naast twee GC-methodes van 20-26 
minuten waren hiervoor ook twee verschillende staalvoorbeidingsprocedures in 
gebruik. Het spreekt vanzelf dat de efficiëntie sterk verhoogd werd door beide 
methodes te vervangen door één enkele GC-MS/MS methode van slechts 15 
minuten.  
In hoofdstuk 3 wordt de ontwikkeling en validatie van de eerste methode op dit 
nieuwe toestel beschreven. Vanuit theoretisch oogpunt bestaat deze methode uit 
twee delen. In het kwantitatieve deel worden de concentraties bepaald van de 
steroïden die deel uitmaken van het klassieke steroïdprofiel. Daarnaast worden ook 
twee endogene steroïden waarvan de excretie niet wordt beïnvloed door het gebruik 
van steroïden (11β-OH-androsterone en 11β-OH-etiocholanolone) en merkers voor 
microbiële degradatie (5α-androstanedione en 5β-androstanedione) kwantitatief 
bepaald. Naast deze zijn ook salbutamol en de belangrijkste metaboliet van cannabis 
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(THCA) in het kwantitatieve deel opgenomen. In vergelijking met de vroeger 
gebruikte methodes werd de kwantificering van deze componenten sterk verbeterd. 
Hierin speelde niet alleen het nieuwe GC-MS/MS systeem een rol, ook de 
overschakeling naar gedeutereerde inwendige standaarden en calibratiecurves over 
6 niveaus zijn van belang. In het kwalitatieve deel wordt gescreend op meer dan 140 
producten die gedetecteerd kunnen worden aan concentraties conform de door 
WADA opgelegde MRPL’s. De combinatie van de selectieve tandem MS detectie met 
de injectie van grotere volumes via het PTV-systeem, liet toe om deze niveau’s te 
bereiken in slechts 1 mL urine. 
Ook aan kwaliteitscontrole wordt meer aandacht besteed. Bij vorige methodes was 
de controle op de staalvoorbereiding beperkt tot het opvolgen van het rendement van 
de extractie en de derivatisatie. In de nieuwe methode worden zowel 
geglucuronideerde als vrije gedeutereerde inwendige standaarden toegevoegd om 
elke stap van de staalvoorbereiding te controleren in elk individueel staal. De 
methode bevat verder ook transities voor de enkelvoudig gederivatiseerde (mono-
TMS) androsterone en etiocholanolone om de derivatisatie reactie op te volgen en 
twee merkers voor eventuele microbiële degradatie van de urine. Het gebruik van 
een kortere HP-Ultra1 kolom met waterstof als dragergas liet toe alle componenten te 
scheiden in slechts 8 minuten. 
Van bij de opstart van de nieuwe GC-MS/MS screeningsprocedure werd verder 
onderzoek gedaan met als doel deze continu te verbeteren. In hoofdstuk 4 worden 
zowel het onderzoek als de uiteindelijke aanpassingen aan de methode beschreven. 
Na de ingebruikname van de methode werd duidelijk dat het gebruikte dragergas 
verantwoordelijk was voor de ervaren stabiliteitsproblemen van de ionisatiebron. 
Daarom werd het waterstofgas vervangen door helium. Dit verlengt de methode tot 
ongeveer 12 minuten, maar maakt de scheiding van enkele meer vluchtige 
componenten mogelijk. Bijgevolg kon het kwalitatieve deel van de methode 
uitgebreid worden tot meer dan 150 componenten uit verschillende klassen. In het 
kwantitatieve deel werd het klassieke steroïdprofiel uitgebreid met 6 zogenaamde 
“minor metabolites”. Eerder onderzoek in DoCoLab heeft aangetoond dat deze 
steroïden de kracht van het steroïdprofiel - als instrument voor de opsporing van 
endogeen steroïdmisbruik - kan vergroten. De kwantificering van deze merkers in de 
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screeningsmethode is mogelijk een eerste stap naar de implementatie ervan in het 
Bayesiaans adaptief model [3]. Momenteel worden grenswaarden gebaseerd op 
populatiestatistiek gebruikt om te beslissen of een eventuele confirmatie via IRMS 
noodzakelijk is [4]. Wanneer echter gegevens over het endogeen steroïdprofiel 
worden ingevoerd in het Athlete Biological Passport [5] – zoals dat nu reeds gebeurt 
voor hematologische merkers – kunnen individuele grenswaarden de ruimte voor 
endogeen steroïdmisbruik verkleinen [6]. 
Wat kwaliteitscontrole betreft, werd gezocht naar optimalisatie van de gebruikte 
parameters. Voor de controle van de hydrolyse efficiëntie werd gebruik gemaakt van 
de verhouding van de inwendige standaarden androsterone-d4 glucuronide over 
etiocholoanolone-d5. Het enkelvoudig gederivatiseerde androsterone (mono-TMS) 
werd geselecteerd als beste merker om de derivatisatie op te volgen. Om een beeld 
te krijgen van de impact van eventuele microbiële degradatie op de concentraties 
van de endogene steroïden werden stabiliteitsexperimenten uitgevoerd. Hieruit kon 
besloten worden dat de relative verhouding van de eerder ingevoerde merkers 
duidelijker de echte impact van de degradatie op de concentraties van het 
steroïdprofiel weerspiegelen. 
In hoofdstuk 5 werd een snelle GC-MS/MS confirmatieprocedure voor THCA 
beschreven. Om te komen tot een snelle en efficiënte methode werden zowel de 
staalvoorbereiding als de GC-methode geoptimaliseerd. Er werd gebruik gemaakt 
van slechts 1 mL urine en een snelle alkalische hydrolyse met NaOH. In vergelijking 
met de oudere methodes is gebleken dat één enkele extractie volstaat om voldoende 
selectiviteit te krijgen op het GC-MS/MS systeem en dat met een 
temperatuursprogramma van slechts 4 minuten. De doorgaans lange derivatisatie 
kon sterk worden ingekort door microgolven te gebruiken voor de warmteoverdracht. 
Deze vereenvoudigde staalvoorbereiding, het gebruik van een PTV-injector en de 
tandem MS detectie maken het mogelijk de concentratie van THCA te bepalen in 1 
mL urine in een tijdspanne van ongeveer 30 minuten. 
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Deel III: Synthetische cannabinoïden 
Klasse S8 van de WADA lijst [7] omvat zowel natuurlijke als synthetische substanties 
die binden op de cannabinoïdreceptoren in het menselijk lichaam. Naast de 
optimalisatie van de confirmatieprocedure voor cannabis in hoofdstuk 3 (deel I), werd 
in deel II van dit werk ook onderzoek gedaan naar andere cannabinoïden. Het 
probleem van de synthetische cannabinoïden is meer dan doping alleen, het is 
onderdeel van een wereldwijd stijgend gebruik van een groot gamma nieuwe 
psychoactieve drugs. Hoewel tot op vandaag het gebruik ervan in competitie eerder 
beperkt is [8], stijgt de populariteit van deze cannabimimetica over de hele wereld [9–
11]. 
Hoofdstuk 6 schetst een beeld van de huidige situatie wat betreft synthetische 
cannabinoïden. Het misbruik ervan werd in kaart gebracht samen met de huidige 
maatregelen van zowel overheden als (inter)nationale organisaties om het probleem 
onder controle te krijgen. Verder werd er aandacht besteed aan de interacties die 
plaatsvinden in het menselijk lichaam, de mogelijke gezondheidsrisico’s bij 
(langdurig) gebruik en de ontwikkelingen op het gebied van detectie van deze 
substanties. 
Om het gebruik van verboden producten op te sporen wordt in veel domeinen – 
waaronder in de dopingcontrole – gebruik gemaakt van urine als matrix. Dit is echter 
niet vanzelfsprekend aangezien dit de kennis vereist van de metabole processen die 
plaatsvinden in het menselijk lichaam. Het is reeds beschreven dat synthetische 
cannabinoïden zeer sterk gemetaboliseerd worden, zelfs in die mate dat de 
onveranderde component doorgaans niet gedecteerd wordt in urine. Bijgevolg is de 
studie van het metabolisme noodzakelijk om de detectie in urine mogelijk te maken. 
Zoals besproken in hoofdstuk 4, is het niet ethisch verantwoord deze producten met 
dit doel toe te dienen aan mensen. Als alternatief hiervoor werd in dit werk een 
strategie beschreven, gebaseerd op de combinatie van twee modellen. 
De toepassing van deze strategie om het metabolisme van JWH-122 te onderzoeken 
werd beschreven in hoofdstuk 7. In een eerste stap werd gebruik gemaakt van een 
in vitro model op basis van humane levermicrosomen. Dit model is eenvoudig uit te 
voeren in een standaard analytisch laboratorium en neemt met een incubatietijd van 
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slechts 4 uur weinig tijd in beslag. Verder bevat de matrix minder interfererende 
substanties dan urine, wat de identificatie van de aanwezige metabolieten 
gemakkelijker maakt. In totaal werden via LC-MS analyse 11 types metabolieten 
gevonden. De JWH-122 molecule werd gemetaboliseerd via hydroxylaties, 
dehydrogenaties of het afsplitsen van de N-pentyl zijketen. Naast enkele 
metabolieten die een dihydrodiol functie bevatten, werd ook een metaboliet 
gevonden met een carboxonzure functie op de N-pentyl keten. Informatie over de 
locatie van deze modificaties werd verkregen via LC-MS/MS fragmentatie 
experimenten (CID). 
In een tweede stap werd getracht de vorming van de eerder gevonden metabolieten 
te bevestigen in een in vivo model. Hiervoor werd gebruik gemaakt van een 
muismodel, ontwikkeld in samenwerking met het Centrum voor Vaccinologie, waarbij 
chimere uPA+/+-SCID muizen het synthetische cannabinoïd oraal toegediend kregen. 
Via LC-MS analyse van de gecollecteerde urine was het mogelijk de meeste 
metabole modificaties te bevestigen. Analyse van dezelfde stalen zonder 
enzymatische hydrolyse toonde aan dat alle metabolieten – weliswaar in 
verschillende mate - glucuronide- of sulfaatconjugatie ondergaan voor de urinaire 
excretie. Voor de selectie van de metaboliet die het meest in aanmerking komt om 
als merker te gebruiken in de screeningsmethode, werden de relatieve 
piekoppervlakken van alle metabolieten vergeleken.  
Hieruit werd duidelijk dat de enkelvoudig gehydroxyleerde metabolieten in de 
grootste hoeveelheden aanwezig waren en bijgevolg te verkiezen zijn om JWH-122 
gebruik in urine op te sporen. 
Dezelfde strategie werd gebruikt voor JWH-200, zoals beschreven in hoofdstuk 8. 
De aanwezigheid van de morfoline ring op de alkyl zijketen van deze component had 
een grote impact op het metabolisme. Naast de reeds voor JWH-122 beschreven 
functionaliteiten, werden extra metabolieten gevormd via modificaties van de 
morfoline ring. Om te kunnen bepalen op welk deel van de molecule de reacties 
plaatsvonden, werden zowel CID (LC-MS/MS) als HCD (LC-HRMS) experimenten 
uitgevoerd. Gebruik maken van hoge resolutie detectie heeft als voordeel dat 
eenduidig de brutoformule van de gevormde fragmenten kan achterhaald worden. 
Echter, in de HCD collisiecel wordt alles gelijktijdig gefragmenteerd (all-ion 
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fragmentation), wat het soms moeilijk maakt component-specificieke fragmenten te 
onderscheiden van andere. Dit probleem treedt vooral op bij lagere concentraties van 
het analiet, maar LC-MS/MS analyse kan hiervoor een oplossing bieden. 
Het aantal gedetecteerde metabolieten in vivo lag beduidend lager dan in vitro, 
hoewel de meeste metabole modificaties konden bevestigd worden. Op dezelfe 
manier als voor JWH-122, werden de JWH-200 metabolieten als glucuronide of 
sulfaat conjugaat teruggevonden. Voor de fase II experimenten werd telkens gebruik 
gemaakt van HRMS detectie. Deze techniek laat toe om via de snelle wisseling 
tussen positieve en negatieve ionisatiemodes alle hoge resolutie data op te nemen in 
één enkele run. Het bevestigen van theoretisch mogelijke fase II metabolieten is 
nadien slechts een kwestie van data processing. Vooral wanneer men slechts 
beschikt over een kleine hoeveelheid monster, zoals bij de muisurine, is dit een groot 
voordeel. 
De JWH-200 metaboliet die gevormd wordt door openvolgende afsplitsing van de 
morfolinering en oxidatie van de overblijvende zijketen tot een carbonzuur, was 
duidelijk aanwezig in de grootste hoeveelheden. Hoewel normaal bij het muismodel 
de klaring volledig is na 24 uur, kon deze metaboliet nog steeds gedetecteerd 
worden in de urine gecollecteerd tot 48 uur na toediening. Dit geeft aan dat deze 
metaboliet aangewezen is voor de detectie van JWH-200 in urine. 
Het onderzoek naar synthetische cannabinoïden beschreven in dit werk kan leiden 
tot de detectie van deze componenten in urine. Daarbij dient gezegd dat dit slechts 
een kleine stap is in het hele cannabinoïd verhaal. Zoals hier reeds besproken, 
vereist dit probleem een globale aanpak, waartoe verschillende expertisedomeinen 
zullen moeten bijdragen. 
Tot op vandaag is het moeilijk in te schatten hoe de situatie zal evolueren. Daarom 
zal het noodzakelijk zijn de huidige opsporingsmethoden te blijven verbeteren, zowel 
voor de vandaag gekende als voor de nieuwe componenten, die zonder enige twijfel 
op de markt zullen komen in de (nabije) toekomst. Wat betreft het opsporen in urine, 
zal zowel aandacht moeten gaan naar nieuw metabolisme onderzoek als naar de 
ontwikkeling van nieuwe methodes. Op basis van de output in de wetenschappelijke 
litteratuur is het duidelijk dat dopingcontrolelaboratoria hier een belangrijke rol in te 
spelen hebben. 
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